AbbVie (ABBV) 10-K 14 Feb 25 2024 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2024	Jan. 31, 2025	Jun. 30, 2024
Entity Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-35565
Entry Registrant Name	AbbVie Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0375147
Entity Address, Address Line One	1 North Waukegan Road
Entity Address, City or Town	North Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60064-6400
City Area Code	847
Local Phone Number	932-7900
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 300,173,162,268
Entity Common Stock, Shares Outstanding		1,765,354,859
Documents Incorporated by Reference	Portions of the 2025 AbbVie Inc. Proxy Statement are incorporated by reference into Part III. The Definitive Proxy Statement will be filed on or about March 24, 2025.
Entity Central Index Key	0001551152
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Common stock | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
Security Exchange Name	NYSE
Common stock | CHICAGO STOCK EXCHANGE, INC
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ABBV
Security Exchange Name	CHX
Sec 0.750 Senior Notes Due 2027 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	0.750% Senior Notes due 2027
Trading Symbol	ABBV27
Security Exchange Name	NYSE
Sec 2.125 Senior Notes due 2028 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	2.125% Senior Notes due 2028
Trading Symbol	ABBV28
Security Exchange Name	NYSE
Sec 2.625 Senior Notes Due 2028 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	2.625% Senior Notes due 2028
Trading Symbol	ABBV28B
Security Exchange Name	NYSE
Sec 2.125 Senior Notes Due 2029 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	2.125% Senior Notes due 2029
Trading Symbol	ABBV29
Security Exchange Name	NYSE
Sec 1.250 Senior Notes Due 2031 | NEW YORK STOCK EXCHANGE, INC.
Entity Information [Line Items]
Title of 12(b) Security	1.250% Senior Notes due 2031
Trading Symbol	ABBV31
Security Exchange Name	NYSE

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Auditor Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Chicago, Illinois
Auditor Firm ID	42

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 56,334	$ 54,318	$ 58,054
Cost of products sold	16,904	20,415	17,414
Selling, general and administrative	14,752	12,872	15,260
Research and development	12,791	7,675	6,510
Acquired IPR&D and milestones	2,757	778	697
Other operating expense (income), net	(7)	(179)	56
Total operating costs and expenses	47,197	41,561	39,937
Operating earnings	9,137	12,757	18,117
Interest expense, net	2,160	1,684	2,044
Net foreign exchange loss	21	146	148
Other expense, net	3,240	4,677	2,448
Earnings before income tax expense	3,716	6,250	13,477
Income tax expense (benefit)	(570)	1,377	1,632
Net earnings	4,286	4,873	11,845
Net earnings attributable to noncontrolling interest	8	10	9
Net earnings attributable to AbbVie Inc.	$ 4,278	$ 4,863	$ 11,836
Per share data
Basic earnings per share (in dollars per share)	$ 2.40	$ 2.73	$ 6.65
Diluted earnings per share (in dollars per share)	$ 2.39	$ 2.72	$ 6.63
Weighted-average basic shares outstanding (in shares)	1,769	1,768	1,771
Weighted-average diluted shares outstanding (in shares)	1,773	1,773	1,778

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net earnings	$ 4,286	$ 4,873	$ 11,845
Foreign currency translation adjustments, net of tax expense (benefit) of $(39) in 2024, $15 in 2023 and $(10) in 2022	(1,008)	407	(943)
Net investment hedging activities, net of tax expense (benefit) of $133 in 2024, $(109) in 2023 and $152 in 2022	484	(399)	555
Pension and post-employment benefits, net of tax expense (benefit) of $206 in 2024, $(6) in 2023 and $272 in 2022	824	(30)	1,088
Cash flow hedging activities, net of tax expense (benefit) of $16 in 2024, $(19) in 2023 and $5 in 2022	80	(84)	0
Other comprehensive income (loss)	380	(106)	700
Comprehensive income	4,666	4,767	12,545
Comprehensive income attributable to noncontrolling interest	8	10	9
Comprehensive income attributable to AbbVie Inc.	$ 4,658	$ 4,757	$ 12,536

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Foreign currency translation adjustments, tax expense (benefit)	$ (39)	$ 15	$ (10)
Net investment hedging activities, tax expense (benefit)	133	(109)	152
Pension and post-employment benefits, tax expense (benefit)	206	(6)	272
Cash flow hedging activities, tax expense (benefit)	$ 16	$ (19)	$ 5

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current assets
Cash and equivalents	$ 5,524	$ 12,814
Short-term investments	31	2
Accounts receivable, net	10,919	11,155
Inventories	4,181	4,099
Prepaid expenses and other	4,927	4,932
Total current assets	25,582	33,002
Investments	279	304
Property and equipment, net	5,134	4,989
Intangible assets, net	60,068	55,610
Goodwill	34,956	32,293
Other assets	9,142	8,513
Total assets	135,161	134,711
Current liabilities
Current portion of long-term debt and finance lease obligations	6,804	7,191
Accounts payable and accrued liabilities	31,945	30,650
Total current liabilities	38,749	37,841
Long-term debt and finance lease obligations	60,340	52,194
Deferred income taxes	2,579	1,952
Other long-term liabilities	30,129	32,327
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,831,594,494 shares issued as of December 31, 2024 and 1,823,046,087 as of December 31, 2023	18	18
Common stock held in treasury, at cost, 66,337,508 shares as of December 31, 2024 and 57,105,354 as of December 31, 2023	(8,201)	(6,533)
Additional paid-in capital	21,333	20,180
Accumulated deficit	(7,900)	(1,000)
Accumulated other comprehensive loss	(1,925)	(2,305)
Total stockholders' equity	3,325	10,360
Noncontrolling interest	39	37
Total equity	3,364	10,397
Total liabilities and equity	$ 135,161	$ 134,711

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,831,594,494	1,823,046,087
Common stock held in treasury, at cost (in shares)	66,337,508	57,105,354

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury Stock, Common	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive loss	Noncontrolling interest
Beginning balance at Dec. 31, 2021	$ 15,436	$ 18	$ (3,143)	$ 18,305	$ 3,127	$ (2,899)	$ 28
Beginning balance (in shares) at Dec. 31, 2021		1,768
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	11,836	$ 0	0	0	11,836	0	0
Other comprehensive income, net of tax	700	0	0	0	0	700	0
Dividends declared	(10,179)	0	0	0	(10,179)	0	0
Purchases of treasury stock	(1,487)	$ 0	(1,487)	0	0	0	0
Purchases of treasury stock (in shares)		(10)
Stock-based compensation plans and other	976	$ 0	36	940	0	0	0
Stock-based compensation plans and other (in shares)		11
Change in noncontrolling interest	5	$ 0	0	0	0	0	5
Ending balance at Dec. 31, 2022	17,287	$ 18	(4,594)	19,245	4,784	(2,199)	33
Ending balance (in shares) at Dec. 31, 2022		1,769
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	4,863	$ 0	0	0	4,863	0	0
Other comprehensive income, net of tax	(106)	0	0	0	0	(106)	0
Dividends declared	(10,647)	0	0	0	(10,647)	0	0
Purchases of treasury stock	(1,978)	$ 0	(1,978)	0	0	0	0
Purchases of treasury stock (in shares)		(12)
Stock-based compensation plans and other	974	$ 0	39	935	0	0	0
Stock-based compensation plans and other (in shares)		9
Change in noncontrolling interest	4	$ 0	0	0	0	0	4
Ending balance at Dec. 31, 2023	10,397	$ 18	(6,533)	20,180	(1,000)	(2,305)	37
Ending balance (in shares) at Dec. 31, 2023		1,766
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	4,278	$ 0	0	0	4,278	0	0
Other comprehensive income, net of tax	380	0	0	0	0	380	0
Dividends declared	(11,178)	0	0	0	(11,178)	0	0
Purchases of treasury stock	(1,703)	$ 0	(1,703)	0	0	0	0
Purchases of treasury stock (in shares)		(9)
Stock-based compensation plans and other	1,188	$ 0	35	1,153	0	0	0
Stock-based compensation plans and other (in shares)		8
Change in noncontrolling interest	2	$ 0	0	0	0	0	2
Ending balance at Dec. 31, 2024	$ 3,364	$ 18	$ (8,201)	$ 21,333	$ (7,900)	$ (1,925)	$ 39
Ending balance (in shares) at Dec. 31, 2024		1,765

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net earnings	$ 4,286	$ 4,873	$ 11,845
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	764	752	778
Amortization of intangible assets	7,622	7,946	7,689
Deferred income taxes	(1,449)	(2,889)	(1,931)
Change in fair value of contingent consideration liabilities	3,771	5,128	2,761
Payments of contingent consideration liabilities	(1,995)	(870)	(164)
Stock-based compensation	911	747	671
Acquired IPR&D and milestones	2,757	778	697
Gain on divestitures	0	0	(172)
Non-cash litigation reserve adjustments, net of cash payments	508	(443)	2,243
Impairment of intangible assets	4,476	4,229	770
Other, net	(63)	(225)	(150)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	207	66	(1,455)
Inventories	(319)	(417)	(686)
Prepaid expenses and other assets	361	(188)	(264)
Accounts payable and other liabilities	177	3,840	1,769
Income tax assets and liabilities, net	(3,208)	(488)	542
Cash flows from operating activities	18,806	22,839	24,943
Cash flows from investing activities
Acquisition of businesses, net of cash acquired	(17,493)	0	(255)
Other acquisitions and investments	(3,024)	(1,223)	(539)
Acquisitions of property and equipment	(974)	(777)	(695)
Purchases of investment securities	(73)	(77)	(1,438)
Sales and maturities of investment securities	555	55	1,530
Other, net	189	13	774
Cash flows from investing activities	(20,820)	(2,009)	(623)
Cash flows from financing activities
Proceeds from Short-Term Debt	5,008	0	0
Repayments of Other Short-Term Debt	(5,008)	0	0
Proceeds from issuance of long-term debt	16,963		2,000
Repayments of long-term debt and finance lease obligations	(9,613)	(4,149)	(14,433)
Debt issuance costs	(99)	(38)	0
Dividends paid	(11,025)	(10,539)	(10,043)
Purchases of treasury stock	(1,708)	(1,972)	(1,487)
Proceeds from the exercise of stock options	214	180	262
Payments of contingent consideration liabilities	0	(752)	(1,132)
Other, net	57	48	30
Cash flows from financing activities	(5,211)	(17,222)	(24,803)
Effect of exchange rate changes on cash and equivalents	(65)	5	(62)
Net change in cash and equivalents	(7,290)	3,613	(545)
Cash and equivalents, beginning of year	12,814	9,201	9,746
Cash and equivalents, end of year	5,524	12,814	9,201
Other supplemental information
Interest paid, net of portion capitalized	2,811	2,469	2,546
Income taxes paid	$ 4,064	$ 4,702	$ 2,988

Background and Basis of Present

Background and Basis of Presentation	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background	Background Background The principal business of AbbVie Inc. (AbbVie or the company) is the discovery, development, manufacturing and sale of a broad line of therapies that address some of the world's most complex and serious diseases. AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, patients or other customers. Outside the United States, AbbVie sells products primarily to wholesalers or through distributors, and depending on the market works through largely centralized national payers systems to agree on reimbursement terms. AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent, publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for rebates, pension and other post-employment benefits, income taxes, litigation, valuation of goodwill and intangible assets and contingent consideration liabilities. Basis of Consolidation The consolidated financial statements include the accounts of AbbVie and all of its subsidiaries in which a controlling interest is maintained. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, where AbbVie is determined to be the primary beneficiary. Investments in companies over which AbbVie has a significant influence but not a controlling interest are accounted for using the equity method with AbbVie's share of earnings or losses reported in other expense, net in the consolidated statements of earnings. Intercompany balances and transactions are eliminated. Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period presentation. Revenue Recognition AbbVie recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration AbbVie expects to be entitled to in exchange for those goods or services. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue. AbbVie generates revenue primarily from product sales. For the majority of sales, the company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. The company recognizes shipping and handling costs as an expense in cost of products sold when the company transfers control to the customer. Payment terms vary depending on the type and location of the customer, are based on customary commercial terms and are generally less than one year. AbbVie does not adjust revenue for the effects of a significant financing component for contracts where AbbVie expects the period between the transfer of the good or service and collection to be one year or less. Cash discounts, rebates and chargebacks, sales incentives, product returns and certain other adjustments are accounted for as variable consideration. Provisions for variable consideration are based on current pricing, executed contracts, government pricing legislation and historical data and are provided for in the period the related revenues are recorded. Rebate amounts are typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, factors used in the calculation of the accrual include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant. In addition to revenue from contracts with customers, the company also recognizes certain collaboration revenues. See Note 6 for additional information related to the collaborations with Janssen Biotech, Inc. and Genentech, Inc. Additionally, see Note 16 for disaggregation of revenue by product and geography. Research and Development Expenses Internal R&D costs are expensed as incurred. Clinical trial costs incurred by third parties are expensed as the contracted work is performed. Acquired IPR&D and Milestones Expenses In an asset acquisition, payments incurred prior to regulatory approval to acquire rights to in-process R&D projects are expensed as acquired IPR&D and milestones expense in the consolidated statements of earnings unless the project has an alternative future use. These costs include upfront and development milestone payments related to R&D collaborations, licensing arrangements, or other asset acquisitions that provide rights to develop, manufacture and/or sell pharmaceutical products. Where contingent development milestone payments are due to third parties, prior to regulatory approval, the payment obligations are expensed when the milestone results are achieved. Regulatory and commercial milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the remaining useful life of the related product. Business Combinations AbbVie utilizes the acquisition method of accounting for business combinations. This method requires, among other things, that results of operations of acquired companies are included in AbbVie's results of operations beginning on the acquisition date and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair value of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other expense, net in the consolidated statements of earnings. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred. In a business combination, the fair value of IPR&D projects acquired is capitalized and accounted for as indefinite-lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as a definite-lived intangible asset, or discontinuation, at which point the intangible asset will be written off. R&D costs incurred by the company after the acquisition are expensed to R&D as incurred. Collaborations and Other Arrangements The company enters into collaborative agreements with third parties to develop and commercialize drug candidates. Collaborative activities may include joint research and development and commercialization of new products. AbbVie generally receives certain licensing rights under these arrangements. These collaborations often require upfront payments and may include additional milestone, research and development cost sharing, royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development and commercialization. Upfront payments associated with collaborative arrangements and subsequent payments made to the partner for the achievement of development milestones prior to regulatory approval are expensed to acquired IPR&D and milestones expense in the consolidated statements of earnings. Regulatory and commercial milestone payments made to the partner subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the estimated useful life of the related asset. Royalties are expensed to cost of products sold in the consolidated statements of earnings when incurred. Advertising Costs associated with advertising are expensed as incurred and are included in selling, general and administrative (SG&A) expense in the consolidated statements of earnings. Advertising expenses were $2.1 billion in 2024, $2.2 billion in 2023 and $2.0 billion in 2022. Pension and Other Post-Employment Benefits AbbVie records annual expenses relating to its defined benefit pension and other post-employment benefit plans based on calculations which utilize various actuarial assumptions including discount rates, rates of return on assets, compensation increases, turnover rates and health care cost trend rates. AbbVie reviews its actuarial assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends. Actuarial gains and losses are deferred in accumulated other comprehensive income (loss) (AOCI), net of tax and are amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return are generally amortized to net periodic benefit cost over a five-year period. Income Taxes Income taxes are accounted for under the asset and liability method. Provisions for federal, state and foreign income taxes are calculated on reported pre-tax earnings based on current tax laws. Deferred taxes are provided using enacted tax rates on the future tax consequences of temporary differences, which are the differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and the tax benefits of carryforwards. A valuation allowance is established or maintained when, based on currently available information, it is more likely than not that all or a portion of a deferred tax asset will not be realized. Cash and Equivalents Cash and equivalents include money market funds and time deposits with original maturities of three months or less. Investments Investments consist primarily of equity securities, held-to-maturity debt securities, marketable debt securities and time deposits. Investments in equity securities that have readily determinable fair values are recorded at fair value. Investments in equity securities that do not have readily determinable fair values are recorded at cost and are remeasured to fair value based on certain observable price changes or impairment events as they occur. Held-to-maturity debt securities are recorded at cost. Gains or losses on investments are included in other expense, net in the consolidated statements of earnings. Investments in marketable debt securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in AOCI on the consolidated balance sheets until realized, at which time the gains or losses are recognized in earnings. AbbVie periodically assesses its marketable debt securities for impairment and credit losses. When a decline in the fair value of marketable debt security is due to credit related factors, an allowance for credit losses is recorded with a corresponding charge to other expense, net in the consolidated statements of earnings. When AbbVie determines that a non-credit related impairment has occurred, the amortized cost basis of the investment, net of allowance for credit losses, is written down with a charge to other expense, net in the consolidated statements of earnings and an available-for-sale investment's unrealized loss is reclassified from AOCI to other expense, net in the consolidated statements of earnings. Realized gains and losses on sales of investments are computed using the first-in, first-out method adjusted for any impairments and credit losses that were recorded in net earnings. Accounts Receivable Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition and both current and forecasted economic conditions. Inventories Inventories are valued at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs. Inventories consisted of the following: as of December 31 (in millions) 2024 2023 Finished goods $ 1,173 $ 1,356 Work-in-process 1,951 1,643 Raw materials 1,057 1,100 Inventories $ 4,181 $ 4,099 Property and Equipment, Net as of December 31 (in millions) 2024 2023 Land $ 284 $ 286 Buildings 2,895 2,827 Equipment 7,995 7,449 Construction in progress 1,093 1,073 Property and equipment, gross 12,267 11,635 Less accumulated depreciation (7,133) (6,646) Property and equipment, net $ 5,134 $ 4,989 Depreciation for property and equipment is recorded on a straight-line basis over the estimated useful lives of the assets. The estimated useful life for buildings ranges from 10 to 50 years. Buildings include leasehold improvements which are amortized over the lesser of the remainder of the lease term or the useful life of the leasehold improvement. The estimated useful life for equipment ranges from 2 to 25 years. Equipment includes certain computer software and software development costs incurred in connection with developing or obtaining software for internal use and is amortized over 3 to 10 years. Depreciation expense was $764 million in 2024, $752 million in 2023 and $778 million in 2022. Leases Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components. The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants. Litigation and Contingencies Loss contingency provisions are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. When a best estimate cannot be made, the minimum loss contingency amount in a probable range is recorded. Legal fees are expensed as incurred. AbbVie accrues for product liability claims on an undiscounted basis. The liabilities are evaluated quarterly and adjusted if necessary as additional information becomes available. Receivables for insurance recoveries for product liability claims, if any, are recorded as assets on an undiscounted basis when it is probable that a recovery will be realized. Goodwill and Intangible Assets Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital and terminal values of market participants. Definite-lived intangibles are amortized over their estimated useful lives using the estimated pattern of economic benefit. AbbVie reviews the recoverability of definite-lived intangible assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. AbbVie first compares the projected undiscounted cash flows to be generated by the asset to its carrying value. If the undiscounted cash flows of an intangible asset are less than the carrying value, the intangible asset is written down to its fair value. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest level for which cash flows are largely independent of the cash flows of other assets and liabilities. Goodwill and indefinite-lived assets are not amortized but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeded the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value. The company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed. AbbVie tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value is less than its carrying amount, a quantitative impairment test is performed. For its quantitative impairment tests, the company uses an estimated future cash flow approach that requires significant judgment with respect to future volume, revenue and expense growth rates, changes in working capital use, the selection of an appropriate discount rate, asset groupings and other assumptions and estimates. The estimates and assumptions used are consistent with the company's business plans and a market participant's views. The use of alternative estimates and assumptions could increase or decrease projected cash flows and the estimated fair value of the related intangible assets. Future changes to these estimates and assumptions could have a material impact on the company's results of operations. Actual results may differ from the company's estimates. Foreign Currency Translation Foreign subsidiary earnings are translated into U.S. dollars using average exchange rates. The net assets of foreign subsidiaries are translated into U.S. dollars using period-end exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recognized in other comprehensive income (loss) in the consolidated statements of comprehensive income. The net assets of subsidiaries in highly inflationary economies are remeasured as if the functional currency were the reporting currency. The remeasurement is recognized in net foreign exchange loss in the consolidated statements of earnings. Derivatives All derivative instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheets and are classified as current or long-term based on the scheduled maturity of the instrument. For derivatives formally designated as hedges, the company assesses at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in the fair value or cash flows of the hedged item. The changes in fair value of a derivative designated as a fair value hedge and of the hedged item attributable to the hedged risk are recognized in earnings immediately. The effective portions of changes in the fair value of a derivative designated as a cash flow hedge are reported in AOCI and are subsequently recognized in earnings consistent with the underlying hedged item. If it is determined that a derivative is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If a hedged forecasted transaction becomes probable of not occurring, any gains or losses are reclassified from AOCI to earnings. Derivatives that are not designated as hedges are adjusted to fair value through current earnings. The company also uses derivative instruments or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. Realized and unrealized gains and losses from these hedges are included in AOCI. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating section of the consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in the investing section of the consolidated statements of cash flows. Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted ASU No. 2024-03 In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40 ). The standard requires further disaggregation of relevant expense captions in a separate note to the financial statements. The standard is effective for AbbVie starting in annual periods in 2027 and interim periods beginning in 2028, with early adoption permitted. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. ASU No. 2023-09 In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) . The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard is effective for AbbVie starting in annual periods in 2025. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. Recently Adopted Accounting Pronouncements ASU No. 2023-07 In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting - Improving Reportable Segment Disclosures (Topic 280) . The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (CODM), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. AbbVie adopted the standard in the fourth quarter of 2024. The adoption did not have a material impact on its consolidated financial statements. See Note 16 for additional information.

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Dec. 31, 2024
Supplemental Financial Information
Supplemental Financial Information	Supplemental Financial Information Interest Expense, Net years ended December 31 (in millions) 2024 2023 2022 Interest expense $ 2,808 $ 2,224 $ 2,230 Interest income (648) (540) (186) Interest expense, net $ 2,160 $ 1,684 $ 2,044 Accounts Payable and Accrued Liabilities as of December 31 (in millions) 2024 2023 Sales rebates $ 14,304 $ 13,627 Dividends payable 2,936 2,783 Accounts payable 2,945 3,688 Current portion of contingent consideration liabilities 2,589 1,952 Salaries, wages and commissions 1,986 1,802 Royalty and license arrangements 527 360 Other 6,658 6,438 Accounts payable and accrued liabilities $ 31,945 $ 30,650 Other Long-Term Liabilities as of December 31 (in millions) 2024 2023 Contingent consideration liabilities $ 19,077 $ 17,938 Liabilities for unrecognized tax benefits 5,049 6,681 Income taxes payable 1,261 2,182 Pension and other post-employment benefits 1,234 1,538 Other 3,508 3,988 Other long-term liabilities $ 30,129 $ 32,327

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method: Years ended December 31, (in millions, except per share data) 2024 2023 2022 Basic EPS Net earnings attributable to AbbVie Inc. $ 4,278 $ 4,863 $ 11,836 Earnings allocated to participating securities 40 43 54 Earnings available to common shareholders $ 4,238 $ 4,820 $ 11,782 Weighted average basic shares of common stock outstanding 1,769 1,768 1,771 Basic earnings per share attributable to AbbVie Inc. $ 2.40 $ 2.73 $ 6.65 Diluted EPS Net earnings attributable to AbbVie Inc. $ 4,278 $ 4,863 $ 11,836 Earnings allocated to participating securities 40 43 54 Earnings available to common shareholders $ 4,238 $ 4,820 $ 11,782 Weighted average shares of common stock outstanding 1,769 1,768 1,771 Effect of dilutive securities 4 5 7 Weighted average diluted shares of common stock outstanding 1,773 1,773 1,778 Diluted earnings per share attributable to AbbVie Inc. $ 2.39 $ 2.72 $ 6.63 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Licensing, Acquisitions, and Ot

Licensing, Acquisitions, and Other Arrangements	12 Months Ended
	Dec. 31, 2024
Licensing, Acquisitions, and Other Arrangements
Licensing, Acquisitions, and Other Arrangements	Licensing, Acquisitions and Other Arrangements Acquisition of Cerevel Therapeutics Holdings, Inc. On August 1, 2024, AbbVie completed its previously announced acquisition of Cerevel Therapeutics. Cerevel Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of differentiated therapies for neuroscience diseases. Cerevel Therapeutics neuroscience pipeline includes multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders. Under the terms of the agreement, AbbVie acquired all outstanding shares of Cerevel Therapeutics for $45.00 per share in cash. The total fair value of the consideration transferred to owners of Cerevel Therapeutics common stock was $8.7 billion ($8.3 billion, net of cash acquired). The acquisition of Cerevel Therapeutics has been accounted for as a business combination using the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The valuation of assets acquired and liabilities assumed has not yet been finalized as of December 31, 2024. As a result, AbbVie recorded preliminary estimates for the fair value of assets acquired and liabilities assumed as of the acquisition date. Finalization of the valuation during the measurement period could result in a change in the amounts recorded for the acquisition date fair value of intangible assets, goodwill and income taxes among other items. The completion of the valuation will occur no later than one year from the acquisition date. The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 361 Short-term investments 382 Prepaid expenses and other current assets 9 Property and equipment, net 25 Investments 121 Intangible assets, net 8,100 Other noncurrent assets 31 Current portion of long-term debt (400) Accounts payable and accrued liabilities (100) Long-term debt (246) Deferred income taxes (1,292) Other long-term liabilities (31) Total identifiable net assets 6,960 Goodwill 1,702 Total assets acquired and liabilities assumed $ 8,662 Intangible assets relate to $8.1 billion of acquired in-process research and development (IPR&D) associated with products that have not yet received regulatory approval. The estimated fair values of identifiable intangible assets were determined using the "income approach" which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product, the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, competitive trends impacting the asset and each cash flow stream, as well as other factors. The current portion of long-term debt assumed by AbbVie consists of $345 million aggregate principal of 2.5% convertible senior notes due 2027. Upon acquisition, the convertible senior notes became callable and note holders could redeem the convertible senior notes for cash at a premium. As of the acquisition date, the convertible senior notes were recognized as current portion of long-term debt on the consolidated balance sheets at an aggregate fair value of $400 million. Following the acquisition date, the company repaid the convertible senior notes and there were no amounts outstanding as of December 31, 2024. Long-term debt assumed by AbbVie relates to funding agreements entered into by Cerevel Therapeutics prior to the acquisition. Under the agreements, Cerevel Therapeutics received funding to support development of tavapadon and agreed to repay regulatory milestones, sales milestones and royalties contingent upon approval of tavapadon by the U.S. Food and Drug Administration (FDA). The funding agreements were accounted for as financing arrangements and the fair value of the related financing liability was $246 million as of the acquisition date. The estimated fair value of the financing liability was determined using a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Assumptions inherent in the development of fair value include discount rates, estimated probabilities and timing of achieving milestones and estimated amounts of future sales. See Note 10 and Note 11 for additional information. Goodwill was calculated as the excess of the consideration transferred over the fair value of net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recognized from the acquisition of Cerevel Therapeutics represents expected synergies, including the ability to: (i) expand AbbVie’s neuroscience pipeline, (ii) leverage AbbVie’s commercial, regulatory and clinical expertise to maximize Cerevel Therapeutic’s assets and (iii) enhance AbbVie’s existing neuroscience discovery capabilities. The goodwill is not deductible for tax purposes. AbbVie also assumed a licensing agreement entered into by Cerevel Therapeutics with Pfizer Inc. (Pfizer) prior to the acquisition. Under the agreement, Cerevel Therapeutics was granted an exclusive global license under certain Pfizer patent rights to develop, manufacture and commercialize compounds included in Cerevel Therapeutic’s pipeline. AbbVie could make additional payments of up to $1.6 billion upon achievement of certain regulatory and commercial milestones for all programs. Additionally, AbbVie will pay tiered royalties on net revenues. Following the acquisition date, the operating results of Cerevel Therapeutics have been included in the consolidated financial statements. For the period from the acquisition date through December 31, 2024, operating losses attributable to Cerevel Therapeutics were $4.9 billion, inclusive of an intangible asset impairment charge Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $44 million for the year ended December 31, 2024 and were included in selling, general and administrative (SG&A) expense in the consolidated statements of earnings. Acquisition of ImmunoGen, Inc. On February 12, 2024, AbbVie completed its previously announced acquisition of ImmunoGen. ImmunoGen is a commercial-stage biotechnology company focused on the discovery, development and commercialization of antibody-drug conjugates (ADC) for cancer patients. ImmunoGen's oncology portfolio includes its flagship cancer therapy Elahere, a first-in-class ADC approved for platinum-resistant ovarian cancer, and a pipeline of promising next-generation ADC's targeting hematologic malignancies and solid tumors. The combination accelerates AbbVie’s entry into the solid tumor space and strengthens its oncology pipeline. Under the terms of the agreement, AbbVie acquired all outstanding shares of ImmunoGen for $31.26 per share in cash. The total fair value of the consideration transferred to owners of ImmunoGen common stock was $9.8 billion ($9.2 billion, net of cash acquired). The acquisition of ImmunoGen has been accounted for as a business combination using the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The valuation of assets acquired and liabilities assumed was finalized during the three months ended December 31, 2024. The following table summarizes the final fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 591 Accounts receivable 171 Inventories 211 Prepaid expenses and other current assets 40 Property and equipment, net 7 Intangible assets, net Developed product rights 7,200 License agreements 125 Acquired in-process research and development 1,280 Other noncurrent assets 273 Current portion of long-term debt (99) Accounts payable and accrued liabilities (312) Deferred income taxes (899) Other long-term liabilities (47) Total identifiable net assets 8,541 Goodwill 1,249 Total assets acquired and liabilities assumed $ 9,790 The fair value step-up adjustment to inventories of $179 million was amortized to cost of products sold when the inventory was sold to customers during the year ended December 31, 2024. Intangible assets relate to $7.3 billion of definite-lived intangible assets and $1.3 billion of acquired IPR&D associated with products that have not yet received regulatory approval. The acquired definite-lived intangible assets consist of developed product rights and license agreements and are being amortized over a weighted-average estimated useful life of approximately 12 years using the estimated pattern of economic benefit. The estimated fair values of identifiable intangible assets were determined using the "income approach" which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the more significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product, the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, competitive trends impacting the asset and each cash flow stream, as well as other factors. Other noncurrent assets primarily consist of $250 million of deferred tax assets. The current portion of long-term debt assumed by AbbVie was repaid concurrent with the acquisition at the fair value of $99 million. See Note 10 for additional information. Goodwill was calculated as the excess of the consideration transferred over the fair value of net assets recognized and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Specifically, the goodwill recognized from the acquisition of ImmunoGen represents expected synergies including, the ability to: (i) expand AbbVie’s product portfolio as well as the potential to increase revenue from future growth platforms, (ii) accelerate AbbVie’s clinical and commercial presence in the solid tumor space within oncology, (iii) leverage the respective strengths of each company, and (iv) enhance AbbVie’s existing ADC development efforts. The goodwill is not deductible for tax purposes. Following the acquisition date, the operating results of ImmunoGen have been included in the consolidated financial statements. For the period from the acquisition date through December 31, 2024, net revenues attributable to ImmunoGen were $578 million and operating losses attributable to ImmunoGen were $682 million, inclusive of $349 million of cash-settled, post-closing expense for ImmunoGen employee incentive awards, $179 million of inventory fair value step-up amortization and $157 million of intangible asset amortization. AbbVie also issued 0.3 million RSUs to holders of ImmunoGen equity awards based on a conversion factor described in the transaction agreement. Stock compensation expense related to RSUs issued at the acquisition date was not significant. Acquisition-related expenses, which were comprised primarily of regulatory, financial advisory and legal fees, totaled $59 million for the year ended December 31, 2024 and were included in SG&A expense in the consolidated statements of earnings. Pro Forma Financial Information The following table presents the unaudited pro forma combined results of AbbVie, ImmunoGen and Cerevel Therapeutics for 2024 and 2023 as if the acquisitions of ImmunoGen and Cerevel Therapeutics had occurred on January 1, 2023: years ended December 31 (in millions) 2024 2023 Net revenues $ 56,389 $ 54,691 Net earnings 4,564 2,862 The unaudited pro forma combined financial information was prepared using the acquisition method of accounting and was based on the historical financial information of AbbVie, ImmunoGen and Cerevel Therapeutics. In order to reflect the occurrence of the acquisitions on January 1, 2023 as required, the unaudited pro forma financial information includes adjustments to reflect incremental amortization expense to be incurred based on the fair values of the identifiable intangible assets acquired; the incremental cost of products sold related to the fair value adjustments associated with acquisition date inventory; the additional interest expense associated with the issuance of debt to finance the acquisition; and the reclassification of acquisition-related costs incurred during the year ended December 31, 2024 to the year ended December 31, 2023. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisitions been completed on January 1, 2023. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company nor does it reflect the expected realization of any synergies or cost savings associated with the acquisitions. Acquisition of DJS Antibodies Ltd In October 2022, AbbVie entered into an agreement to acquire DJS Antibodies Ltd (DJS) including its lead program DJS-002 and proprietary HEPTAD platform. DJS-002 is an LPAR1 antagonist antibody currently in preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases. HEPTAD platform is a potential novel approach to antibody discovery with specific capabilities targeting transmembrane protein targets. The aggregate purchase price of $287 million was comprised of a $255 million upfront cash payment and $32 million for the acquisition date fair value of contingent consideration liabilities, for which AbbVie may owe up to $95 million in future payments upon achievement of certain development milestones. The transaction was accounted for as a business combination using the acquisition method of accounting. As of the acquisition date, AbbVie acquired $233 million of intangible assets for in-process research and development, $22 million of intangible assets for developed product rights and $60 million of deferred tax liabilities. Other assets and liabilities assumed were insignificant. The acquisition resulted in the recognition of $92 million of goodwill which is not deductible for tax purposes. Other Licensing & Acquisitions Activity Cash outflows related to other acquisitions and investments totaled $3.0 billion in 2024, $1.2 billion in 2023 and $539 million in 2022. AbbVie recorded acquired IPR&D and milestones expense of $2.8 billion in 2024, $778 million in 2023 and $697 million in 2022. Significant arrangements impacting 2024, 2023 and 2022, some of which require contingent milestone payments, are summarized below. Nimble Therapeutics, Inc. Subsequent to December 31, 2024, AbbVie completed its previously announced acquisition of Nimble Therapeutics, Inc. (Nimble). Nimble is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics and its lead asset, an investigational oral peptide IL23R inhibitor, is in preclinical development for the treatment of psoriasis. Under the terms of the agreement, AbbVie made an upfront cash payment of approximately $200 million at closing to acquire all outstanding equity of Nimble. AbbVie could make additional future payments of up to $130 million upon the achievement of certain development milestones. The accounting impact of this acquisition will be included in the consolidated financial statements beginning in the first quarter of 2025. Aliada Therapeutics Holdings, Inc. In December 2024, AbbVie completed its previously announced acquisition of Aliada Therapeutics Holdings, Inc. (Aliada) including its lead program ALIA-1758 and accounted for the transaction as an asset acquisition. ALIA-1758 is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer’s Disease. Under the terms of the agreement, AbbVie made an upfront cash payment of approximately $1.4 billion to acquire all outstanding equity of Aliada which was recorded in acquired IPR&D and milestones expense in the consolidated statement of earnings in the fourth quarter of 2024. Celsius Therapeutics, Inc. In June 2024, AbbVie acquired Celsius Therapeutics, Inc. (Celsius Therapeutics) including its lead pipeline asset CEL383. Celsius Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of precision medicine in inflammatory bowel disease. The transaction was accounted as an asset acquisition as CEL383 represented substantially all of the fair value of the gross assets acquired. The upfront payment of $250 million was recorded in acquired IPR&D and milestones expense in the consolidated statement of earnings in the second quarter of 2024. Syndesi Therapeutics SA In February 2022, AbbVie acquired Syndesi Therapeutics SA and its portfolio of novel modulators of the synaptic vesicle protein 2A, including its lead molecule ABBV-552, previously named SDI-118, and accounted for the transaction as an asset acquisition. ABBV-552 is a small molecule, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Under the terms of the agreement, AbbVie made an upfront payment of $130 million which was recorded in acquired IPR&D and milestones expense in the consolidated statement of earnings in the first quarter of 2022. The agreement also includes additional future payments of up to $870 million upon the achievement of certain development, regulatory and commercial milestones. Juvise Pharmaceuticals In June 2022, AbbVie and Laboratories Juvise Pharmaceuticals (Juvise) entered into an asset purchase agreement where Juvise acquired worldwide commercial rights of a mature brand Pylera, which is used for the treatment of peptic ulcers with an infection by the bacterium Helicobacter pylori. The transaction was accounted for as the sale of an asset. Upon completion of the transaction, AbbVie received net cash proceeds of $215 million and recognized a pre-tax gain of $172 million which was recorded in other operating income in the consolidated statement of earnings in the second quarter of 2022. Other Arrangements In addition to the significant arrangements described above, AbbVie entered into several other arrangements resulting in charges related to upfront payments of $975 million in 2024, $582 million in 2023 and $315 million in 2022. In connection with the other individually insignificant early-stage arrangements entered into in 2024, AbbVie could make additional payments of up to $10.1 billion upon the achievement of certain development, regulatory and commercial milestones. Acquired IPR&D and milestones expense also included development milestones of $130 million in 2024, $196 million in 2023 and $252 million in 2022

Collaborations

Collaborations	12 Months Ended
	Dec. 31, 2024
Collaborative Arrangements [Abstract]
Collaborations	Collaborations The company has ongoing transactions with other entities through collaboration agreements. The following represent the significant collaboration agreements impacting 2024, 2023 and 2022. Collaboration with Janssen Biotech, Inc. In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of Imbruvica, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase and certain compounds structurally related to Imbruvica, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States. The collaboration provides Janssen with an exclusive license to commercialize Imbruvica outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs. In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of Imbruvica are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. Outside the United States, Janssen is responsible for and has exclusive rights to commercialize Imbruvica. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. The following table shows the profit and cost sharing relationship between Janssen and AbbVie: years ended December 31 (in millions) 2024 2023 2022 United States - Janssen's share of profits (included in cost of products sold) $ 1,140 $ 1,245 $ 1,607 International - AbbVie's share of profits (included in net revenues) 899 931 1,142 Global - AbbVie's share of other costs (included in respective line items) 162 228 268 AbbVie’s receivable from Janssen, included in accounts receivable, net, was $237 million at December 31, 2024 and $236 million at December 31, 2023. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $282 million at December 31, 2024 and $307 million at December 31, 2023. Collaboration with Genentech, Inc. AbbVie and Genentech, Inc. (Genentech), a member of the Roche Group, are parties to a collaboration and license agreement executed in 2007 to jointly research, develop and commercialize human therapeutic products containing BCL-2 inhibitors and certain other compound inhibitors which includes Venclexta, a BCL-2 inhibitor used to treat certain hematological malignancies. AbbVie shares equally with Genentech all pre-tax profits and losses from the development and commercialization of Venclexta in the United States. AbbVie pays royalties on Venclexta net revenues outside the United States. AbbVie manufactures and distributes Venclexta globally and is the principal in the end-customer product sales. Sales of Venclexta are included in AbbVie's net revenues. Genentech's share of United States profits is included in AbbVie's cost of products sold. AbbVie records sales and marketing costs associated with the United States collaboration as part of SG&A expenses and global development costs as part of R&D expenses, net of Genentech’s share. Royalties paid for Venclexta revenues outside the United States are also included in AbbVie’s cost of products sold. The following table shows the profit and cost sharing relationship between Genentech and AbbVie: years ended December 31 (in millions) 2024 2023 2022 Genentech's share of profits, including royalties (included in cost of products sold) $ 990 $ 869 $ 778 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 29 41 37 AbbVie's share of development costs (included in R&D) 84 109 121

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2022 $ 32,156 Foreign currency translation adjustments and other 137 Balance as of December 31, 2023 32,293 Additions (a) 2,951 Foreign currency translation adjustments and other (288) Balance as of December 31, 2024 $ 34,956 (a) Goodwill additions related to the acquisitions of ImmunoGen and Cerevel Therapeutics (see Note 5). The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of December 31, 2024 and 2023, there were no accumulated goodwill impairment losses. Intangible Assets, Net The following table summarizes intangible assets: 2024 2023 as of December 31 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 81,428 $ (28,253) $ 53,175 $ 75,142 $ (22,455) $ 52,687 License agreements 8,315 (6,624) 1,691 8,191 (5,571) 2,620 Total definite-lived intangible assets 89,743 (34,877) 54,866 83,333 (28,026) 55,307 Indefinite-lived intangible assets 5,202 — 5,202 303 — 303 Total intangible assets, net $ 94,945 $ (34,877) $ 60,068 $ 83,636 $ (28,026) $ 55,610 Definite-Lived Intangible Assets The increase in definite-lived intangible assets during 2024 was primarily due to the acquisition of ImmunoGen. The intangible assets will be amortized using the estimated pattern of economic benefit. See Note 5 for additional information regarding the acquisitions. In the fourth quarter of 2023, the company made a decision to reduce current sales and marketing investment related to both CoolSculpting, a body contouring technology for aesthetic nonsurgical fat reduction, and Liletta, an on-market women’s health product. Each of these strategic decisions contributed to significant decreases in the estimated future cash flows for the respective products and represented triggering events that required an evaluation of the underlying definite-lived intangible assets for impairment. The company used a discounted cash flow analysis for both products. For CoolSculpting, the fair value of $290 million was lower than the carrying value of $1.3 billion resulting in a partial impairment of both the gross and net carrying amount. For Liletta, the fair value of $241 million was lower than the carrying value of $561 million resulting in a partial impairment of both the gross and net carrying amount. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $1.4 billion to costs of products sold in the consolidated statement of earnings for the fourth quarter of 2023. In August 2023, as part of the Inflation Reduction Act of 2022, the company’s oncology product Imbruvica sold in the United States (U.S.) was included on the list of products subject to government-set prices by the Centers for Medicare & Medicaid Services. The selection resulted in a significant decrease in the estimated future cash flows for the product and represented a triggering event which required the company to evaluate the underlying definite-lived intangible asset for impairment. The company utilized a discounted cash flow analysis to determine the fair value of $1.9 billion, which was lower than the carrying value of $4.0 billion and resulted in a partial impairment of both the gross and net carrying amount as of August 29, 2023. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $2.1 billion to cost of products sold In September 2022, the company made a strategic decision to reduce ongoing sales and marketing investment related to Vuity, an on-market product to treat presbyopia. This strategic decision contributed to a significant decrease in the estimated future cash flows for the product and represented a triggering event which required the company to evaluate the underlying definite lived-intangible asset for impairment. The company utilized a discounted cash flow analysis to estimate the fair value of the intangible asset resulting in a full impairment of both the gross and net carrying amount. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $770 million to cost of products sold in the consolidated statement of earnings for the third quarter of 2022. Fair value measurements for the above evaluations were based on Level 3 inputs including estimated net revenues, cost of products sold, R&D costs, selling and marketing costs and discount rate. Definite-lived intangible assets are amortized over their estimated useful lives, which range between 1 to 16 years with an average of 12 years for developed product rights and 11 years for license agreements. Amortization expense was $7.6 billion in 2024, $7.9 billion in 2023 and $7.7 billion in 2022 and was included in cost of products sold in the consolidated statements of earnings. The anticipated annual amortization expense for definite-lived intangible assets recorded as of December 31, 2024 is as follows: (in billions) 2025 2026 2027 2028 2029 Anticipated annual amortization expense $ 7.3 $ 6.7 $ 6.1 $ 6.3 $ 5.7 Indefinite-Lived Intangible Assets Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. The increase in indefinite-lived intangible assets during 2024 was primarily due to the acquisitions of ImmunoGen and Cerevel Therapeutics. See Note 5 for additional information regarding the acquisitions. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist. In November 2024, the company announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale total score compared to the placebo group at week 6. The results of these trials represented a triggering event which required the company to evaluate the underlying indefinite-lived intangible asset for impairment which resulted in a significant decrease in the estimated future cash flows for the product. The company utilized a discounted cash flow analysis to determine the fair value of $2.4 billion, which was lower than the carrying value of $6.9 billion and resulted in a partial impairment of the intangible asset carrying amount as of November 11, 2024. The fair value measurement was based on Level 3 inputs including estimated net revenues, cost of products sold, R&D costs, selling and marketing costs and discount rates. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $4.5 billion to research and development expense During the first quarter of 2023, the company made a decision to revise the research and development plan for AGN-151607, a novel investigational neurotoxin for the prevention of postoperative atrial fibrillation in cardiac surgery patients. This decision contributed to a delay in the estimated timing of regulatory approval as well as a significant decrease in estimated future cash flows of the product and represented a triggering event which required the company to evaluate the underlying indefinite-lived intangible asset for impairment. The company utilized a discounted cash flow analysis to estimate the fair value which was below the carrying value of the intangible asset. Based on the revised cash flows, the company recorded a pre-tax impairment charge of $630 million to research and development

Restructuring Plans

Restructuring Plans	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring Plans	Restructuring Plans AbbVie continuously evaluates its operations to identify opportunities to optimize its manufacturing and R&D operations, commercial infrastructure and administrative costs and to respond to changes in its business environment. As a result, AbbVie management periodically approves individual restructuring plans to achieve these objectives. In 2024, 2023 and 2022, no such plans were individually significant. Restructuring charges recorded were $189 million in 2024, $132 million in 2023 and $241 million in 2022 and were primarily related to employee severance and contractual obligations. These charges were recorded in cost of products sold, R&D expense and SG&A expenses in the consolidated statements of earnings based on the classification of the affected employees or operations. The following table summarizes the cash activity in the restructuring reserve for 2024, 2023 and 2022: (in millions) Accrued balance as of December 31, 2021 $ 33 Charges 193 Payments and other adjustments (50) Accrued balance as of December 31, 2022 176 Charges 107 Payments and other adjustments (87) Accrued balance as of December 31, 2023 196 Charges 168 Payments and other adjustments (128) Accrued balance as of December 31, 2024 $ 236 Allergan Integration Plan Following the closing of the Allergan acquisition, AbbVie implemented an integration plan designed to reduce costs, integrate and optimize the combined organization and incurred total cumulative charges of $2.5 billion through 2023. These costs consisted of severance and employee benefit costs (cash severance, non-cash severance, including accelerated equity award compensation expense, retention and other termination benefits) and other integration expenses. The Allergan integration plan was substantially complete as of December 31, 2023 and the remaining accrual as of December 31, 2024 is not significant. The following table summarizes the charges associated with the Allergan acquisition integration plan: year ended December 31 (in millions) 2023 2022 Cost of products sold $ 89 $ 117 Research and development 7 23 Selling, general and administrative 192 399 Total charges $ 288 $ 539

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Leases AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. The following table summarizes the amounts and location of operating and finance leases on the consolidated balance sheets: as of December 31 (in millions) Balance sheet caption 2024 2023 Assets Operating Other assets $ 723 $ 744 Finance Property and equipment, net 33 35 Total lease assets $ 756 $ 779 Liabilities Operating Current Accounts payable and accrued liabilities $ 178 $ 166 Noncurrent Other long-term liabilities 697 735 Finance Current Current portion of long-term debt and finance lease obligations 17 15 Noncurrent Long-term debt and finance lease obligations 23 27 Total lease liabilities $ 915 $ 943 The following table summarizes the lease costs recognized in the consolidated statements of earnings: years ended December 31 (in millions) 2024 2023 2022 Operating lease cost $ 196 $ 189 $ 201 Short-term lease cost 65 28 67 Variable lease cost 86 88 71 Total lease cost $ 347 $ 305 $ 339 In December 2022, the company entered into an agreement to sublease a portion of its Madison, New Jersey office space through the end of the original lease maturity in 2030. As a result of this agreement, the company recognized an impairment loss on its right-of-use asset of $69 million and wrote-off the related leasehold improvements of $37 million. These losses were recorded in SG&A expense Sublease income and finance lease costs were insignificant in 2024, 2023 and 2022. The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases: years ended December 31 2024 2023 2022 Weighted-average remaining lease term (years) Operating 7 7 8 Finance 5 3 2 Weighted-average discount rate Operating 3.3 % 3.0 % 2.6 % Finance 4.2 % 3.6 % 1.5 % The following table presents supplementary cash flow information regarding the company's leases: years ended December 31 (in millions) 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 204 $ 214 $ 212 Right-of-use assets obtained in exchange for new operating lease liabilities 159 173 235 Finance lease cash flows were insignificant in 2024, 2023 and 2022. The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of December 31, 2024: (in millions) Operating Finance Total (a) 2025 $ 204 $ 18 $ 222 2026 182 15 197 2027 145 4 149 2028 118 2 120 2029 102 1 103 Thereafter 223 2 225 Total lease payments 974 42 1,016 Less: Interest 99 2 101 Present value of lease liabilities $ 875 $ 40 $ 915 (a) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
Leases	Leases AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. The following table summarizes the amounts and location of operating and finance leases on the consolidated balance sheets: as of December 31 (in millions) Balance sheet caption 2024 2023 Assets Operating Other assets $ 723 $ 744 Finance Property and equipment, net 33 35 Total lease assets $ 756 $ 779 Liabilities Operating Current Accounts payable and accrued liabilities $ 178 $ 166 Noncurrent Other long-term liabilities 697 735 Finance Current Current portion of long-term debt and finance lease obligations 17 15 Noncurrent Long-term debt and finance lease obligations 23 27 Total lease liabilities $ 915 $ 943 The following table summarizes the lease costs recognized in the consolidated statements of earnings: years ended December 31 (in millions) 2024 2023 2022 Operating lease cost $ 196 $ 189 $ 201 Short-term lease cost 65 28 67 Variable lease cost 86 88 71 Total lease cost $ 347 $ 305 $ 339 In December 2022, the company entered into an agreement to sublease a portion of its Madison, New Jersey office space through the end of the original lease maturity in 2030. As a result of this agreement, the company recognized an impairment loss on its right-of-use asset of $69 million and wrote-off the related leasehold improvements of $37 million. These losses were recorded in SG&A expense Sublease income and finance lease costs were insignificant in 2024, 2023 and 2022. The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases: years ended December 31 2024 2023 2022 Weighted-average remaining lease term (years) Operating 7 7 8 Finance 5 3 2 Weighted-average discount rate Operating 3.3 % 3.0 % 2.6 % Finance 4.2 % 3.6 % 1.5 % The following table presents supplementary cash flow information regarding the company's leases: years ended December 31 (in millions) 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 204 $ 214 $ 212 Right-of-use assets obtained in exchange for new operating lease liabilities 159 173 235 Finance lease cash flows were insignificant in 2024, 2023 and 2022. The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of December 31, 2024: (in millions) Operating Finance Total (a) 2025 $ 204 $ 18 $ 222 2026 182 15 197 2027 145 4 149 2028 118 2 120 2029 102 1 103 Thereafter 223 2 225 Total lease payments 974 42 1,016 Less: Interest 99 2 101 Present value of lease liabilities $ 875 $ 40 $ 915 (a) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

Debt, Credit Facilities and Com

Debt, Credit Facilities and Commitments and Contingencies	12 Months Ended
	Dec. 31, 2024
Debt, Credit Facilities and Commitments and Contingencies
Debt, Credit Facilities and Commitments and Contingencies	Debt, Credit Facilities and Commitments and Contingencies The following table summarizes long-term debt: as of December 31 (dollars in millions) 2024 Effective interest rate (a) 2024 2023 Effective interest rate (a) 2023 1.25-3.85% aggregate notes due 2024 0.65-2.69% $ — 0.65-2.69% $ 7,169 Floating rate term loans due 2025 6.22 % — 5.95 % 2,000 3.60% senior notes due 2025 3.66 % 3,750 3.66 % 3,750 3.80% senior notes due 2025 2.09 % 3,021 2.09 % 3,021 2.95% senior notes due 2026 3.02 % 4,000 3.02 % 4,000 3.20% senior notes due 2026 3.28 % 2,000 3.28 % 2,000 4.549% term loan due 2027 4.61 % 2,000 — — 0.75% senior euro notes due 2027 (€750 principal) 0.86 % 778 0.86 % 833 4.80% senior notes due 2027 4.93 % 2,250 — — 4.25% senior notes due 2028 4.38 % 1,750 4.38 % 1,750 2.125% senior euro notes due 2028 (€750 principal) 2.18 % 778 2.18 % 833 2.625% senior euro notes due 2028 (€500 principal) 1.20 % 519 1.20 % 555 3.20% senior notes due 2029 3.25 % 5,500 3.25 % 5,500 2.125% senior euro notes due 2029 (€550 principal) 1.19 % 570 1.19 % 611 4.80% senior notes due 2029 4.91 % 2,500 — — 1.25% senior euro notes due 2031 (€650 principal) 1.30 % 674 1.30 % 722 4.95% senior notes due 2031 5.02 % 2,000 — — 5.05% senior notes due 2034 5.13 % 3,000 — — 4.55% senior notes due 2035 3.52 % 1,789 3.52 % 1,789 4.50% senior notes due 2035 4.58 % 2,500 4.58 % 2,500 4.30% senior notes due 2036 4.37 % 1,000 4.37 % 1,000 4.05% senior notes due 2039 4.11 % 4,000 4.11 % 4,000 4.40% senior notes due 2042 4.46 % 2,600 4.46 % 2,600 4.625% senior notes due 2042 4.00 % 457 4.00 % 457 4.85% senior notes due 2044 4.11 % 1,074 4.11 % 1,074 5.35% senior notes due 2044 5.39 % 750 — — 4.70% senior notes due 2045 4.73 % 2,700 4.73 % 2,700 4.75% senior notes due 2045 4.20 % 881 4.20 % 881 4.45% senior notes due 2046 4.50 % 2,000 4.50 % 2,000 4.875% senior notes due 2048 4.94 % 1,750 4.94 % 1,750 4.25% senior notes due 2049 4.29 % 5,750 4.29 % 5,750 5.40% senior notes due 2054 5.44 % 3,000 — — 5.50% senior notes due 2064 5.53 % 1,500 — — Fair value hedges (224) (266) Unamortized bond discounts (130) (106) Unamortized deferred financing costs (266) (198) Unamortized bond premiums 555 668 Financing liability 328 — Other 40 42 Total long-term debt and finance lease obligations 67,144 59,385 Current portion 6,804 7,191 Noncurrent portion $ 60,340 $ 52,194 (a) Excludes the effect of any related interest rate swaps. Senior notes and floating rate term loans are redeemable prior to maturity at a redemption price equal to the principal amount plus a make-whole premium and AbbVie may redeem these debt securities at par generally between one and six months prior to maturity. At December 31, 2024, the company was in compliance with its senior note covenants and term loan covenants. Maturities of Long-Term Debt as of and for the years ending December 31 (in millions) 2025 $ 6,771 2026 6,000 2027 5,028 2028 3,047 2029 8,570 Thereafter 37,425 Total obligations and commitments 66,841 Fair value hedges, unamortized bond premiums/discounts, deferred financing costs, finance lease obligations and financing liability 303 Total long-term debt and finance lease obligations $ 67,144 Financing Related to ImmunoGen and Cerevel Therapeutics Acquisitions In connection with the acquisitions of ImmunoGen and Cerevel Therapeutics, in February 2024, the company issued $15.0 billion aggregate principal amount of unsecured senior notes. The notes are unsecured, unsubordinated obligations of AbbVie and will rank equally in right of payment with all of AbbVie’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations. AbbVie may redeem the fixed-rate senior notes prior to maturity at a redemption price equal to the greater of the principal amount or the sum of present values of the remaining scheduled payments of principal and interest on the fixed-rate senior notes to be redeemed plus a make-whole premium. AbbVie may also redeem the fixed-rate senior notes at par between one and six months prior to maturity. In connection with the offering, debt issuance costs incurred totaled $99 million and debt discounts totaled $37 million, which are being amortized over the respective terms of the notes to interest expense, net in the consolidated statements of earnings. AbbVie used the net proceeds received from the issuance of the notes to finance the acquisition of ImmunoGen, repay its term-loan, repay commercial paper borrowings, pay fees and expenses in respect of the foregoing, finance general corporate purposes and, together with cash on hand, fund AbbVie’s acquisition of Cerevel Therapeutics. See Note 5 for additional information. In December 2023, AbbVie entered into a $9.0 billion 364-day bridge credit agreement and $5.0 billion 364-day term loan credit agreement. In February 2024, AbbVie borrowed and repaid $5.0 billion under the term loan credit agreement. Interest charged on this borrowing was based on Secured Overnight Financing Rate Reference Rate (SOFR) +0.975% with an effective interest rate of 6.29%. Subsequent to the $15.0 billion issuance of senior notes, AbbVie terminated both the bridge and term loan credit agreements in the first quarter of 2024. In February 2024, concurrent with the ImmunoGen acquisition, the company assumed and repaid an ImmunoGen senior secured term loan at a fair value of $99 million. In connection with the acquisition of Cerevel Therapeutics, the company assumed $345 million aggregate principal of 2.5% convertible senior notes due 2027. Upon acquisition, the convertible senior notes became callable and note holders could redeem the convertible senior notes for cash at a premium. As of the acquisition date, the convertible senior notes were recognized as current portion of long-term debt on the consolidated balance sheets at an aggregate fair value of $400 million. Following the acquisition date, the company repaid the convertible senior notes and there were no amounts outstanding as of December 31, 2024. The company also assumed funding agreements entered into by Cerevel Therapeutics prior to the acquisition. Under the agreements, Cerevel Therapeutics received funding to support development of tavapadon and agreed to repay regulatory milestones, sales milestones and royalties contingent upon approval of tavapadon by the U.S. Food and Drug Administration (FDA). In addition, upon acquisition the company has the option to satisfy payment obligations early by making a payment equal to the amount of funding provided to Cerevel Therapeutics plus a variable premium. In all circumstances, total repayments under the funding agreements will not exceed $531 million in aggregate. The funding agreements were accounted for as financing arrangements and the fair value of the related financing liability was $246 million as of the acquisition date. In conjunction with the funding agreements, AbbVie also assumed security agreements entered into by Cerevel Therapeutics prior to the acquisition pursuant to which Cerevel Therapeutics granted the funding investors a security interest in the assets material to the development and commercialization of tavapadon in the United States. Repayment and Issuance of Long-Term Debt In 2024, the company repaid $3.8 billion aggregate principal amount of 2.60% senior notes, €1.5 billion aggregate principal amount of 1.38% senior euro notes, €700 million aggregate principal amount of 1.25% senior euro notes and $1.0 billion aggregate principal amount of 3.85% senior notes. During the quarter ended December 31, 2024, the company refinanced its $2.0 billion floating rate three-year term loan. As part of the refinancing, the company repaid the existing $2.0 billion term loan due May 2025 and borrowed $2.0 billion under a new term loan due April 2027 at a fixed rate of 4.549%. These term notes rank equally with all other unsecured and unsubordinated indebtedness of the company. AbbVie may redeem the fixed-rate term notes between fifteen and twenty-one months at a redemption price equal to the notional amount plus one percent make whole amount and can be redeemed at par after twenty-one months. All other significant terms of the loan remained unchanged after the refinancing. In 2023, the company repaid a $1.0 billion floating rate three-year term loan, $350 million aggregate principal amount of 2.80% senior notes and $1.0 billion aggregate principal amount of 2.85% senior notes at maturity. During the quarter ended December 31, 2023, the company also repaid €500 million aggregate principal amount of 1.50% senior euro notes and $1.3 billion aggregate principal amount of 3.75% senior notes at maturity. Short-Term Borrowings During the twelve months ended December 31, 2024, AbbVie issued and redeemed $7.7 billion of commercial paper. Subsequent to December 31, 2024, AbbVie issued commercial paper borrowings of which $3.3 billion were outstanding as of date of filing of this Annual Report on Form 10-K. There were no commercial paper borrowings outstanding as of December 31, 2024 and December 31, 2023. The weighted average interest rate on commercial paper borrowings was 4.91% for the twelve months ended December 31, 2024. AbbVie currently has an existing $5.0 billion five-year revolving credit facility that matures in March 2028. Subsequent to December 31, 2024, in addition to the existing revolving credit facility, AbbVie entered into a new $3.0 billion five-year revolving credit facility that matures in January 2030. The revolving credit facilities enable the company to borrow funds on an unsecured basis at variable interest rates and contain various covenants. At December 31, 2024, the company was in compliance with all covenants and commitment fees under the credit facility were insignificant. No amounts were outstanding under the company's credit facilities as of December 31, 2024 and December 31, 2023. Contingencies and Guarantees In connection with the separation, AbbVie has indemnified Abbott for all liabilities resulting from the operation of AbbVie's business other than income tax liabilities with respect to periods prior to the distribution date and other liabilities as agreed to by AbbVie and Abbott. AbbVie has no material exposures to off-balance sheet arrangements and no special-purpose entities. In the ordinary course of business, AbbVie has periodically entered into third-party agreements, such as the assignment of product rights, which have resulted in AbbVie becoming secondarily liable for obligations for which AbbVie had previously been primarily liable. Based upon past experience, the likelihood of payments under these agreements is remote.

Financial Instruments and Fair

Financial Instruments and Fair Value Measures	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measures	Financial Instruments and Fair Value Measures Risk Management Policy The company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. AbbVie's hedging policy attempts to manage these risks to an acceptable level based on the company's judgment of the appropriate trade-off between risk, opportunity and costs. The company uses derivative and nonderivative instruments to reduce its exposure to foreign currency exchange rates. AbbVie also periodically enters into interest rate swaps in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. Derivative instruments are not used for trading purposes or to manage exposure to changes in interest rates for investment securities, and none of the company's outstanding derivative instruments contain credit risk related contingent features; collateral is generally not required. Financial Instruments Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling In 2019, the company entered into treasury rate lock agreements with notional amounts totaling $10.0 billion to hedge exposure to variability in future cash flows resulting from changes in interest rates related to the issuance of long-term debt in connection with the acquisition of Allergan. The treasury rate lock agreements were designated as cash flow hedges and recorded at fair value. The agreements were net settled upon issuance of the senior notes in 2019 and the resulting net gain was included in AOCI. This gain is reclassified to interest expense, net over the term of the related debt. The company was a party to interest rate swap contracts designated as cash flow hedges that matured in November 2022. The effect of the hedge contracts was to change a floating-rate interest obligation to a fixed rate for that portion of the floating-rate debt. Realized and unrealized gains or losses were included in AOCI and reclassified to interest expense, net over the lives of the floating-rate debt. In June 2023, the company entered into a cross-currency swap contract that matured in November 2023 with a notional amount totaling €433 million to hedge the company’s exposure to changes in future cash flows of foreign currency denominated debt related to changes in foreign exchange rates. The cross-currency swap contract was designated as a cash flow hedge and effectively converted the interest and principal payments of the related foreign currency denominated debt to U.S. dollars. The unrealized gains and losses on the contract were included in AOCI and reclassified to net foreign exchange loss over the term of the related debt. The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated debt, trade payables, receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gains or loss in the consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $5.9 billion at December 31, 2024 and $7.9 billion at December 31, 2023. The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company had an aggregate principal amount of senior Euro notes designated as net investment hedges of €3.1 billion at December 31, 2024 and €5.4 billion December 31, 2023. In addition, the company had foreign currency forward exchange contracts designated as net investment hedges with notional amounts totaling €6.2 billion, SEK1.4 billion, CAD500 million and CHF50 million at December 31, 2024 and €4.9 billion, SEK1.4 billion, CAD750 million and CHF50 million at December 31, 2023. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument. The company is a party to interest rate swap contracts designated as fair value hedges with notional amounts totaling $3.5 billion at December 31, 2024 and $5.0 billion at December 31, 2023. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges. The following table summarizes the amounts and location of AbbVie's derivative instruments on the consolidated balance sheets: Fair value - Derivatives in asset position Fair value - as of December 31 (in millions) Balance sheet caption 2024 2023 Balance sheet caption 2024 2023 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 119 $ 12 Accounts payable and accrued liabilities $ 5 $ 32 Designated as net investment hedges Prepaid expenses and other 4 13 Accounts payable and accrued liabilities — 66 Designated as net investment hedges Other assets 148 — Other long-term liabilities — 69 Not designated as hedges Prepaid expenses and other 42 41 Accounts payable and accrued liabilities 30 36 Interest rate swap contracts Designated as fair value hedges Other assets — — Other long-term liabilities 231 293 Total derivatives $ 313 $ 66 $ 266 $ 496 While certain derivatives are subject to netting arrangements with the company's counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheets. The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss): years ended in December 31 (in millions) 2024 2023 2022 Foreign currency forward exchange contracts Designated as cash flow hedges $ 192 $ (2) $ 103 Designated as net investment hedges 435 (144) 395 Cross-currency swap contracts designated as cash flow hedges — (6) — Interest rate swap contracts designated as cash flow hedges — — 6 Assuming market rates remain constant through contract maturities, the company expects to reclassify pre-tax gains of $126 million into cost of products sold for foreign currency cash flow hedges and pre-tax gains of $21 million into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months. Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) pre-tax gains of $305 million in 2024, pre-tax losses of $252 million in 2023 and pre-tax gains of $406 million in 2022. The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 13 for the amount of net gains (losses) reclassified out of AOCI. years ended December 31 (in millions) Statement of earnings caption 2024 2023 2022 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 73 $ 77 $ 82 Designated as net investment hedges Interest expense, net 123 112 94 Not designated as hedges Net foreign exchange loss 6 33 (156) Treasury rate lock agreements designated as cash flow hedges Interest expense, net 23 24 23 Cross-currency swap contracts designated as cash flow hedges Net foreign exchange loss — (6) — Interest rate swap contracts Designated as cash flow hedges Interest expense, net — — (1) Designated as fair value hedges Interest expense, net 62 98 (402) Debt designated as hedged item in fair value hedges Interest expense, net (62) (98) 402 Fair Value Measures The fair value hierarchy consists of the following three levels: • Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access; • Level 2—Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and • Level 3—Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company's management about the assumptions market participants would use in pricing the asset or liability. The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2024: Basis of fair value measurement (in millions) Total Quoted prices in active markets for Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 5,524 $ 5,179 $ 345 $ — Money market funds and time deposits 10 — 10 — Debt securities 33 — 33 — Equity securities 98 70 28 — Foreign currency contracts 313 — 313 — Total assets $ 5,978 $ 5,249 $ 729 $ — Liabilities Interest rate swap contracts $ 231 $ — $ 231 $ — Foreign currency contracts 35 — 35 — Financing liability 328 — — 328 Contingent consideration 21,666 — — 21,666 Total liabilities $ 22,260 $ — $ 266 $ 21,994 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2023: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 12,814 $ 6,223 $ 6,591 $ — Money market funds and time deposits 10 — 10 — Debt securities 26 — 26 — Equity securities 111 86 25 — Foreign currency contracts 66 — 66 — Total assets $ 13,027 $ 6,309 $ 6,718 $ — Liabilities Interest rate swap contracts $ 293 $ — $ 293 $ — Foreign currency contracts 203 — 203 — Contingent consideration 19,890 — — 19,890 Total liabilities $ 20,386 $ — $ 496 $ 19,890 Money market funds and time deposits are valued using relevant observable market inputs including quoted prices for similar assets and interest rate curves. Equity securities primarily consist of investments for which the fair values were determined by using the published market prices per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using observable market inputs including published interest rate curves and both forward and spot prices for foreign currencies. The financing liability is related to funding agreements entered into by Cerevel Therapeutics prior to the acquisition and assumed by AbbVie. The funding agreements represent financial instruments that are accounted for as financing arrangements and the company elected to account for the financing liability in accordance with the fair value option, as permitted under ASC 825 Financial Instruments . The fair value measurement of the financing liability was determined based on significant unobservable inputs. Potential payments are estimated by applying a probability-weighted expected payment model for regulatory milestone payments and a Monte Carlo simulation model for sales milestones and royalty payments, which are then discounted to present value. Changes to the fair value of the financing liability can result from changes to one or a number of inputs, including discount rates, estimated probabilities and timing of achieving milestones and estimated amounts of future sales. The change in fair value recognized in net earnings is recorded in other expense, net in the consolidated statements of earnings and included a charge of $82 million in 2024. The change in fair value attributable to instrument-specific credit risk is recognized in other comprehensive loss and was not significant. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. The potential contingent consideration payments are estimated by applying a probability-weighted expected payment model for contingent milestone payments and a Monte Carlo simulation model for contingent royalty payments, which are then discounted to present value. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of certain of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs: 2024 2023 years ended December 31 (in millions) Range Weighted Average (a) Range Weighted Average (a) Discount rate 4.6% - 5.2% 4.8% 4.3% - 5.9% 4.5 % Probability of payment for royalties by indication (b) 100% 100% 89% - 100% 99 % Projected year of payments 2025 - 2034 2029 2024 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excluding approved indications, the estimated probability of payment was 89% at December 31, 2023. There have been no transfers of assets or liabilities into or out of Level 3 of the fair value hierarchy. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: years ended December 31 (in millions) 2024 2023 2022 Beginning balance $ 19,890 $ 16,384 $ 14,887 Additions (a) — — 32 Change in fair value recognized in net earnings 3,771 5,128 2,761 Payments (1,995) (1,622) (1,296) Ending balance $ 21,666 $ 19,890 $ 16,384 (a) Additions during the year ended December 31, 2022, represent contingent consideration liabilities assumed in the DJS acquisition. The change in fair value recognized in net earnings is recorded in other expense, net in the consolidated statements of earnings and included charges of $3.8 billion in 2024, $5.1 billion in 2023 and $2.8 billion in 2022. In 2024, the change in fair value reflected higher estimated Skyrizi sales and the passage of time, partially offset by higher discount rates. In 2023, the change in fair value reflected higher estimated Skyrizi sales driven by stronger market share uptake, the passage of time and lower discount rates. In 2022, the change in fair value reflected higher estimated Skyrizi sales driven by stronger market share uptake and the passage of time, partially offset by higher discount rates. Contingent consideration payments of amounts up to the initial acquisition date fair value are classified as cash outflows from financing activities and payments of amounts in excess of the initial acquisition date fair value are classified as cash outflows from operating activities in the consolidated statements of cash flows. Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2024 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair values Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 6,797 $ 6,767 $ 6,620 $ 147 $ — Long-term debt and finance lease obligations, excluding fair value hedges and financing liability 60,243 55,836 53,441 2,395 — Total liabilities $ 67,040 $ 62,603 $ 60,061 $ 2,542 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2023 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair values Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 7,191 $ 7,069 $ 6,862 $ 207 $ — Long-term debt and finance lease obligations, excluding fair value hedges 52,460 49,541 48,983 558 — Total liabilities $ 59,651 $ 56,610 $ 55,845 $ 765 $ — AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $169 million as of December 31, 2024 and $159 million as of December 31, 2023. No significant cumulative upward or downward adjustments have been recorded for these investments as of December 31, 2024. Concentrations of Risk Of total net accounts receivable, three U.S. wholesalers accounted for 81% as of December 31, 2024 and December 31, 2023, and substantially all of AbbVie's pharmaceutical product net revenues in the United States were to these three wholesalers.	[1]
[1] Additions during the year ended December 31, 2022, represent contingent consideration liabilities assumed in the DJS acquisition.

Post-Employment Benefits

Post-Employment Benefits	12 Months Ended
	Dec. 31, 2024
Postemployment Benefits [Abstract]
Post-Employment Benefits	Post-Employment Benefits AbbVie sponsors various pension and other post-employment benefit plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. In addition, AbbVie provides medical benefits, primarily to eligible retirees in the United States and Puerto Rico, through other post-retirement benefit plans. Net obligations for these plans have been reflected on the consolidated balance sheets as of December 31, 2024 and 2023. The following table summarizes benefit plan information for the global AbbVie-sponsored defined benefit and other post-employment plans: Defined benefit plans Other post-employment plans as of and for the years ended December 31 (in millions) 2024 2023 2024 2023 Projected benefit obligations Beginning of period $ 9,544 $ 8,588 $ 796 $ 667 Service cost 286 270 43 37 Interest cost 451 432 41 37 Actuarial (gain) loss (855) 491 (62) 89 Benefits paid (347) (316) (31) (35) Other, primarily foreign currency translation adjustments (115) 79 (1) 1 End of period 8,964 9,544 786 796 Fair value of plan assets Beginning of period 9,839 8,472 — — Actual return on plan assets 865 1,230 — — Company contributions 326 366 31 35 Benefits paid (347) (316) (31) (35) Other, primarily foreign currency translation adjustments (132) 87 — — End of period 10,551 9,839 — — Funded status, end of period $ 1,587 $ 295 $ (786) $ (796) Amounts recognized on the consolidated balance sheets Other assets $ 2,097 $ 1,086 $ — $ — Accounts payable and accrued liabilities (20) (17) (42) (32) Other long-term liabilities (490) (774) (744) (764) Net asset (obligation) $ 1,587 $ 295 $ (786) $ (796) Actuarial loss, net $ 1,303 $ 2,290 $ 203 $ 282 Prior service cost (credit) 1 1 (261) (297) Accumulated other comprehensive loss (income) $ 1,304 $ 2,291 $ (58) $ (15) Related to international defined benefit plans the projected benefit obligations in the table above included $2.2 billion at December 31, 2024 and $2.4 billion at December 31, 2023. For plans reflected in the table above, the accumulated benefit obligations were $8.1 billion at December 31, 2024 and $8.6 billion at December 31, 2023. The 2024 actuarial gain of $855 million for qualified pension plans and actuarial gain of $62 million for other post-employment plans were primarily driven by an increase in the discount rate. The 2023 actuarial loss of $491 million for qualified pension plans and actuarial loss of $89 million for other post-employment plans were primarily driven by a decrease in the discount rate and changes to experience impact and medical trends assumptions. Information For Pension Plans With An Accumulated Benefit Obligation In Excess Of Plan Assets as of December 31 (in millions) 2024 2023 Accumulated benefit obligation $ 527 $ 1,410 Fair value of plan assets 94 890 Information For Pension Plans With A Projected Benefit Obligation In Excess Of Plan Assets as of December 31 (in millions) 2024 2023 Projected benefit obligation $ 775 $ 6,343 Fair value of plan assets 265 5,552 Amounts Recognized in Other Comprehensive Income (Loss) The following table summarizes the pre-tax losses (gains) included in other comprehensive income (loss): years ended December 31 (in millions) 2024 2023 2022 Defined benefit plans Actuarial gain $ (935) $ (16) $ (925) Amortization of prior service cost — (1) (2) Amortization of actuarial loss (52) (16) (231) Foreign exchange loss (gain) and other — (44) 17 Total gain $ (987) $ (77) $ (1,141) Other post-employment plans Actuarial loss (gain) $ (62) $ 89 $ (229) Prior service credit — — (2) Amortization of prior service credit 36 36 38 Amortization of actuarial loss (17) (12) (26) Total loss (gain) $ (43) $ 113 $ (219) Net Periodic Benefit Cost years ended December 31 (in millions) 2024 2023 2022 Defined benefit plans Service cost $ 286 $ 270 $ 454 Interest cost 451 432 297 Expected return on plan assets (785) (723) (712) Amortization of prior service cost — 1 2 Amortization of actuarial loss 52 16 231 Net periodic benefit cost (credit) $ 4 $ (4) $ 272 Other post-employment plans Service cost $ 43 $ 37 $ 51 Interest cost 41 37 23 Amortization of prior service credit (36) (36) (38) Amortization of actuarial loss 17 12 26 Net periodic benefit cost $ 65 $ 50 $ 62 The components of net periodic benefit cost other than service cost are included in other expense, net in the consolidated statements of earnings. Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date as of December 31 2024 2023 Defined benefit plans Discount rate 5.4 % 4.8 % Rate of compensation increases 4.4 % 4.8 % Cash balance interest crediting rate 4.0 % 4.4 % Other post-employment plans Discount rate 5.7 % 5.1 % The assumptions used in calculating the December 31, 2024 measurement date benefit obligations will be used in the calculation of net periodic benefit cost in 2025. Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost years ended December 31 2024 2023 2022 Defined benefit plans Discount rate for determining service cost 4.8 % 5.0 % 3.0 % Discount rate for determining interest cost 4.8 % 4.9 % 2.6 % Expected long-term rate of return on plan assets 7.5 % 7.3 % 7.1 % Expected rate of change in compensation 4.4 % 4.8 % 5.2 % Cash balance interest crediting rate 4.4 % 2.7 % 2.7 % Other post-employment plans Discount rate for determining service cost 5.2 % 5.3 % 3.3 % Discount rate for determining interest cost 4.9 % 5.1 % 2.7 % For the December 31, 2024 post-retirement health care obligations remeasurement, the company assumed a 6.6% pre-65 (2.0% post-65) annual rate of increase in the per capita cost of covered health care benefits. The pre-65 rate was assumed to decrease gradually to 4.5% (1.8% post-65) in 2033 and remain at that level thereafter. For purposes of measuring the 2024 post-retirement health care costs, the company assumed a 7.4% pre-65 (2.1% post-65) annual rate of increase in the per capita cost of covered health care benefits. The pre-65 rate was assumed to decrease gradually to 4.5% (1.8% post-65) for 2032 and remain at that level thereafter. Defined Benefit Pension Plan Assets Basis of fair value measurement as of December 31 (in millions) 2024 Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs (Level 3) Equities U.S. large cap (a) $ 1,131 $ 1,131 $ — $ — U.S. mid cap (b) 176 176 — — International (c) 408 408 — — Fixed income securities U.S. government securities (d) 414 18 396 — Corporate debt instruments (d) 609 29 580 — Non-U.S. government securities (d) 346 183 163 — Other (d) 20 15 5 — Absolute return funds (e) 176 82 94 — Other (f) 351 350 1 — Total $ 3,631 $ 2,392 $ 1,239 $ — Total assets measured at NAV 6,920 Fair value of plan assets $ 10,551 Basis of fair value measurement as of December 31 (in millions) 2023 Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Equities U.S. large cap (a) $ 1,018 $ 1,018 $ — $ — U.S. mid cap (b) 173 173 — — International (c) 488 488 — — Fixed income securities U.S. government securities (d) 246 62 184 — Corporate debt instruments (d) 714 155 559 — Non-U.S. government securities (d) 461 301 160 — Other (d) 126 124 2 — Absolute return funds (e) 155 66 89 — Other (f) 414 413 1 — Total $ 3,795 $ 2,800 $ 995 $ — Total assets measured at NAV 6,044 Fair value of plan assets $ 9,839 (a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices. (b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid cap indices. (c) A mix of index funds and actively managed equity accounts that are benchmarked to various non-U.S. equity indices in both developed and emerging markets. (d) Securities held by actively managed accounts, index funds and mutual funds. (e) Primarily funds having global mandates with the flexibility to allocate capital broadly across a wide range of asset classes and strategies, including but not limited to equities, fixed income, commodities, financial futures, currencies and other securities, with objectives to outperform agreed upon benchmarks of specific return and volatility targets. (f) Investments in cash and cash equivalents. Equities and registered investment companies having quoted prices are valued at the published market prices. Fixed income securities that are valued using significant other observable inputs are quoted at prices obtained from independent financial service industry-recognized vendors. Investments held in pooled investment funds, common collective trusts or limited partnerships are valued at the net asset value (NAV) practical expedient to estimate fair value. The NAV is provided by the fund administrator and is based on the value of the underlying assets owned by the fund minus its liabilities. The investment mix of equity securities, fixed income and other asset allocation strategies is based upon achieving a desired return, balancing higher return, more volatile equity securities and lower return, less volatile fixed income securities. Investment allocations are established for each plan and are generally made across a range of markets, industry sectors, capitalization sizes and in the case of fixed income securities, maturities and credit quality. The 2024 target investment allocation for the AbbVie Pension Plan was 62.5% in equity securities, 22.5% in fixed income securities and 15% in asset allocation strategies and other holdings. There are no known significant concentrations of risk in the plan assets of the AbbVie Pension Plan or of any other plans. The expected return on plan assets assumption for each plan is based on management's expectations of long-term average rates of return to be achieved by the underlying investment portfolio. In establishing this assumption, management considers historical and expected returns for the asset classes in which the plans are invested, as well as current economic and capital market conditions. Expected Benefit Payments The following table summarizes total benefit payments expected to be paid to plan participants including payments funded from both plan and company assets: years ending December 31 (in millions) Defined Other 2025 $ 363 $ 42 2026 383 46 2027 410 49 2028 435 53 2029 464 57 2030 to 2034 3,007 330 Defined Contribution Plan AbbVie maintains defined contribution savings plans for the benefit of its eligible employees. The expense recognized for these plans was $425 million in 2024, $398 million in 2023 and $474 million in 2022. AbbVie provides certain other post-employment benefits, primarily salary continuation arrangements, to qualifying employees and accrues for the related cost over the service lives of the employees.

Equity

Equity	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Equity	Equity Stock-Based Compensation In May 2021, stockholders of the company approved the AbbVie Amended and Restated 2013 Incentive Stock Program (the Amended Plan), which amends and restates the AbbVie 2013 Incentive Stock Program (2013 ISP). AbbVie grants stock-based awards to eligible employees pursuant to the Amended Plan, which provides for several different forms of benefits, including non-qualified stock options, RSUs and various performance-based awards. Under the Amended Plan, a total of 144 million shares of AbbVie common stock have been reserved for issuance as awards to AbbVie employees. AbbVie measures compensation expense for stock-based awards based on the grant date fair value of the awards and the estimated number of awards that are expected to vest. Forfeitures are estimated based on historical experience at the time of grant and are revised in subsequent periods if actual forfeitures differ from those estimates. Compensation cost for stock-based awards is amortized over the service period, which could be shorter than the vesting period if an employee is retirement eligible. Retirement eligible employees generally are those who are age 55 or older and have at least 10 years of service. Stock-based compensation expense is principally related to awards issued pursuant to the 2013 ISP and the Amended Plan and is summarized as follows: years ended December 31 (in millions) 2024 2023 2022 Cost of products sold $ 55 $ 46 $ 38 Research and development 341 278 232 Selling, general and administrative 515 423 401 Pre-tax compensation expense 911 747 671 Tax benefit 159 136 122 After-tax compensation expense $ 752 $ 611 $ 549 Realized excess tax benefits associated with stock-based compensation totaled $84 million in 2024, $90 million in 2023 and $116 million in 2022. In addition to stock-based compensation expense included in the table above and in connection with the acquisitions of ImmunoGen and Cerevel Therapeutics, AbbVie incurred cash-settled, post-closing expense for ImmunoGen and Cerevel Therapeutics employee incentive awards, which is summarized in the table below: year ended December 31 (in millions) 2024 Cost of products sold $ 36 Research and development 184 Selling, general and administrative 290 Total post-closing cash settled expense $ 510 Stock Options Stock options awarded to employees typically have a contractual term of 10 years and generally vest in one-third increments over a 3-year period. The exercise price is equal to at least 100% of the market value on the date of grant. The fair value is determined using the Black-Scholes model. The weighted-average grant-date fair values of stock options granted were $31.53 in 2024, $29.89 in 2023 and $22.83 in 2022. The following table summarizes AbbVie stock option activity in 2024: (options in thousands, aggregate intrinsic value in millions) Options Weighted- average Weighted-average remaining Aggregate intrinsic value Outstanding at December 31, 2023 7,481 $ 102.80 5.0 $ 390 Granted 648 175.26 Exercised (2,420) 89.01 Lapsed and forfeited (96) 81.16 Outstanding at December 31, 2024 5,613 $ 117.48 5.6 $ 338 Exercisable at December 31, 2024 4,295 $ 104.07 4.7 $ 316 The total intrinsic value of options exercised was $202 million in 2024, $189 million in 2023 and $295 million in 2022. The total fair value of options vested during 2024 was $18 million. As of December 31, 2024, $6 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years. RSUs and Performance Shares RSUs awarded to employees other than senior executives and other key employees generally vest in ratable increments over a three The majority of the equity awards AbbVie grants to its senior executives and other key employees are performance-based. Equity awards granted to senior executives and other key employees consist of a combination of performance-vested RSUs and performance shares as well as non-qualified stock options described above. The performance-vested RSUs have the potential to vest in one-third increments during a three-year performance period and may be earned based on AbbVie’s return on invested capital (ROIC) performance relative to a defined peer group of pharmaceutical, biotech and life science companies. The recipient may receive one share of AbbVie common stock for each vested award. The performance shares have the potential to vest over a three-year performance period and may be earned based on AbbVie’s EPS achievement and AbbVie’s total stockholder return (TSR) (a market condition) relative to a defined peer group of pharmaceutical, biotech and life sciences companies. Dividend equivalents on performance-vested RSUs and performance shares accrue during the performance period and are payable at vesting only to the extent that shares are earned. The weighted-average grant-date fair value of RSUs and performance shares generally is determined based on the number of shares/units granted and the quoted price of AbbVie’s common stock on the date of grant. The weighted-average grant-date fair values of performance shares with a TSR market condition are determined using the Monte Carlo simulation model. The following table summarizes AbbVie RSU and performance share activity for 2024: (share units in thousands) Share units Weighted-average grant date fair value Outstanding at December 31, 2023 10,739 $ 136.42 Granted 5,558 168.62 Granted in acquisitions 605 168.24 Vested (6,052) 128.28 Forfeited (463) 152.79 Outstanding at December 31, 2024 10,387 $ 159.52 The fair market value of RSUs and performance shares (as applicable) vested was $1.1 billion in 2024, $1.0 billion in 2023 and $1.0 billion in 2022. In connection with the ImmunoGen and Cerevel Therapeutics acquisitions, AbbVie issued 0.6 million RSUs to holders of ImmunoGen and Cerevel Therapeutics equity awards based on a conversion factor described in each of the transaction agreements. See Note 5 for additional information regarding the ImmunoGen and Cerevel Therapeutics acquisitions. As of December 31, 2024, $655 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years. Cash Dividends Cash dividends declared per common share totaled $6.29 in 2024, $5.99 in 2023 and $5.71 in 2022. The following table summarizes quarterly cash dividends declared during 2024, 2023 and 2022: 2024 2023 2022 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 10/30/24 02/14/25 $1.64 10/26/23 02/15/24 $1.55 10/28/22 02/15/23 $1.48 09/06/24 11/15/24 $1.55 09/08/23 11/15/23 $1.48 09/09/22 11/15/22 $1.41 06/21/24 08/15/24 $1.55 06/22/23 08/15/23 $1.48 06/23/22 08/15/22 $1.41 02/15/24 05/15/24 $1.55 02/16/23 05/15/23 $1.48 02/17/22 05/16/22 $1.41 Stock Repurchase Program The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management’s discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses and are available for general corporate purposes. On February 16, 2023, AbbVie's board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization. AbbVie repurchased 7 million shares for $1.3 billion in 2024, 10 million shares for $1.6 billion in 2023 and 8 million shares for $1.1 billion in 2022. AbbVie's remaining stock repurchase authorization was $3.5 billion as of December 31, 2024. Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2024, 2023 and 2022: (in millions) (brackets denote losses) Foreign currency translation adjustments Net investment hedging activities Pension Cash flow hedging activities Total Balance as of December 31, 2021 $ (570) $ (91) $ (2,546) $ 308 $ (2,899) Other comprehensive income (loss) before reclassifications (943) 629 915 91 692 Net losses (gains) reclassified from accumulated other comprehensive loss — (74) 173 (91) 8 Net current-period other comprehensive income (loss) (943) 555 1,088 — 700 Balance as of December 31, 2022 (1,513) 464 (1,458) 308 (2,199) Other comprehensive income (loss) before reclassifications 407 (311) (23) (10) 63 Net gains reclassified from accumulated other comprehensive loss — (88) (7) (74) (169) Net current-period other comprehensive income (loss) 407 (399) (30) (84) (106) Balance as of December 31, 2023 (1,106) 65 (1,488) 224 (2,305) Other comprehensive income (loss) before reclassifications (1,008) 580 799 155 526 Net losses (gains) reclassified from accumulated other comprehensive loss — (96) 25 (75) (146) Net current-period other comprehensive income (loss) (1,008) 484 824 80 380 Balance as of December 31, 2024 $ (2,114) $ 549 $ (664) $ 304 $ (1,925) Other comprehensive income (loss) for 2024 included pension and post-employment benefit plan gains of $824 million primarily due to actuarial gains driven by higher discount rates. Other comprehensive income (loss) for 2024 also included foreign currency translation adjustments totaling losses of $1.0 billion principally due to the impact of the weakening of the Euro on the translation of the company's Euro-denominated assets and the offsetting impact of net investment hedging activities totaling gains of $484 million. Other comprehensive income (loss) for 2023 included foreign currency translation adjustments totaling gains of $407 million principally due to the impact of the strengthening of the Euro on the translation of the company’s Euro-denominated assets and the offsetting impact of net investment hedging activities totaling losses of $399 million. Other comprehensive income for 2022 included pension and post-employment benefit plan gains of $1.1 billion primarily due to actuarial gains driven by higher discount rates partially offset by losses on plan assets. Other comprehensive income (loss) for 2022 also included foreign currency translation adjustments totaling losses of $943 million principally due to the impact of the weakening of the Euro on the translation of the company's Euro-denominated assets and the offsetting impact of net investment hedging activities totaling gains of $555 million. The table below presents the impact on AbbVie's consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: years ended December 31 (in millions) (brackets denote gains) 2024 2023 2022 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (123) $ (112) $ (94) Tax expense 27 24 20 Total reclassifications, net of tax $ (96) $ (88) $ (74) Pension and post-employment benefits Amortization of actuarial losses (gains) and other (b) $ 33 $ (7) $ 221 Tax benefit (8) — (48) Total reclassifications, net of tax $ 25 $ (7) $ 173 Cash flow hedging activities Gains on foreign currency forward exchange contracts (c) $ (73) $ (77) $ (82) Gains on treasury rate lock agreements (a) (23) (24) (23) Losses on interest rate swap contracts (a) — — 1 Losses on cross-currency swap contracts (d) — 6 — Tax expense 21 21 13 Total reclassifications, net of tax $ (75) $ (74) $ (91) (a) Amounts are included in interest expense, net (see Note 11). (b) Amounts are included in the computation of net periodic benefit cost (see Note 12). (c) Amounts are included in cost of products sold (see Note 11). (d) Amounts are included in net foreign exchange loss (see Note 11). Other In addition to common stock, AbbVie's authorized capital includes 200 million shares of preferred stock, par value $0.01. As of December 31, 2024, no shares of preferred stock were issued or outstanding.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Earnings Before Income Tax Expense years ended December 31 (in millions) 2024 2023 2022 Domestic $ (7,743) $ (3,475) $ (4,608) Foreign 11,459 9,725 18,085 Total earnings before income tax expense $ 3,716 $ 6,250 $ 13,477 Income Tax Expense years ended December 31 (in millions) 2024 2023 2022 Current Domestic $ (331) $ 3,272 $ 2,647 Foreign 1,210 994 916 Total current taxes $ 879 $ 4,266 $ 3,563 Deferred Domestic $ (1,303) $ (2,324) $ (1,512) Foreign (146) (565) (419) Total deferred taxes $ (1,449) $ (2,889) $ (1,931) Total income tax expense (benefit) $ (570) $ 1,377 $ 1,632 Effective Tax Rate Reconciliation years ended December 31 2024 2023 2022 Statutory tax rate 21.0 % 21.0 % 21.0 % Effect of foreign operations 7.6 8.0 (4.4) U.S. tax credits (5.4) (3.1) (2.8) Stock-based compensation (1.2) (1.0) (0.6) Non-deductible expenses 1.1 0.7 0.4 Tax law changes and related structuring (0.3) (3.8) (2.4) Tax audits, settlements and reserves (51.4) (1.1) 0.9 Acquisition costs 13.4 0.2 — All other, net (0.1) 1.1 — Effective tax rate (15.3) % 22.0 % 12.1 % The effective income tax rate fluctuates year to year due to the allocation of the company’s taxable earnings among jurisdictions, as well as certain discrete factors and events in each year, including changes in tax law and business development activities. The effective income tax rates in 2024, 2023 and 2022 differed from the statutory tax rate principally due to the impact of foreign operations with lower income tax rates in locations outside the United States, the U.S. global minimum tax, changes in fair value of contingent consideration, tax audits and settlements, tax credits and incentives in the United States, Puerto Rico and other foreign tax jurisdictions, and business development activities. The effective income tax rate in 2024 was lower than prior periods due to the resolutions of various tax positions pertaining to multiple prior tax years, including the closing of U.S. IRS examinations covering three tax years, partially offset by increases in unrecognized tax benefits pertaining to prior years. The lower effective income tax rate in 2024 also reflects an increase due to acquisition costs related to certain business development activities and a decrease related to changes in fair value of contingent consideration. The effective income tax rate in 2023 was higher than prior periods due to increased changes in fair value of contingent consideration, intangible asset impairments and the impacts of the transition from the Puerto Rico excise tax to an income tax. In 2022, Puerto Rico enacted Act 52-2022 (the Puerto Rico Act) allowing for a transition from a Puerto Rico excise tax levied on gross inventory purchases to an income-based tax beginning in 2023. The company completed the transition requirements of the Puerto Rico Act in 2022, resulting in the remeasurement of certain deferred tax assets and liabilities based on income tax rates at which they are expected to reverse in the future. The net tax benefit recognized in 2022 from the remeasurement of deferred taxes related to the Puerto Rico Act was $323 million. The Tax Cuts and Jobs Act (the Act) was signed into law in December 2017, resulting in significant changes to the U.S. corporate tax system, including a one-time transition tax on a mandatory deemed repatriation of earnings of certain foreign subsidiaries that were previously untaxed. The Act also created a U.S. global minimum tax on certain foreign sourced earnings. The company’s accounting policy for the minimum tax on foreign sourced earnings is to report the tax effects on the basis that the minimum tax will be recognized in tax expense in the year it is incurred as a period expense. Deferred Tax Assets and Liabilities as of December 31 (in millions) 2024 2023 Deferred tax assets Compensation and employee benefits $ 215 $ 519 Accruals and reserves 1,253 1,113 Chargebacks and rebates 1,354 1,431 Advance payments 66 298 Net operating losses and other carryforwards 15,815 14,316 Other 2,156 2,259 Total deferred tax assets 20,859 19,936 Valuation allowances (14,823) (13,478) Total net deferred tax assets 6,036 6,458 Deferred tax liabilities Excess of book basis over tax basis of intangible assets (1,969) (1,535) Excess of book basis over tax basis in investments (302) (374) Other (718) (746) Total deferred tax liabilities (2,989) (2,655) Net deferred tax assets $ 3,047 $ 3,803 The decrease in deferred tax assets is primarily related to a decrease in compensation, employee benefits and advance payments. The increase in deferred tax liabilities is primarily due to the acquisition of Cerevel Therapeutics and ImmunoGen in which the company recorded the excess of book basis over tax basis of intangible assets, offset by amortization and impairment of intangible assets. The company had valuation allowances of $14.8 billion as of December 31, 2024 and $13.5 billion as of December 31, 2023. These were principally related to foreign and state net operating losses and other credit carryforwards that are not expected to be realized. The company incurred carryforward deductions in a foreign jurisdiction where realization of the future income tax benefit was, in previous reporting periods, considered so remote that the income tax benefit was not recognized as a deferred tax asset. In 2024, the company concluded that the future income tax benefit of the carryforward balances is no longer remote and therefore, a deferred tax asset was recognized. The company also recognized an offsetting valuation allowance, resulting in no net impact to deferred tax assets as such carryforward balances are not expected to be realized in the foreseeable future. As of December 31, 2024, the company had U.S. federal, state and foreign credit carryforwards of $669 million as well as U.S. federal, state and foreign net operating loss carryforwards of $38.9 billion, which will expire at various times through 2044. The company also had foreign loss carryforwards of $33.3 billion that have no expiration. Unremitted foreign earnings subject to the Act’s transition tax are not considered indefinitely reinvested. Post-2017 earnings subject to the U.S. minimum tax on foreign sourced earnings or eligible for the 100 percent foreign dividends received deduction are also not considered indefinitely reinvested earnings. However, the company generally considers instances of outside basis differences in foreign subsidiaries that would incur additional U.S. tax upon reversal (e.g., capital gain distributions) to be permanent in duration. The unrecognized tax liability is not practicable to determine. Unrecognized Tax Benefits years ended December 31 (in millions) 2024 2023 2022 Beginning balance $ 5,762 $ 5,670 $ 5,489 Increase due to current year tax positions 173 129 88 Increase due to prior year tax positions 454 109 243 Decrease due to prior year tax positions (1,741) (21) (33) Settlements (284) (86) (7) Increase due to acquisitions 82 — — Lapse of statutes of limitations (45) (39) (110) Ending balance $ 4,401 $ 5,762 $ 5,670 If recognized, the net amount of potential tax benefits that would impact the company's effective tax rate is $4.3 billion in 2024 and $5.6 billion in 2023. The "Increase due to current year tax positions" and "Increase due to prior year tax positions" in the table above include amounts related to federal, state and international tax items. AbbVie recognizes interest and penalties related to income tax matters in income tax expense in the consolidated statements of earnings. AbbVie recognized a gross income tax benefit of $179 million in 2024 and gross income tax expense of $430 million in 2023 and $339 million in 2022 for interest and penalties related to income tax matters. AbbVie had an accrual for the payment of gross interest and penalties of $1.4 billion at December 31, 2024, $1.6 billion at December 31, 2023 and $1.1 billion at December 31, 2022.

Legal Proceedings and Contingen

Legal Proceedings and Contingencies	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. The recorded accrual balance for litigation was approximately $2.5 billion as of December 31, 2024 and $2.0 billion as of December 31, 2023. For litigation matters discussed below for which a loss is probable or reasonably possible, the company is unable to estimate the possible loss or range of loss, if any, beyond the amounts accrued. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows. Subject to certain exceptions specified in the separation agreement by and between Abbott Laboratories (Abbott) and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. Antitrust Litigation Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violated federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits pending in federal court consist of six individual plaintiff lawsuits and a certified class action by Niaspan direct purchasers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the federal multi-district litigation (MDL) Rules as In re: Niaspan Antitrust Litigation, MDL No. 2460. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In November 2022, the State of Oregon filed a lawsuit in the Multnomah County, Oregon Circuit Court, alleging that 2011 patent litigation by Abbott with a generic company regarding AndroGel was sham litigation and the settlement of that litigation violated state antitrust law. Oregon also brought a claim under the Oregon False Claims Act, which the court dismissed on October 31, 2024. In November 2024, the parties reached an agreement in principle to resolve this lawsuit. Government Proceedings Lawsuits are pending against Allergan and several other manufacturers generally alleging that they improperly promoted and sold prescription opioid products. Approximately 435 lawsuits are pending against Allergan in federal and state courts. Most of the federal court lawsuits are consolidated for pre-trial purposes in the United States District Court for the Northern District of Ohio under the MDL rules as In re: National Prescription Opiate Litigation, MDL No. 2804. Approximately 35 of the lawsuits are pending in various state courts. The plaintiffs in these lawsuits, which include states, counties, cities, other municipal entities, Native American tribes, union trust funds and other third-party payors, private hospitals and personal injury claimants, generally seek compensatory and punitive damages. Of these approximately 435 lawsuits, approximately 25 of them are brought by states, counties, cities, and other municipal entities, approximately 5 of which are in the process of being dismissed pursuant to the previously announced settlement. Another approximately 45 of the approximately 435 lawsuits are covered by a proposed class settlement between Allergan and a class of acute care hospitals, which is subject to court approval and other contingencies. In March 2023, AbbVie Inc. filed a petition in the United States Tax Court, AbbVie Inc. and Subsidiaries v. Commissioner of Internal Revenue. The petition disputes the Internal Revenue Service determination concerning a $572 million income tax benefit recorded in 2014 related to a payment made to a third party for the termination of a proposed business combination. Shareholder and Securities Litigation In October 2018, a federal securities lawsuit, Holwill v. AbbVie Inc., et al., was filed in the United States District Court for the Northern District of Illinois against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for Humira sales growth in financial filings between 2013 and 2018 were misleading because they omitted alleged misconduct in connection with Humira patient and reimbursement support services and other services and items of value that allegedly induced Humira prescriptions. In September 2021, the court granted plaintiffs' motion to certify a class. In May and July 2022, two shareholder derivative lawsuits, Treppel Family Trust v. Gonzalez et al., and Katcher v. Gonzalez, et al., were filed in the United States District Court for the Northern District of Illinois, alleging that certain AbbVie directors and officers breached fiduciary and other legal duties in making or allowing alleged misstatements regarding the potential effect that safety information about another company’s product would have on the Food and Drug Administration’s approval and labeling for AbbVie’s Rinvoq. In October 2024, the court granted defendants’ motion to dismiss without prejudice. In November 2024, the dismissal was converted to one with prejudice. Product Liability and General Litigation In April 2023, a putative class action lawsuit, Camargo v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois on behalf of Humira patients who paid for Humira based on its list price or who, after losing insurance coverage, discontinued Humira because they could not pay based on its list price, alleging that Humira’s list price is excessive in violation of multiple states’ unfair and deceptive trade practices statutes. The plaintiff generally seeks monetary damages, injunctive relief, and attorneys’ fees. In 2018, a qui tam lawsuit, U.S. ex rel. Silbersher v. Allergan Inc., et al., was filed in the United States District Court for the Northern District of California against several Allergan entities and others, alleging that their conduct before the U.S. Patent Office resulted in false claims for payment being made to federal and state healthcare payors for Namenda XR and Namzaric. The plaintiff-relator sought damages and attorneys' fees under the federal False Claims Act and state law analogues. The federal government and state governments declined to intervene in the lawsuit. In March 2023, the court granted Allergan’s motion to dismiss, dismissing plaintiff-relator’s federal law claims with prejudice and state law claims without prejudice. The plaintiff-relator is appealing the court’s motion to dismiss ruling. Lawsuits are pending against various Allergan entities in the United States and other countries including Brazil, Canada, South Korea, and the Netherlands, in which plaintiffs generally allege that they developed, or may develop, breast implant- associated anaplastic large cell lymphoma (ALCL) or other injuries from Allergan’s Biocell® textured breast implants, which were voluntarily withdrawn from worldwide markets in 2019. Approximately 135 ALCL lawsuits and 1,100 other lawsuits are coordinated for pre-trial purposes in the United States District Court for the District of New Jersey under the MDL rules as In re: Allergan Biocell Textured Breast Implant Product Liability Litigation, MDL No. 2921. Approximately 75 ALCL lawsuits and 460 other lawsuits are pending in various state courts. Approximately 60 ALCL and 1,000 other lawsuits are pending in other countries. Plaintiffs generally seek monetary damages, medical monitoring, and attorneys’ fees. In January 2025, a putative class action lawsuit, Sheet Metal Workers’ Health Plan of Southern California, Arizona, and Nevada v. AbbVie Inc., was filed in the United States District Court for the Northern District of Illinois on behalf of third-party payors of Humira, alleging that AbbVie’s rebating practices are impairing biosimilar competition with Humira in violation of federal and state antitrust laws. The plaintiff generally seeks monetary damages, injunctive relief and attorneys' fees. Intellectual Property Litigation AbbVie Inc. is seeking to enforce patent rights relating to upadacitinib (a drug sold under the trademark Rinvoq). Litigation was filed in the United States District Court for the District of Delaware in November 2023 against Hetero USA, Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd., Sandoz, Inc., Sandoz Private Limited, Sandoz GMBH, and Sun Pharmaceutical Industries, Ltd. AbbVie alleges defendants’ proposed generic upadacitinib products infringe certain patents and seeks declaratory and injunctive relief. AbbVie Inc. is seeking to enforce patent rights related to ubrogepant (a drug sold under the trademark Ubrelvy). Litigation was filed in the United States District Court for the District of New Jersey in March 2024 against Aurobindo Pharma U.S.A., Inc., Aurobindo Pharma Limited, and Apitoria Pharma Private Limited; Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited; MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited; and Hetero USA Inc., Hetero Labs Limited Unit-III, and Hetero Labs Limited. AbbVie alleges defendants’ proposed generic ubrogepant products infringe certain patents and seeks declaratory and injunctive relief. Merck Sharp & Dohme LLC, which exclusively licenses certain patents to AbbVie, is a co-plaintiff in the litigation.

Segment and Geographic Area Inf

Segment and Geographic Area Information	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment and Geographic Area Information	Segment and Geographic Area Information AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as Chief Operating Decision Maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods. The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by CODM are reported on the Consolidated Statement of Earnings for the years ended December 31, 2024, 2023 and 2022. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included. Substantially all of AbbVie's pharmaceutical product net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues: years ended December 31 (in millions) 2024 2023 2022 Immunology Humira United States $ 7,142 $ 12,160 $ 18,619 International 1,851 2,244 2,618 Total $ 8,993 $ 14,404 $ 21,237 Skyrizi United States $ 10,086 $ 6,753 $ 4,484 International 1,632 1,010 681 Total $ 11,718 $ 7,763 $ 5,165 Rinvoq United States $ 4,259 $ 2,824 $ 1,794 International 1,712 1,145 728 Total $ 5,971 $ 3,969 $ 2,522 Oncology Imbruvica United States $ 2,448 $ 2,665 $ 3,426 Collaboration revenues 899 931 1,142 Total $ 3,347 $ 3,596 $ 4,568 Venclexta United States $ 1,234 $ 1,087 $ 1,009 International 1,349 1,201 1,000 Total $ 2,583 $ 2,288 $ 2,009 Elahere (a) United States $ 477 $ — $ — International 2 — — Total $ 479 $ — $ — Epkinly Collaboration revenues $ 118 $ 28 $ — International 28 3 — Total $ 146 $ 31 $ — Aesthetics Botox Cosmetic United States $ 1,682 $ 1,670 $ 1,654 International 1,038 1,012 961 Total $ 2,720 $ 2,682 $ 2,615 Juvederm Collection United States $ 469 $ 519 $ 548 International 708 859 880 Total $ 1,177 $ 1,378 $ 1,428 Other Aesthetics United States $ 1,118 $ 1,060 $ 1,122 International 161 174 168 Total $ 1,279 $ 1,234 $ 1,290 Neuroscience Botox Therapeutic United States $ 2,718 $ 2,476 $ 2,255 International 565 515 464 Total $ 3,283 $ 2,991 $ 2,719 Vraylar United States $ 3,260 $ 2,755 $ 2,037 International 7 4 1 Total $ 3,267 $ 2,759 $ 2,038 Duodopa United States $ 96 $ 97 $ 95 International 351 371 363 Total $ 447 $ 468 $ 458 Ubrelvy United States $ 981 $ 803 $ 680 International 25 12 — Total $ 1,006 $ 815 $ 680 Qulipta United States $ 628 $ 405 $ 158 International 30 3 — Total $ 658 $ 408 $ 158 years ended December 31 (in millions) 2024 2023 2022 Other Neuroscience United States $ 224 $ 254 $ 456 International 114 22 19 Total $ 338 $ 276 $ 475 Eye Care Ozurdex United States $ 138 $ 143 $ 139 International 356 329 289 Total $ 494 $ 472 $ 428 Lumigan/Ganfort United States $ 187 $ 173 $ 242 International 242 259 272 Total $ 429 $ 432 $ 514 Alphagan/Combigan United States $ 95 $ 121 $ 202 International 153 151 144 Total $ 248 $ 272 $ 346 Restasis United States $ 172 $ 382 $ 621 International 52 54 45 Total $ 224 $ 436 $ 666 Other Eye Care United States $ 472 $ 433 $ 399 International 375 370 348 Total $ 847 $ 803 $ 747 Other Key Products Mavyret United States $ 595 $ 659 $ 755 International 716 771 786 Total $ 1,311 $ 1,430 $ 1,541 Creon United States $ 1,383 $ 1,268 $ 1,278 Linzess/Constella United States $ 916 $ 1,073 $ 1,003 International 38 35 32 Total $ 954 $ 1,108 $ 1,035 All other $ 3,032 $ 3,035 $ 4,137 Total net revenues $ 56,334 $ 54,318 $ 58,054 (a) Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024. Net revenues to external customers by geographic area, based on product shipment destination, were as follows: years ended December 31 (in millions) 2024 2023 2022 United States $ 43,029 $ 41,883 $ 45,713 Germany 1,465 1,266 1,340 Japan 1,122 1,008 956 Canada 1,088 1,076 1,159 China 917 950 912 France 776 780 787 Spain 528 501 506 United Kingdom 522 417 462 Italy 511 484 444 Brazil 464 439 430 Australia 463 472 508 All other countries 5,449 5,042 4,837 Total net revenues $ 56,334 $ 54,318 $ 58,054 See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 7), intangible assets impairment expense (Note 7), change in fair value of contingent consideration (Note 11), interest income and expense (Note 3), depreciation expense (Note 2), litigation matters (Note 15), income tax expense (Note 14) and restructuring expense (Note 8). Long-lived assets, primarily net property and equipment, by geographic area were as follows: as of December 31 (in millions) 2024 2023 United States $ 3,331 $ 3,139 Europe 1,485 1,433 All other 318 417 Total long-lived assets $ 5,134 $ 4,989

Fourth Quarter Financial Result

Fourth Quarter Financial Results (unaudited)	12 Months Ended
	Dec. 31, 2024
Quarterly Financial Information Disclosure [Abstract]
Fourth Quarter Financial Results (unaudited)	Fourth Quarter Financial Results (unaudited) quarter ended December 31 (in millions except per share data) 2024 Net revenues $ 15,102 Gross margin 10,706 Net loss attributable to AbbVie Inc. (22) Basic loss per share attributable to AbbVie Inc. $ (0.02) Diluted loss per share attributable to AbbVie Inc. $ (0.02) Cash dividends declared per common share $ 1.64

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (22)	$ 4,278	$ 4,863	$ 11,836

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	OTHER INFORMATION During the three months ended December 31, 2024, no director or officer of the company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as provided below. Name & Title Action Taken Date Adopted Type of Trading Arrangement (1) Aggregate Number of Shares to be Sold Pursuant to Trading Arrangement (2) Duration of Trading Arrangement (3) Perry C. Siatis Executive Vice President, Adoption 11/19/2024 Rule 10b5-1 Trading Arrangement Up to 48,568 Shares to be Sold 11/19/2025 Timothy J. Richmond Executive Vice President, Adoption 11/27/2024 Rule 10b5-1 Trading Arrangement Up to 83,887 Shares to be Sold 07/01/2025 1. Except as indicated by footnote, each trading arrangement marked as a "Rule 10b5-1 Trading Arrangement" is intended to satisfy the affirmative defense of Rule 10b5-1(c), as amended. 2. The number of shares to be sold under each trading arrangement represents the maximum actual number of shares issuable under the applicable performance stock awards. The actual number of shares to be sold under each trading arrangement will depend on the achievement of applicable performance conditions under the performance stock awards and the number of shares withheld to satisfy tax obligations upon the vesting of the awards. 3. Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table. Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” only permitted or only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule.
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Perry C. Siatis [Member]
Trading Arrangements, by Individual
Name	Perry C. Siatis
Title	Executive Vice President,General Counsel and Secretary
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	11/19/2024
Expiration Date	11/19/2025
Aggregate Available	48,568
Timothy J. Richmond [Member]
Trading Arrangements, by Individual
Name	Timothy J. Richmond
Title	Executive Vice President,Chief Human ResourcesOfficer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	11/27/2024
Expiration Date	07/01/2025
Aggregate Available	83,887

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	CYBERSECURITY We rely on complex information technology systems and various software applications to operate our business. We have developed a comprehensive cybersecurity program designed to protect our systems and the confidentiality, integrity and availability of our data. We have implemented processes that are intended to govern, manage and reduce cybersecurity risks. We maintain a global incident response plan and disaster recovery management plan, each designed to protect against, identify, detect, respond to and recover from an incident. These plans anticipate an array of potential scenarios and provide for the assembly of a cybersecurity incident response team in the event of a cyber incident. The incident response team is a cross-functional group that may be composed of both company personnel and external service providers, and which is tailored to a particular incident so that individuals with appropriate experience and expertise are available. We regularly conduct exercises to help ensure the plans’ effectiveness and our overall preparedness. We also have invested in tools and technologies to protect our and our patients' and customers' data and information technology, and we regularly monitor our information technology systems and infrastructure to identify and assess cybersecurity risks. We have designed a Threat Intelligence function that actively looks for emerging threats and risks that target the pharmaceutical industry generally or AbbVie specifically. We rely in part on third parties (including assessors, consultants, advisors and others) in connection with our processes for assessing, identifying, managing and reducing cyber risks. In addition, we have implemented a cybersecurity awareness program designed to educate and train our entire employee network on how to identify and report cybersecurity threats. Training programs are conducted on a periodic basis and are focused on giving employees information to manage and defend against the most relevant and prevalent cybersecurity risks to AbbVie. We also provide specialized training for employees in specialized information technology roles and for business functions who may be impacted by a cyber incident. We conduct regular drills, such as tabletop exercises, to help with our overall preparedness. We take measures to regularly update and improve our cybersecurity program, including conducting independent program assessments, penetration testing and scanning of our systems for vulnerabilities. We follow the National Institute of Standards and Technology (NIST) Cybersecurity Framework and undergo a third-party assessment every two years to measure the maturity of our cybersecurity program against the NIST Cybersecurity Framework. In addition, we periodically engage third-party advisors to assess the effectiveness and capabilities of our cybersecurity program, strengthen our cybersecurity policies and practices and identify potential vulnerabilities of our systems. With respect to third-party service providers, our information security program includes conducting due diligence of relevant service providers’ information security programs prior to onboarding. We also contractually require third-party service providers with access to our information technology systems, sensitive business data or personally identifiable information to implement and maintain appropriate security controls and contractually restrict their ability to use our data, including personally identifiable information, for purposes other than to provide services to us, except as required by law. To oversee the risks associated with these service providers, we work with them to help ensure that their cybersecurity protocols are appropriate to the risk presented by their access to or use of our systems and/or data, including notification and coordination concerning incidents occurring on third-party systems that may affect us. These relevant service providers are contractually required to notify us promptly of information security incidents that may affect our systems or data, including personally identifiable information. While we conduct due diligence on the security and business controls of our third-party service providers and take steps to monitor their compliance with our security requirements, we may not have the ability in all cases to effectively monitor or oversee the implementation of these control measures. As of December 31, 2024, cybersecurity risks have not materially affected our business, strategy, results of operations, or financial condition. Although we have invested in the protection of our data and information technology and monitor our systems on an ongoing basis, there can be no assurance that such efforts will in the future prevent material compromises to our information technology systems that could have a material adverse effect on our business. We maintain cybersecurity insurance coverage to mitigate our financial exposure to certain incidents. For additional information about our cybersecurity risks, see Item 1A, "Risk Factors - AbbVie depends on information technology and a failure of, or significant disruption to, those systems could have a material adverse effect on AbbVie's business." Our board of directors has risk oversight responsibility for AbbVie and administers this responsibility both directly and with assistance from its committees. Each of the committees periodically reports to the board of directors on its risk oversight activities. Cybersecurity is a critical component of our enterprise risk management program, which is designed to be business aligned, risk-focused and multi-faceted to protect our and our patients', customers' and business partners' data. Our board of directors is actively involved in reviewing our information security and technology risks and opportunities (including cybersecurity) and discusses these topics on a regular basis. The Audit Committee, comprised solely of independent directors, oversees our enterprise risk management program and assists the board of directors in fulfilling its oversight responsibility with respect to our information security and technology risks (including cybersecurity), which are fully integrated into our enterprise risk management program. The Audit Committee reviews and discusses our information security and technology risks (such as cybersecurity), including our information security and risk management programs. Our cybersecurity program is led by our Chief Information Security Officer, who is responsible for assessing and managing our information security and technology risks (including cybersecurity). He has more than 25 years of experience in information security and information technology risk management, holding chief information security officer positions with Fortune 500 companies in the retail, healthcare and life sciences industries. He has also served on the Health-ISAC board of directors and is a Certified Information System Security Professional (CISSP). Our Chief Information Security Officer meets regularly with our information technology teams as well as other members of management to review and discuss our cybersecurity and other information technology risks and opportunities. Our global incident response plan sets forth a detailed security incident management and reporting protocol, with escalation timelines and responsibilities. The Audit Committee receives regular updates from the Chief Information Security Officer and other members of management on our cybersecurity program, including on information security and technology risks, program assessments, and risk management practices. Our Chief Information Security Officer and other senior information technology executives also provides similar topical updates to the full board of directors at least annually.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and necessarily include amounts based on estimates and assumptions by management. Actual results could differ from those amounts. Significant estimates include amounts for rebates, pension and other post-employment benefits, income taxes, litigation, valuation of goodwill and intangible assets and contingent consideration liabilities.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of AbbVie and all of its subsidiaries in which a controlling interest is maintained. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, where AbbVie is determined to be the primary beneficiary. Investments in companies over which AbbVie has a significant influence but not a controlling interest are accounted for using the equity method with AbbVie's share of earnings or losses reported in other expense, net in the consolidated statements of earnings. Intercompany balances and transactions are eliminated. Certain reclassifications have been made to conform the prior period consolidated financial statements to the current period presentation.
Revenue Recognition	Revenue Recognition AbbVie recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration AbbVie expects to be entitled to in exchange for those goods or services. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue. AbbVie generates revenue primarily from product sales. For the majority of sales, the company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. The company recognizes shipping and handling costs as an expense in cost of products sold when the company transfers control to the customer. Payment terms vary depending on the type and location of the customer, are based on customary commercial terms and are generally less than one year. AbbVie does not adjust revenue for the effects of a significant financing component for contracts where AbbVie expects the period between the transfer of the good or service and collection to be one year or less. Cash discounts, rebates and chargebacks, sales incentives, product returns and certain other adjustments are accounted for as variable consideration. Provisions for variable consideration are based on current pricing, executed contracts, government pricing legislation and historical data and are provided for in the period the related revenues are recorded. Rebate amounts are typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, factors used in the calculation of the accrual include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant. In addition to revenue from contracts with customers, the company also recognizes certain collaboration revenues. See Note 6 for additional information related to the collaborations with Janssen Biotech, Inc. and Genentech, Inc. Additionally, see Note 16 for disaggregation of revenue by product and geography.
Research and Development Expenses	Research and Development Expenses
Acquired In-Process Research and Development	Acquired IPR&D and Milestones Expenses
Business Combinations	Business Combinations AbbVie utilizes the acquisition method of accounting for business combinations. This method requires, among other things, that results of operations of acquired companies are included in AbbVie's results of operations beginning on the acquisition date and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair value of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other expense, net in the consolidated statements of earnings. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred.
Collaborations and Other Arrangements	Collaborations and Other Arrangements The company enters into collaborative agreements with third parties to develop and commercialize drug candidates. Collaborative activities may include joint research and development and commercialization of new products. AbbVie generally receives certain licensing rights under these arrangements. These collaborations often require upfront payments and may include additional milestone, research and development cost sharing, royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development and commercialization. Upfront payments associated with collaborative arrangements and subsequent payments made to the partner for the achievement of development milestones prior to regulatory approval are expensed to acquired IPR&D and milestones expense in the consolidated statements of earnings. Regulatory and commercial milestone payments made to the partner subsequent to regulatory approval are capitalized as intangible assets and amortized to cost of products sold over the estimated useful life of the related asset. Royalties are expensed to cost of products sold in the consolidated statements of earnings when incurred.
Advertising	Advertising
Pension and Other Post-Employment Benefits	Pension and Other Post-Employment Benefits AbbVie records annual expenses relating to its defined benefit pension and other post-employment benefit plans based on calculations which utilize various actuarial assumptions including discount rates, rates of return on assets, compensation increases, turnover rates and health care cost trend rates. AbbVie reviews its actuarial assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends. Actuarial gains and losses are deferred in accumulated other comprehensive income (loss) (AOCI), net of tax and are amortized over the remaining service attribution periods of the employees under the corridor method. Differences between the expected long-term return on plan assets and the actual annual return are generally amortized to net periodic benefit cost over a five-year period.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Provisions for federal, state and foreign income taxes are calculated on reported pre-tax earnings based on current tax laws. Deferred taxes are provided using enacted tax rates on the future tax consequences of temporary differences, which are the differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases and the tax benefits of carryforwards. A valuation allowance is established or maintained when, based on currently available information, it is more likely than not that all or a portion of a deferred tax asset will not be realized.
Cash and Equivalents	Cash and Equivalents Cash and equivalents include money market funds and time deposits with original maturities of three months or less.
Investments	Investments Investments consist primarily of equity securities, held-to-maturity debt securities, marketable debt securities and time deposits. Investments in equity securities that have readily determinable fair values are recorded at fair value. Investments in equity securities that do not have readily determinable fair values are recorded at cost and are remeasured to fair value based on certain observable price changes or impairment events as they occur. Held-to-maturity debt securities are recorded at cost. Gains or losses on investments are included in other expense, net in the consolidated statements of earnings. Investments in marketable debt securities are classified as available-for-sale and are recorded at fair value with any unrealized holding gains or losses, net of tax, included in AOCI on the consolidated balance sheets until realized, at which time the gains or losses are recognized in earnings. AbbVie periodically assesses its marketable debt securities for impairment and credit losses. When a decline in the fair value of marketable debt security is due to credit related factors, an allowance for credit losses is recorded with a corresponding charge to other expense, net in the consolidated statements of earnings. When AbbVie determines that a non-credit related impairment has occurred, the amortized cost basis of the investment, net of allowance for credit losses, is written down with a charge to other expense, net in the consolidated statements of earnings and an available-for-sale investment's unrealized loss is reclassified from AOCI to other expense, net in the consolidated statements of earnings. Realized gains and losses on sales of investments are computed using the first-in, first-out method adjusted for any impairments and credit losses that were recorded in net earnings.
Accounts Receivable	Accounts Receivable Accounts receivable are stated at amortized cost less allowance for credit losses. The allowance for credit losses reflects the best estimate of future losses over the contractual life of outstanding accounts receivable and is determined on the basis of historical experience, specific allowances for known troubled accounts, other currently available information including customer financial condition and both current and forecasted economic conditions.
Inventories	Inventories
Property and Equipment	Depreciation for property and equipment is recorded on a straight-line basis over the estimated useful lives of the assets. The estimated useful life for buildings ranges from 10 to 50 years. Buildings include leasehold improvements which are amortized over the lesser of the remainder of the lease term or the useful life of the leasehold improvement. The estimated useful life for equipment ranges from 2 to 25 years. Equipment includes certain computer software and software development costs incurred in connection with developing or obtaining software for internal use and is amortized over 3 to 10 years.
Leases	Leases Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components. The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option. Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.
Short-Term Leases	Short-term leases with a term of 12 months or less are not recorded on the balance sheet.
Litigation and Contingencies	Litigation and Contingencies Loss contingency provisions are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information. When a best estimate cannot be made, the minimum loss contingency amount in a probable range is recorded. Legal fees are expensed as incurred. AbbVie accrues for product liability claims on an undiscounted basis. The liabilities are evaluated quarterly and adjusted if necessary as additional information becomes available. Receivables for insurance recoveries for product liability claims, if any, are recorded as assets on an undiscounted basis when it is probable that a recovery will be realized.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, risk, the cost of capital and terminal values of market participants. Definite-lived intangibles are amortized over their estimated useful lives using the estimated pattern of economic benefit. AbbVie reviews the recoverability of definite-lived intangible assets whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. AbbVie first compares the projected undiscounted cash flows to be generated by the asset to its carrying value. If the undiscounted cash flows of an intangible asset are less than the carrying value, the intangible asset is written down to its fair value. Where cash flows cannot be identified for an individual asset, the review is applied at the lowest level for which cash flows are largely independent of the cash flows of other assets and liabilities. Goodwill and indefinite-lived assets are not amortized but are subject to an impairment review annually and more frequently when indicators of impairment exist. An impairment of goodwill could occur if the carrying amount of a reporting unit exceeded the fair value of that reporting unit. An impairment of indefinite-lived intangible assets would occur if the fair value of the intangible asset is less than the carrying value. The company tests its goodwill for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value of the reporting unit is less than its carrying amount, a quantitative impairment test is performed. AbbVie tests indefinite-lived intangible assets for impairment by first assessing qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If the company concludes it is more likely than not that the fair value is less than its carrying amount, a quantitative impairment test is performed. For its quantitative impairment tests, the company uses an estimated future cash flow approach that requires significant judgment with respect to future volume, revenue and expense growth rates, changes in working capital use, the selection of an appropriate discount rate, asset groupings and other assumptions and estimates. The estimates and assumptions used are consistent with the company's business plans and a market participant's views. The use of alternative estimates and assumptions could increase or decrease projected cash flows and the estimated fair value of the related intangible assets. Future changes to these estimates and assumptions could have a material impact on the company's results of operations. Actual results may differ from the company's estimates.
Foreign Currency Translation	Foreign Currency Translation
Derivatives	Derivatives All derivative instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheets and are classified as current or long-term based on the scheduled maturity of the instrument. For derivatives formally designated as hedges, the company assesses at inception and quarterly thereafter whether the hedging derivatives are highly effective in offsetting changes in the fair value or cash flows of the hedged item. The changes in fair value of a derivative designated as a fair value hedge and of the hedged item attributable to the hedged risk are recognized in earnings immediately. The effective portions of changes in the fair value of a derivative designated as a cash flow hedge are reported in AOCI and are subsequently recognized in earnings consistent with the underlying hedged item. If it is determined that a derivative is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If a hedged forecasted transaction becomes probable of not occurring, any gains or losses are reclassified from AOCI to earnings. Derivatives that are not designated as hedges are adjusted to fair value through current earnings. The company also uses derivative instruments or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. Realized and unrealized gains and losses from these hedges are included in AOCI. Derivative cash flows, with the exception of net investment hedges, are principally classified in the operating section of the consolidated statements of cash flows, consistent with the underlying hedged item. Cash flows related to net investment hedges are classified in the investing section of the consolidated statements of cash flows.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted ASU No. 2024-03 In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40 ). The standard requires further disaggregation of relevant expense captions in a separate note to the financial statements. The standard is effective for AbbVie starting in annual periods in 2027 and interim periods beginning in 2028, with early adoption permitted. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. ASU No. 2023-09 In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) . The standard requires disaggregation of the effective rate reconciliation into standard categories, enhances disclosure of income taxes paid, and modifies other income tax-related disclosures. The standard is effective for AbbVie starting in annual periods in 2025. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements. Recently Adopted Accounting Pronouncements ASU No. 2023-07 In November 2023, the FASB issued ASU No. 2023-07 Segment Reporting - Improving Reportable Segment Disclosures (Topic 280) . The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (CODM), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. AbbVie adopted the standard in the fourth quarter of 2024. The adoption did not have a material impact on its consolidated financial statements. See Note 16 for additional information.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of inventories	Inventories are valued at the lower of cost (first-in, first-out basis) or market. Cost includes material and conversion costs. Inventories consisted of the following: as of December 31 (in millions) 2024 2023 Finished goods $ 1,173 $ 1,356 Work-in-process 1,951 1,643 Raw materials 1,057 1,100 Inventories $ 4,181 $ 4,099
Schedule of property and equipment	Property and Equipment, Net as of December 31 (in millions) 2024 2023 Land $ 284 $ 286 Buildings 2,895 2,827 Equipment 7,995 7,449 Construction in progress 1,093 1,073 Property and equipment, gross 12,267 11,635 Less accumulated depreciation (7,133) (6,646) Property and equipment, net $ 5,134 $ 4,989

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Dec. 31, 2024
Supplemental Financial Information
Schedule of interest expense, net	Interest Expense, Net years ended December 31 (in millions) 2024 2023 2022 Interest expense $ 2,808 $ 2,224 $ 2,230 Interest income (648) (540) (186) Interest expense, net $ 2,160 $ 1,684 $ 2,044
Schedule of accounts payable and accrued liabilities	Accounts Payable and Accrued Liabilities as of December 31 (in millions) 2024 2023 Sales rebates $ 14,304 $ 13,627 Dividends payable 2,936 2,783 Accounts payable 2,945 3,688 Current portion of contingent consideration liabilities 2,589 1,952 Salaries, wages and commissions 1,986 1,802 Royalty and license arrangements 527 360 Other 6,658 6,438 Accounts payable and accrued liabilities $ 31,945 $ 30,650
Schedule of other long-term liabilities	Other Long-Term Liabilities as of December 31 (in millions) 2024 2023 Contingent consideration liabilities $ 19,077 $ 17,938 Liabilities for unrecognized tax benefits 5,049 6,681 Income taxes payable 1,261 2,182 Pension and other post-employment benefits 1,234 1,538 Other 3,508 3,988 Other long-term liabilities $ 30,129 $ 32,327

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of basic and diluted earnings per share, impact of two-class method	The following table summarizes the impact of the two-class method: Years ended December 31, (in millions, except per share data) 2024 2023 2022 Basic EPS Net earnings attributable to AbbVie Inc. $ 4,278 $ 4,863 $ 11,836 Earnings allocated to participating securities 40 43 54 Earnings available to common shareholders $ 4,238 $ 4,820 $ 11,782 Weighted average basic shares of common stock outstanding 1,769 1,768 1,771 Basic earnings per share attributable to AbbVie Inc. $ 2.40 $ 2.73 $ 6.65 Diluted EPS Net earnings attributable to AbbVie Inc. $ 4,278 $ 4,863 $ 11,836 Earnings allocated to participating securities 40 43 54 Earnings available to common shareholders $ 4,238 $ 4,820 $ 11,782 Weighted average shares of common stock outstanding 1,769 1,768 1,771 Effect of dilutive securities 4 5 7 Weighted average diluted shares of common stock outstanding 1,773 1,773 1,778 Diluted earnings per share attributable to AbbVie Inc. $ 2.39 $ 2.72 $ 6.63

Licensing, Acquisitions, and _2

Licensing, Acquisitions, and Other Arrangements (Tables)	12 Months Ended
	Dec. 31, 2024
Licensing, Acquisitions, and Other Arrangements
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 361 Short-term investments 382 Prepaid expenses and other current assets 9 Property and equipment, net 25 Investments 121 Intangible assets, net 8,100 Other noncurrent assets 31 Current portion of long-term debt (400) Accounts payable and accrued liabilities (100) Long-term debt (246) Deferred income taxes (1,292) Other long-term liabilities (31) Total identifiable net assets 6,960 Goodwill 1,702 Total assets acquired and liabilities assumed $ 8,662 The following table summarizes the final fair value of assets acquired and liabilities assumed as of the acquisition date: (in millions) Assets acquired and liabilities assumed Cash and equivalents $ 591 Accounts receivable 171 Inventories 211 Prepaid expenses and other current assets 40 Property and equipment, net 7 Intangible assets, net Developed product rights 7,200 License agreements 125 Acquired in-process research and development 1,280 Other noncurrent assets 273 Current portion of long-term debt (99) Accounts payable and accrued liabilities (312) Deferred income taxes (899) Other long-term liabilities (47) Total identifiable net assets 8,541 Goodwill 1,249 Total assets acquired and liabilities assumed $ 9,790
Business Acquisition, Pro Forma Information	The following table presents the unaudited pro forma combined results of AbbVie, ImmunoGen and Cerevel Therapeutics for 2024 and 2023 as if the acquisitions of ImmunoGen and Cerevel Therapeutics had occurred on January 1, 2023: years ended December 31 (in millions) 2024 2023 Net revenues $ 56,389 $ 54,691 Net earnings 4,564 2,862

Collaborations (Tables)

Collaborations (Tables)	12 Months Ended
	Dec. 31, 2024
Janssen Biotech, Inc
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Janssen and AbbVie: years ended December 31 (in millions) 2024 2023 2022 United States - Janssen's share of profits (included in cost of products sold) $ 1,140 $ 1,245 $ 1,607 International - AbbVie's share of profits (included in net revenues) 899 931 1,142 Global - AbbVie's share of other costs (included in respective line items) 162 228 268
Genentech, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Genentech and AbbVie: years ended December 31 (in millions) 2024 2023 2022 Genentech's share of profits, including royalties (included in cost of products sold) $ 990 $ 869 $ 778 AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) 29 41 37 AbbVie's share of development costs (included in R&D) 84 109 121

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of changes in the carrying amount of goodwill	The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2022 $ 32,156 Foreign currency translation adjustments and other 137 Balance as of December 31, 2023 32,293 Additions (a) 2,951 Foreign currency translation adjustments and other (288) Balance as of December 31, 2024 $ 34,956 (a) Goodwill additions related to the acquisitions of ImmunoGen and Cerevel Therapeutics (see Note 5).
Schedule of definite-lived intangible assets	The following table summarizes intangible assets: 2024 2023 as of December 31 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 81,428 $ (28,253) $ 53,175 $ 75,142 $ (22,455) $ 52,687 License agreements 8,315 (6,624) 1,691 8,191 (5,571) 2,620 Total definite-lived intangible assets 89,743 (34,877) 54,866 83,333 (28,026) 55,307 Indefinite-lived intangible assets 5,202 — 5,202 303 — 303 Total intangible assets, net $ 94,945 $ (34,877) $ 60,068 $ 83,636 $ (28,026) $ 55,610
Schedule of indefinite-lived intangible assets	The following table summarizes intangible assets: 2024 2023 as of December 31 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 81,428 $ (28,253) $ 53,175 $ 75,142 $ (22,455) $ 52,687 License agreements 8,315 (6,624) 1,691 8,191 (5,571) 2,620 Total definite-lived intangible assets 89,743 (34,877) 54,866 83,333 (28,026) 55,307 Indefinite-lived intangible assets 5,202 — 5,202 303 — 303 Total intangible assets, net $ 94,945 $ (34,877) $ 60,068 $ 83,636 $ (28,026) $ 55,610
Schedule of anticipated annual amortization expense	The anticipated annual amortization expense for definite-lived intangible assets recorded as of December 31, 2024 is as follows: (in billions) 2025 2026 2027 2028 2029 Anticipated annual amortization expense $ 7.3 $ 6.7 $ 6.1 $ 6.3 $ 5.7

Restructuring Plans (Tables)

Restructuring Plans (Tables)	12 Months Ended
	Dec. 31, 2024
Restructuring charges
Summary of cash activity in the restructuring reserve	The following table summarizes the cash activity in the restructuring reserve for 2024, 2023 and 2022: (in millions) Accrued balance as of December 31, 2021 $ 33 Charges 193 Payments and other adjustments (50) Accrued balance as of December 31, 2022 176 Charges 107 Payments and other adjustments (87) Accrued balance as of December 31, 2023 196 Charges 168 Payments and other adjustments (128) Accrued balance as of December 31, 2024 $ 236
Allergan integration plan
Restructuring charges
Summary of charges associated with integration plan	The following table summarizes the charges associated with the Allergan acquisition integration plan: year ended December 31 (in millions) 2023 2022 Cost of products sold $ 89 $ 117 Research and development 7 23 Selling, general and administrative 192 399 Total charges $ 288 $ 539

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Summary of amounts and location of operating and finance leases on the consolidated balance sheets	The following table summarizes the amounts and location of operating and finance leases on the consolidated balance sheets: as of December 31 (in millions) Balance sheet caption 2024 2023 Assets Operating Other assets $ 723 $ 744 Finance Property and equipment, net 33 35 Total lease assets $ 756 $ 779 Liabilities Operating Current Accounts payable and accrued liabilities $ 178 $ 166 Noncurrent Other long-term liabilities 697 735 Finance Current Current portion of long-term debt and finance lease obligations 17 15 Noncurrent Long-term debt and finance lease obligations 23 27 Total lease liabilities $ 915 $ 943
Summary of lease costs recognized in the condensed consolidated statements of earnings	The following table summarizes the lease costs recognized in the consolidated statements of earnings: years ended December 31 (in millions) 2024 2023 2022 Operating lease cost $ 196 $ 189 $ 201 Short-term lease cost 65 28 67 Variable lease cost 86 88 71 Total lease cost $ 347 $ 305 $ 339 In December 2022, the company entered into an agreement to sublease a portion of its Madison, New Jersey office space through the end of the original lease maturity in 2030. As a result of this agreement, the company recognized an impairment loss on its right-of-use asset of $69 million and wrote-off the related leasehold improvements of $37 million. These losses were recorded in SG&A expense
Schedule of weighted-average remaining lease term and weighted-average discount rate for operating and finance leases	The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases: years ended December 31 2024 2023 2022 Weighted-average remaining lease term (years) Operating 7 7 8 Finance 5 3 2 Weighted-average discount rate Operating 3.3 % 3.0 % 2.6 % Finance 4.2 % 3.6 % 1.5 %
Schedule of supplementary cash flow information regarding the company's leases	The following table presents supplementary cash flow information regarding the company's leases: years ended December 31 (in millions) 2024 2023 2022 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 204 $ 214 $ 212 Right-of-use assets obtained in exchange for new operating lease liabilities 159 173 235
Summary of future maturities of AbbVie's operating lease liabilities	The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of December 31, 2024: (in millions) Operating Finance Total (a) 2025 $ 204 $ 18 $ 222 2026 182 15 197 2027 145 4 149 2028 118 2 120 2029 102 1 103 Thereafter 223 2 225 Total lease payments 974 42 1,016 Less: Interest 99 2 101 Present value of lease liabilities $ 875 $ 40 $ 915 (a) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
Summary of future maturities of AbbVie's finance lease liabilities	The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of December 31, 2024: (in millions) Operating Finance Total (a) 2025 $ 204 $ 18 $ 222 2026 182 15 197 2027 145 4 149 2028 118 2 120 2029 102 1 103 Thereafter 223 2 225 Total lease payments 974 42 1,016 Less: Interest 99 2 101 Present value of lease liabilities $ 875 $ 40 $ 915 (a) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

Debt, Credit Facilities and C_2

Debt, Credit Facilities and Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2024
Debt, Credit Facilities and Commitments and Contingencies
Summary of long-term debt	The following table summarizes long-term debt: as of December 31 (dollars in millions) 2024 Effective interest rate (a) 2024 2023 Effective interest rate (a) 2023 1.25-3.85% aggregate notes due 2024 0.65-2.69% $ — 0.65-2.69% $ 7,169 Floating rate term loans due 2025 6.22 % — 5.95 % 2,000 3.60% senior notes due 2025 3.66 % 3,750 3.66 % 3,750 3.80% senior notes due 2025 2.09 % 3,021 2.09 % 3,021 2.95% senior notes due 2026 3.02 % 4,000 3.02 % 4,000 3.20% senior notes due 2026 3.28 % 2,000 3.28 % 2,000 4.549% term loan due 2027 4.61 % 2,000 — — 0.75% senior euro notes due 2027 (€750 principal) 0.86 % 778 0.86 % 833 4.80% senior notes due 2027 4.93 % 2,250 — — 4.25% senior notes due 2028 4.38 % 1,750 4.38 % 1,750 2.125% senior euro notes due 2028 (€750 principal) 2.18 % 778 2.18 % 833 2.625% senior euro notes due 2028 (€500 principal) 1.20 % 519 1.20 % 555 3.20% senior notes due 2029 3.25 % 5,500 3.25 % 5,500 2.125% senior euro notes due 2029 (€550 principal) 1.19 % 570 1.19 % 611 4.80% senior notes due 2029 4.91 % 2,500 — — 1.25% senior euro notes due 2031 (€650 principal) 1.30 % 674 1.30 % 722 4.95% senior notes due 2031 5.02 % 2,000 — — 5.05% senior notes due 2034 5.13 % 3,000 — — 4.55% senior notes due 2035 3.52 % 1,789 3.52 % 1,789 4.50% senior notes due 2035 4.58 % 2,500 4.58 % 2,500 4.30% senior notes due 2036 4.37 % 1,000 4.37 % 1,000 4.05% senior notes due 2039 4.11 % 4,000 4.11 % 4,000 4.40% senior notes due 2042 4.46 % 2,600 4.46 % 2,600 4.625% senior notes due 2042 4.00 % 457 4.00 % 457 4.85% senior notes due 2044 4.11 % 1,074 4.11 % 1,074 5.35% senior notes due 2044 5.39 % 750 — — 4.70% senior notes due 2045 4.73 % 2,700 4.73 % 2,700 4.75% senior notes due 2045 4.20 % 881 4.20 % 881 4.45% senior notes due 2046 4.50 % 2,000 4.50 % 2,000 4.875% senior notes due 2048 4.94 % 1,750 4.94 % 1,750 4.25% senior notes due 2049 4.29 % 5,750 4.29 % 5,750 5.40% senior notes due 2054 5.44 % 3,000 — — 5.50% senior notes due 2064 5.53 % 1,500 — — Fair value hedges (224) (266) Unamortized bond discounts (130) (106) Unamortized deferred financing costs (266) (198) Unamortized bond premiums 555 668 Financing liability 328 — Other 40 42 Total long-term debt and finance lease obligations 67,144 59,385 Current portion 6,804 7,191 Noncurrent portion $ 60,340 $ 52,194 (a) Excludes the effect of any related interest rate swaps.
Summary of maturities of long-term debt	as of and for the years ending December 31 (in millions) 2025 $ 6,771 2026 6,000 2027 5,028 2028 3,047 2029 8,570 Thereafter 37,425 Total obligations and commitments 66,841 Fair value hedges, unamortized bond premiums/discounts, deferred financing costs, finance lease obligations and financing liability 303 Total long-term debt and finance lease obligations $ 67,144

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measures (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Summary of amounts and location of derivatives on the consolidated balance sheets	The following table summarizes the amounts and location of AbbVie's derivative instruments on the consolidated balance sheets: Fair value - Derivatives in asset position Fair value - as of December 31 (in millions) Balance sheet caption 2024 2023 Balance sheet caption 2024 2023 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 119 $ 12 Accounts payable and accrued liabilities $ 5 $ 32 Designated as net investment hedges Prepaid expenses and other 4 13 Accounts payable and accrued liabilities — 66 Designated as net investment hedges Other assets 148 — Other long-term liabilities — 69 Not designated as hedges Prepaid expenses and other 42 41 Accounts payable and accrued liabilities 30 36 Interest rate swap contracts Designated as fair value hedges Other assets — — Other long-term liabilities 231 293 Total derivatives $ 313 $ 66 $ 266 $ 496
Schedule of pre-tax amounts of derivatives recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss): years ended in December 31 (in millions) 2024 2023 2022 Foreign currency forward exchange contracts Designated as cash flow hedges $ 192 $ (2) $ 103 Designated as net investment hedges 435 (144) 395 Cross-currency swap contracts designated as cash flow hedges — (6) — Interest rate swap contracts designated as cash flow hedges — — 6
Summary of pre-tax amounts and location of derivatives recognized in the consolidated statement of earnings	The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 13 for the amount of net gains (losses) reclassified out of AOCI. years ended December 31 (in millions) Statement of earnings caption 2024 2023 2022 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ 73 $ 77 $ 82 Designated as net investment hedges Interest expense, net 123 112 94 Not designated as hedges Net foreign exchange loss 6 33 (156) Treasury rate lock agreements designated as cash flow hedges Interest expense, net 23 24 23 Cross-currency swap contracts designated as cash flow hedges Net foreign exchange loss — (6) — Interest rate swap contracts Designated as cash flow hedges Interest expense, net — — (1) Designated as fair value hedges Interest expense, net 62 98 (402) Debt designated as hedged item in fair value hedges Interest expense, net (62) (98) 402
Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis	The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2024: Basis of fair value measurement (in millions) Total Quoted prices in active markets for Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 5,524 $ 5,179 $ 345 $ — Money market funds and time deposits 10 — 10 — Debt securities 33 — 33 — Equity securities 98 70 28 — Foreign currency contracts 313 — 313 — Total assets $ 5,978 $ 5,249 $ 729 $ — Liabilities Interest rate swap contracts $ 231 $ — $ 231 $ — Foreign currency contracts 35 — 35 — Financing liability 328 — — 328 Contingent consideration 21,666 — — 21,666 Total liabilities $ 22,260 $ — $ 266 $ 21,994 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the consolidated balance sheet as of December 31, 2023: Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant unobservable inputs Assets Cash and equivalents $ 12,814 $ 6,223 $ 6,591 $ — Money market funds and time deposits 10 — 10 — Debt securities 26 — 26 — Equity securities 111 86 25 — Foreign currency contracts 66 — 66 — Total assets $ 13,027 $ 6,309 $ 6,718 $ — Liabilities Interest rate swap contracts $ 293 $ — $ 293 $ — Foreign currency contracts 203 — 203 — Contingent consideration 19,890 — — 19,890 Total liabilities $ 20,386 $ — $ 496 $ 19,890
Summary of significant level 3 unobservable inputs	The fair value of the company's contingent consideration liabilities was calculated using the following significant unobservable inputs: 2024 2023 years ended December 31 (in millions) Range Weighted Average (a) Range Weighted Average (a) Discount rate 4.6% - 5.2% 4.8% 4.3% - 5.9% 4.5 % Probability of payment for royalties by indication (b) 100% 100% 89% - 100% 99 % Projected year of payments 2025 - 2034 2029 2024 - 2034 2027 (a) Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities. (b) Excluding approved indications, the estimated probability of payment was 89% at December 31, 2023.	[1],[2]
Summary of changes in fair value of Level 3 inputs	The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: years ended December 31 (in millions) 2024 2023 2022 Beginning balance $ 19,890 $ 16,384 $ 14,887 Additions (a) — — 32 Change in fair value recognized in net earnings 3,771 5,128 2,761 Payments (1,995) (1,622) (1,296) Ending balance $ 21,666 $ 19,890 $ 16,384 (a) Additions during the year ended December 31, 2022, represent contingent consideration liabilities assumed in the DJS acquisition.
Schedule of book values, approximate fair values and bases used to measure certain financial instruments	The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2024 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair values Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 6,797 $ 6,767 $ 6,620 $ 147 $ — Long-term debt and finance lease obligations, excluding fair value hedges and financing liability 60,243 55,836 53,441 2,395 — Total liabilities $ 67,040 $ 62,603 $ 60,061 $ 2,542 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2023 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair values Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Liabilities Current portion of long-term debt and finance lease obligations, excluding fair value hedges $ 7,191 $ 7,069 $ 6,862 $ 207 $ — Long-term debt and finance lease obligations, excluding fair value hedges 52,460 49,541 48,983 558 — Total liabilities $ 59,651 $ 56,610 $ 55,845 $ 765 $ —
[1] Excluding approved indications, the estimated probability of payment was 89% at December 31, 2023. Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.

Post-Employment Benefits (Table

Post-Employment Benefits (Tables)	12 Months Ended
	Dec. 31, 2024
Postemployment Benefits [Abstract]
Schedule of benefit plan information	The following table summarizes benefit plan information for the global AbbVie-sponsored defined benefit and other post-employment plans: Defined benefit plans Other post-employment plans as of and for the years ended December 31 (in millions) 2024 2023 2024 2023 Projected benefit obligations Beginning of period $ 9,544 $ 8,588 $ 796 $ 667 Service cost 286 270 43 37 Interest cost 451 432 41 37 Actuarial (gain) loss (855) 491 (62) 89 Benefits paid (347) (316) (31) (35) Other, primarily foreign currency translation adjustments (115) 79 (1) 1 End of period 8,964 9,544 786 796 Fair value of plan assets Beginning of period 9,839 8,472 — — Actual return on plan assets 865 1,230 — — Company contributions 326 366 31 35 Benefits paid (347) (316) (31) (35) Other, primarily foreign currency translation adjustments (132) 87 — — End of period 10,551 9,839 — — Funded status, end of period $ 1,587 $ 295 $ (786) $ (796) Amounts recognized on the consolidated balance sheets Other assets $ 2,097 $ 1,086 $ — $ — Accounts payable and accrued liabilities (20) (17) (42) (32) Other long-term liabilities (490) (774) (744) (764) Net asset (obligation) $ 1,587 $ 295 $ (786) $ (796) Actuarial loss, net $ 1,303 $ 2,290 $ 203 $ 282 Prior service cost (credit) 1 1 (261) (297) Accumulated other comprehensive loss (income) $ 1,304 $ 2,291 $ (58) $ (15)
Information For Pension Plans With An Accumulated Benefit Obligation In Excess Of Plan Assets	Information For Pension Plans With An Accumulated Benefit Obligation In Excess Of Plan Assets as of December 31 (in millions) 2024 2023 Accumulated benefit obligation $ 527 $ 1,410 Fair value of plan assets 94 890
Information For Pension Plans With A Projected Benefit Obligation In Excess Of Plan Assets	Information For Pension Plans With A Projected Benefit Obligation In Excess Of Plan Assets as of December 31 (in millions) 2024 2023 Projected benefit obligation $ 775 $ 6,343 Fair value of plan assets 265 5,552
Summary of pretax gains and losses included in other comprehensive income (loss)	The following table summarizes the pre-tax losses (gains) included in other comprehensive income (loss): years ended December 31 (in millions) 2024 2023 2022 Defined benefit plans Actuarial gain $ (935) $ (16) $ (925) Amortization of prior service cost — (1) (2) Amortization of actuarial loss (52) (16) (231) Foreign exchange loss (gain) and other — (44) 17 Total gain $ (987) $ (77) $ (1,141) Other post-employment plans Actuarial loss (gain) $ (62) $ 89 $ (229) Prior service credit — — (2) Amortization of prior service credit 36 36 38 Amortization of actuarial loss (17) (12) (26) Total loss (gain) $ (43) $ 113 $ (219)
Summary of net periodic benefit cost relating to the company's defined benefit and other post-employment plans	Net Periodic Benefit Cost years ended December 31 (in millions) 2024 2023 2022 Defined benefit plans Service cost $ 286 $ 270 $ 454 Interest cost 451 432 297 Expected return on plan assets (785) (723) (712) Amortization of prior service cost — 1 2 Amortization of actuarial loss 52 16 231 Net periodic benefit cost (credit) $ 4 $ (4) $ 272 Other post-employment plans Service cost $ 43 $ 37 $ 51 Interest cost 41 37 23 Amortization of prior service credit (36) (36) (38) Amortization of actuarial loss 17 12 26 Net periodic benefit cost $ 65 $ 50 $ 62
Schedule of weighted-average assumptions used in determining benefit obligations at the measurement date	Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date as of December 31 2024 2023 Defined benefit plans Discount rate 5.4 % 4.8 % Rate of compensation increases 4.4 % 4.8 % Cash balance interest crediting rate 4.0 % 4.4 % Other post-employment plans Discount rate 5.7 % 5.1 %
Schedule of weighted-average assumptions used in determining net periodic benefit cost	Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost years ended December 31 2024 2023 2022 Defined benefit plans Discount rate for determining service cost 4.8 % 5.0 % 3.0 % Discount rate for determining interest cost 4.8 % 4.9 % 2.6 % Expected long-term rate of return on plan assets 7.5 % 7.3 % 7.1 % Expected rate of change in compensation 4.4 % 4.8 % 5.2 % Cash balance interest crediting rate 4.4 % 2.7 % 2.7 % Other post-employment plans Discount rate for determining service cost 5.2 % 5.3 % 3.3 % Discount rate for determining interest cost 4.9 % 5.1 % 2.7 %
Schedule of defined benefit pension plan assets	Defined Benefit Pension Plan Assets Basis of fair value measurement as of December 31 (in millions) 2024 Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs (Level 3) Equities U.S. large cap (a) $ 1,131 $ 1,131 $ — $ — U.S. mid cap (b) 176 176 — — International (c) 408 408 — — Fixed income securities U.S. government securities (d) 414 18 396 — Corporate debt instruments (d) 609 29 580 — Non-U.S. government securities (d) 346 183 163 — Other (d) 20 15 5 — Absolute return funds (e) 176 82 94 — Other (f) 351 350 1 — Total $ 3,631 $ 2,392 $ 1,239 $ — Total assets measured at NAV 6,920 Fair value of plan assets $ 10,551 Basis of fair value measurement as of December 31 (in millions) 2023 Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Equities U.S. large cap (a) $ 1,018 $ 1,018 $ — $ — U.S. mid cap (b) 173 173 — — International (c) 488 488 — — Fixed income securities U.S. government securities (d) 246 62 184 — Corporate debt instruments (d) 714 155 559 — Non-U.S. government securities (d) 461 301 160 — Other (d) 126 124 2 — Absolute return funds (e) 155 66 89 — Other (f) 414 413 1 — Total $ 3,795 $ 2,800 $ 995 $ — Total assets measured at NAV 6,044 Fair value of plan assets $ 9,839 (a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices. (b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid cap indices. (c) A mix of index funds and actively managed equity accounts that are benchmarked to various non-U.S. equity indices in both developed and emerging markets. (d) Securities held by actively managed accounts, index funds and mutual funds. (e) Primarily funds having global mandates with the flexibility to allocate capital broadly across a wide range of asset classes and strategies, including but not limited to equities, fixed income, commodities, financial futures, currencies and other securities, with objectives to outperform agreed upon benchmarks of specific return and volatility targets. (f) Investments in cash and cash equivalents.
Schedule of expected benefit payments	Expected Benefit Payments The following table summarizes total benefit payments expected to be paid to plan participants including payments funded from both plan and company assets: years ending December 31 (in millions) Defined Other 2025 $ 363 $ 42 2026 383 46 2027 410 49 2028 435 53 2029 464 57 2030 to 2034 3,007 330

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Schedule of share-based compensation expense	Stock-based compensation expense is principally related to awards issued pursuant to the 2013 ISP and the Amended Plan and is summarized as follows: years ended December 31 (in millions) 2024 2023 2022 Cost of products sold $ 55 $ 46 $ 38 Research and development 341 278 232 Selling, general and administrative 515 423 401 Pre-tax compensation expense 911 747 671 Tax benefit 159 136 122 After-tax compensation expense $ 752 $ 611 $ 549
Cash Settled Stock Based Compensation in Connection with Acquisitions	In addition to stock-based compensation expense included in the table above and in connection with the acquisitions of ImmunoGen and Cerevel Therapeutics, AbbVie incurred cash-settled, post-closing expense for ImmunoGen and Cerevel Therapeutics employee incentive awards, which is summarized in the table below: year ended December 31 (in millions) 2024 Cost of products sold $ 36 Research and development 184 Selling, general and administrative 290 Total post-closing cash settled expense $ 510
Summary of AbbVie stock option activity	The following table summarizes AbbVie stock option activity in 2024: (options in thousands, aggregate intrinsic value in millions) Options Weighted- average Weighted-average remaining Aggregate intrinsic value Outstanding at December 31, 2023 7,481 $ 102.80 5.0 $ 390 Granted 648 175.26 Exercised (2,420) 89.01 Lapsed and forfeited (96) 81.16 Outstanding at December 31, 2024 5,613 $ 117.48 5.6 $ 338 Exercisable at December 31, 2024 4,295 $ 104.07 4.7 $ 316
Summary of AbbVie RSA and RSU activity	The following table summarizes AbbVie RSU and performance share activity for 2024: (share units in thousands) Share units Weighted-average grant date fair value Outstanding at December 31, 2023 10,739 $ 136.42 Granted 5,558 168.62 Granted in acquisitions 605 168.24 Vested (6,052) 128.28 Forfeited (463) 152.79 Outstanding at December 31, 2024 10,387 $ 159.52
Summary of quarterly cash dividends	The following table summarizes quarterly cash dividends declared during 2024, 2023 and 2022: 2024 2023 2022 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 10/30/24 02/14/25 $1.64 10/26/23 02/15/24 $1.55 10/28/22 02/15/23 $1.48 09/06/24 11/15/24 $1.55 09/08/23 11/15/23 $1.48 09/09/22 11/15/22 $1.41 06/21/24 08/15/24 $1.55 06/22/23 08/15/23 $1.48 06/23/22 08/15/22 $1.41 02/15/24 05/15/24 $1.55 02/16/23 05/15/23 $1.48 02/17/22 05/16/22 $1.41
Summary of changes in each component of accumulated other comprehensive loss, net of tax	The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for 2024, 2023 and 2022: (in millions) (brackets denote losses) Foreign currency translation adjustments Net investment hedging activities Pension Cash flow hedging activities Total Balance as of December 31, 2021 $ (570) $ (91) $ (2,546) $ 308 $ (2,899) Other comprehensive income (loss) before reclassifications (943) 629 915 91 692 Net losses (gains) reclassified from accumulated other comprehensive loss — (74) 173 (91) 8 Net current-period other comprehensive income (loss) (943) 555 1,088 — 700 Balance as of December 31, 2022 (1,513) 464 (1,458) 308 (2,199) Other comprehensive income (loss) before reclassifications 407 (311) (23) (10) 63 Net gains reclassified from accumulated other comprehensive loss — (88) (7) (74) (169) Net current-period other comprehensive income (loss) 407 (399) (30) (84) (106) Balance as of December 31, 2023 (1,106) 65 (1,488) 224 (2,305) Other comprehensive income (loss) before reclassifications (1,008) 580 799 155 526 Net losses (gains) reclassified from accumulated other comprehensive loss — (96) 25 (75) (146) Net current-period other comprehensive income (loss) (1,008) 484 824 80 380 Balance as of December 31, 2024 $ (2,114) $ 549 $ (664) $ 304 $ (1,925)
Schedule of the impact of significant amounts reclassified out of each component of accumulated other comprehensive loss	The table below presents the impact on AbbVie's consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: years ended December 31 (in millions) (brackets denote gains) 2024 2023 2022 Net investment hedging activities Gains on derivative amount excluded from effectiveness testing (a) $ (123) $ (112) $ (94) Tax expense 27 24 20 Total reclassifications, net of tax $ (96) $ (88) $ (74) Pension and post-employment benefits Amortization of actuarial losses (gains) and other (b) $ 33 $ (7) $ 221 Tax benefit (8) — (48) Total reclassifications, net of tax $ 25 $ (7) $ 173 Cash flow hedging activities Gains on foreign currency forward exchange contracts (c) $ (73) $ (77) $ (82) Gains on treasury rate lock agreements (a) (23) (24) (23) Losses on interest rate swap contracts (a) — — 1 Losses on cross-currency swap contracts (d) — 6 — Tax expense 21 21 13 Total reclassifications, net of tax $ (75) $ (74) $ (91) (a) Amounts are included in interest expense, net (see Note 11). (b) Amounts are included in the computation of net periodic benefit cost (see Note 12). (c) Amounts are included in cost of products sold (see Note 11). (d) Amounts are included in net foreign exchange loss (see Note 11).

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of earnings before income tax expense	Earnings Before Income Tax Expense years ended December 31 (in millions) 2024 2023 2022 Domestic $ (7,743) $ (3,475) $ (4,608) Foreign 11,459 9,725 18,085 Total earnings before income tax expense $ 3,716 $ 6,250 $ 13,477
Schedule of income tax expense	Income Tax Expense years ended December 31 (in millions) 2024 2023 2022 Current Domestic $ (331) $ 3,272 $ 2,647 Foreign 1,210 994 916 Total current taxes $ 879 $ 4,266 $ 3,563 Deferred Domestic $ (1,303) $ (2,324) $ (1,512) Foreign (146) (565) (419) Total deferred taxes $ (1,449) $ (2,889) $ (1,931) Total income tax expense (benefit) $ (570) $ 1,377 $ 1,632
Summary of effective tax rate reconciliation	Effective Tax Rate Reconciliation years ended December 31 2024 2023 2022 Statutory tax rate 21.0 % 21.0 % 21.0 % Effect of foreign operations 7.6 8.0 (4.4) U.S. tax credits (5.4) (3.1) (2.8) Stock-based compensation (1.2) (1.0) (0.6) Non-deductible expenses 1.1 0.7 0.4 Tax law changes and related structuring (0.3) (3.8) (2.4) Tax audits, settlements and reserves (51.4) (1.1) 0.9 Acquisition costs 13.4 0.2 — All other, net (0.1) 1.1 — Effective tax rate (15.3) % 22.0 % 12.1 %
Schedule of deferred tax assets and liabilities	Deferred Tax Assets and Liabilities as of December 31 (in millions) 2024 2023 Deferred tax assets Compensation and employee benefits $ 215 $ 519 Accruals and reserves 1,253 1,113 Chargebacks and rebates 1,354 1,431 Advance payments 66 298 Net operating losses and other carryforwards 15,815 14,316 Other 2,156 2,259 Total deferred tax assets 20,859 19,936 Valuation allowances (14,823) (13,478) Total net deferred tax assets 6,036 6,458 Deferred tax liabilities Excess of book basis over tax basis of intangible assets (1,969) (1,535) Excess of book basis over tax basis in investments (302) (374) Other (718) (746) Total deferred tax liabilities (2,989) (2,655) Net deferred tax assets $ 3,047 $ 3,803
Schedule of Unrecognized Tax Benefits Roll Forward	Unrecognized Tax Benefits years ended December 31 (in millions) 2024 2023 2022 Beginning balance $ 5,762 $ 5,670 $ 5,489 Increase due to current year tax positions 173 129 88 Increase due to prior year tax positions 454 109 243 Decrease due to prior year tax positions (1,741) (21) (33) Settlements (284) (86) (7) Increase due to acquisitions 82 — — Lapse of statutes of limitations (45) (39) (110) Ending balance $ 4,401 $ 5,762 $ 5,670

Segment and Geographic Area I_2

Segment and Geographic Area Information (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of net revenues by product	The following tables detail AbbVie's worldwide net revenues: years ended December 31 (in millions) 2024 2023 2022 Immunology Humira United States $ 7,142 $ 12,160 $ 18,619 International 1,851 2,244 2,618 Total $ 8,993 $ 14,404 $ 21,237 Skyrizi United States $ 10,086 $ 6,753 $ 4,484 International 1,632 1,010 681 Total $ 11,718 $ 7,763 $ 5,165 Rinvoq United States $ 4,259 $ 2,824 $ 1,794 International 1,712 1,145 728 Total $ 5,971 $ 3,969 $ 2,522 Oncology Imbruvica United States $ 2,448 $ 2,665 $ 3,426 Collaboration revenues 899 931 1,142 Total $ 3,347 $ 3,596 $ 4,568 Venclexta United States $ 1,234 $ 1,087 $ 1,009 International 1,349 1,201 1,000 Total $ 2,583 $ 2,288 $ 2,009 Elahere (a) United States $ 477 $ — $ — International 2 — — Total $ 479 $ — $ — Epkinly Collaboration revenues $ 118 $ 28 $ — International 28 3 — Total $ 146 $ 31 $ — Aesthetics Botox Cosmetic United States $ 1,682 $ 1,670 $ 1,654 International 1,038 1,012 961 Total $ 2,720 $ 2,682 $ 2,615 Juvederm Collection United States $ 469 $ 519 $ 548 International 708 859 880 Total $ 1,177 $ 1,378 $ 1,428 Other Aesthetics United States $ 1,118 $ 1,060 $ 1,122 International 161 174 168 Total $ 1,279 $ 1,234 $ 1,290 Neuroscience Botox Therapeutic United States $ 2,718 $ 2,476 $ 2,255 International 565 515 464 Total $ 3,283 $ 2,991 $ 2,719 Vraylar United States $ 3,260 $ 2,755 $ 2,037 International 7 4 1 Total $ 3,267 $ 2,759 $ 2,038 Duodopa United States $ 96 $ 97 $ 95 International 351 371 363 Total $ 447 $ 468 $ 458 Ubrelvy United States $ 981 $ 803 $ 680 International 25 12 — Total $ 1,006 $ 815 $ 680 Qulipta United States $ 628 $ 405 $ 158 International 30 3 — Total $ 658 $ 408 $ 158 years ended December 31 (in millions) 2024 2023 2022 Other Neuroscience United States $ 224 $ 254 $ 456 International 114 22 19 Total $ 338 $ 276 $ 475 Eye Care Ozurdex United States $ 138 $ 143 $ 139 International 356 329 289 Total $ 494 $ 472 $ 428 Lumigan/Ganfort United States $ 187 $ 173 $ 242 International 242 259 272 Total $ 429 $ 432 $ 514 Alphagan/Combigan United States $ 95 $ 121 $ 202 International 153 151 144 Total $ 248 $ 272 $ 346 Restasis United States $ 172 $ 382 $ 621 International 52 54 45 Total $ 224 $ 436 $ 666 Other Eye Care United States $ 472 $ 433 $ 399 International 375 370 348 Total $ 847 $ 803 $ 747 Other Key Products Mavyret United States $ 595 $ 659 $ 755 International 716 771 786 Total $ 1,311 $ 1,430 $ 1,541 Creon United States $ 1,383 $ 1,268 $ 1,278 Linzess/Constella United States $ 916 $ 1,073 $ 1,003 International 38 35 32 Total $ 954 $ 1,108 $ 1,035 All other $ 3,032 $ 3,035 $ 4,137 Total net revenues $ 56,334 $ 54,318 $ 58,054 (a) Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.
Schedule of net revenues to external customers by geographic area	Net revenues to external customers by geographic area, based on product shipment destination, were as follows: years ended December 31 (in millions) 2024 2023 2022 United States $ 43,029 $ 41,883 $ 45,713 Germany 1,465 1,266 1,340 Japan 1,122 1,008 956 Canada 1,088 1,076 1,159 China 917 950 912 France 776 780 787 Spain 528 501 506 United Kingdom 522 417 462 Italy 511 484 444 Brazil 464 439 430 Australia 463 472 508 All other countries 5,449 5,042 4,837 Total net revenues $ 56,334 $ 54,318 $ 58,054
Schedule of long-lived assets by geographic area	Long-lived assets, primarily net property and equipment, by geographic area were as follows: as of December 31 (in millions) 2024 2023 United States $ 3,331 $ 3,139 Europe 1,485 1,433 All other 318 417 Total long-lived assets $ 5,134 $ 4,989

Fourth Quarter Financial Resu_2

Fourth Quarter Financial Results (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2024
Quarterly Financial Information Disclosure [Abstract]
Schedule of fourth quarter financial results	quarter ended December 31 (in millions except per share data) 2024 Net revenues $ 15,102 Gross margin 10,706 Net loss attributable to AbbVie Inc. (22) Basic loss per share attributable to AbbVie Inc. $ (0.02) Diluted loss per share attributable to AbbVie Inc. $ (0.02) Cash dividends declared per common share $ 1.64

Background and Basis of Prese_2

Background and Basis of Presentation (Details)	Jan. 01, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Percentage of outstanding common stock distributed to Abbott shareholders	100%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional information (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Advertising expenses	$ 2.1	$ 2.2	$ 2
Amortization period of differences between the expected and actual return on plan assets	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Finished goods	$ 1,173	$ 1,356
Work-in-process	1,951	1,643
Raw materials	1,057	1,100
Inventories	$ 4,181	$ 4,099

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property and Equipment
Property and equipment, gross	$ 12,267	$ 11,635
Less accumulated depreciation	(7,133)	(6,646)
Property and equipment, net	5,134	4,989
Depreciation expense	764	752	$ 778
Land
Property and Equipment
Property and equipment, gross	284	286
Buildings
Property and Equipment
Property and equipment, gross	$ 2,895	2,827
Buildings | Minimum
Property and Equipment
Estimated useful lives	10 years
Buildings | Maximum
Property and Equipment
Estimated useful lives	50 years
Equipment
Property and Equipment
Property and equipment, gross	$ 7,995	7,449
Equipment | Minimum
Property and Equipment
Estimated useful lives	2 years
Amortization period of software costs included in equipment	3 years
Equipment | Maximum
Property and Equipment
Estimated useful lives	25 years
Amortization period of software costs included in equipment	10 years
Construction in progress
Property and Equipment
Property and equipment, gross	$ 1,093	$ 1,073

Supplemental Financial Inform_3

Supplemental Financial Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Interest Expense, Net
Interest expense	$ 2,808	$ 2,224	$ 2,230
Interest income	(648)	(540)	(186)
Interest expense, net	2,160	1,684	$ 2,044
Accounts Payable and Accrued Liabilities
Sales rebates	14,304	13,627
Dividends payable	2,936	2,783
Accounts payable	2,945	3,688
Current portion of contingent consideration liabilities	2,589	1,952
Salaries, wages and commissions	1,986	1,802
Royalty and license arrangements	527	360
Other	6,658	6,438
Accounts payable and accrued liabilities	31,945	30,650
Other Long-Term Liabilities
Contingent consideration liabilities	19,077	17,938
Liabilities for unrecognized tax benefits	5,049	6,681
Income taxes payable	1,261	2,182
Pension and other post-employment benefits	1,234	1,538
Other	3,508	3,988
Other long-term liabilities	$ 30,129	$ 32,327

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Basic EPS
Net earnings attributable to AbbVie Inc.	$ (22)	$ 4,278	$ 4,863	$ 11,836
Earnings allocated to participating securities		40	43	54
Earnings available to common shareholders		$ 4,238	$ 4,820	$ 11,782
Weighted-average basic shares outstanding (in shares)		1,769	1,768	1,771
Basic earnings per share (in dollars per share)	$ (0.02)	$ 2.40	$ 2.73	$ 6.65
Diluted EPS
Net earnings attributable to AbbVie Inc.	$ (22)	$ 4,278	$ 4,863	$ 11,836
Earnings allocated to participating securities		40	43	54
Earnings available to common shareholders		$ 4,238	$ 4,820	$ 11,782
Weighted-average basic shares outstanding (in shares)		1,769	1,768	1,771
Effect of dilutive securities (in shares)		4	5	7
Weighted-average diluted shares outstanding (in shares)		1,773	1,773	1,778
Diluted earnings per share (in dollars per share)	$ (0.02)	$ 2.39	$ 2.72	$ 6.63

Licensing, Acquisitions, and _3

Licensing, Acquisitions, and Other Arrangements (Details) - Cerevel Therapeutics - USD ($) $ / shares in Units, shares in Thousands, $ in Millions		5 Months Ended	11 Months Ended	12 Months Ended
	Aug. 01, 2024	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition
Payments to Acquire Businesses, Net of Cash Acquired				$ 17,493	$ 0	$ 255
Goodwill		$ 34,956	$ 34,956	$ 34,956	$ 32,293	$ 32,156
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized			$ 510
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]		Research and development
RSUs
Business Acquisition
Granted (in shares)		300	300	600
Pfizer License Agreement
Business Acquisition
Aggregate Amount of Commercial Milestones Payable	$ 1,600
Cerevel Therapeutics
Business Acquisition
Cash per share received by shareholders (in dollars per share)	$ 45
Cash consideration paid	$ 8,700
Payments to Acquire Businesses, Net of Cash Acquired	8,300
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	361
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities	382
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	25
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets	121
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assumed In Process Research and Development	8,100
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	31
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt	(400)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	(100)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt	(246)
Deferred tax liabilities	(1,292)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other	(31)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	6,960
Goodwill	1,702
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	8,662
Aggregate principal amount of debt	$ 345
Stated interest rate (as a percent)	2.50%
Short-term borrowings	$ (400)
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ (4,900)
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized		161
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)		$ 4,500
Cerevel Therapeutics | Selling, general and administrative
Business Acquisition
Business Combination, Acquisition Related Costs				$ 44

Licensing, Acquisitions, and _4

Licensing, Acquisitions, and Other Arrangements (Details) - ImmunoGen - USD ($) $ / shares in Units, shares in Thousands, $ in Millions		5 Months Ended	11 Months Ended	12 Months Ended
	Feb. 12, 2024	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition
Payments to Acquire Businesses, Net of Cash Acquired				$ 17,493	$ 0	$ 255
Goodwill		$ 34,956	$ 34,956	34,956	32,293	32,156
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized			$ 510
Amortization of intangible assets				7,622	7,946	$ 7,689
Business Acquisition, Pro Forma Revenue				56,389	54,691
Business Acquisition, Pro Forma Net Income (Loss)				$ 4,564	$ 2,862
RSUs
Business Acquisition
Granted (in shares)		300	300	600
ImmunoGen
Business Acquisition
Cash per share received by shareholders (in dollars per share)	$ 31.26
Cash consideration paid	$ 9,800
Payments to Acquire Businesses, Net of Cash Acquired	9,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	591
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	171
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	211
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	40
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	7
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Product Rights	7,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, License agreements	125
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assumed In Process Research and Development	1,280
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets	273
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt	(99)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	(312)
Deferred tax liabilities	(899)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other	(47)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	8,541
Goodwill	1,249
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net	9,790
Fair value step-up adjustment to inventories	179
Intangible assets - Developed product rights	7,300
Intangible assets - In-process research and development	$ 1,300
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	12 years
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets	$ 250
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 578
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			(682)
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized			349
Inventory fair value step-up amortization			179
Amortization of intangible assets			157
ImmunoGen | Selling, general and administrative
Business Acquisition
Business Combination, Acquisition Related Costs			$ 59

Licensing, Acquisitions, and _5

Licensing, Acquisitions, and Other Arrangement- Acquisitions of DJS (Details) - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Goodwill		$ 34,956	$ 32,293	$ 32,156
DJS Antibodies LTD
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Total consideration	$ 287
Upfront cash payment	255
Contingent consideration	32
Maximum future payments upon achievement of certain milestones	95
Intangible assets - Developed product rights	233
Intangible assets - In-process research and development	22
Deferred tax liabilities	60
Goodwill	$ 92

Licensing, Acquisitions, and _6

Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended					12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024	Jun. 30, 2024	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Aug. 01, 2024	Feb. 12, 2024	Feb. 28, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Other acquisitions and investments						$ (3,024)	$ (1,223)	$ (539)
Acquired IPR&D and milestones						2,757	778	697
Gain (Loss) on Disposition of Other Assets						0	0	172
Other operating expense (income), net						(7)	(179)	56
Cerevel Therapeutics
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Cash per share received by shareholders (in dollars per share)									$ 45
ImmunoGen
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Cash per share received by shareholders (in dollars per share)										$ 31.26
Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Research and Development Milestone Expenses						130	196	252
Syndesi Therapeutics SA
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones					$ 130
Syndesi Therapeutics SA | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments											$ 870
Juvise Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Proceeds from Sale of Other Assets				$ 215
Other individually insignificant arrangements | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones						975	$ 582	$ 315
Other individually insignificant arrangements | Maximum | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments		$ 10,100				$ 10,100
Celsius Therapeutics
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones			$ 250
Aiada Therapeutics
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones		$ 1,400
Nimble Therapeutics | Subsequent event
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Acquired IPR&D and milestones	$ 200
Nimble Therapeutics | Collaborative arrangement | Subsequent event
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Potential additional milestone payments	$ 130
Other operating income | Juvise Pharmaceuticals
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Gain (Loss) on Disposition of Other Assets				$ 172

Collaborations (Details)

Collaborations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions
AbbVie's receivable from Janssen	$ 10,919	$ 11,155
AbbVie's payable to Janssen	$ 31,945	30,650
Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Share of collaboration development costs responsible by the entity (as a percent)	40%
Janssen Biotech, Inc | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Milestone payments	$ 200
Share of collaboration development costs responsible by Janssen (as a percent)	60%
Global - AbbVie's share of other costs (included in respective line items)	$ 162	228	$ 268
AbbVie's receivable from Janssen	237	236
AbbVie's payable to Janssen	282	307
Janssen Biotech, Inc | Collaborative arrangement | United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	1,140	1,245	1,607
Janssen Biotech, Inc | Collaborative arrangement | International
Collaborative Arrangements and Non-collaborative Arrangement Transactions
International - AbbVie's share of profits (included in net revenues)	899	931	1,142
Genentech, Inc. | Collaborative arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)	990	869	778
AbbVie's share of development costs (included in R&D)	84	109	121
Genentech, Inc. | Collaborative arrangement | United States
Collaborative Arrangements and Non-collaborative Arrangement Transactions
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)	$ 29	$ 41	$ 37

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) - USD ($)		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Changes in the carrying amount of goodwill
Balance at the beginning of the period		$ 32,293,000,000	$ 32,156,000,000
Additions	[1]	2,951,000,000
Foreign currency translation adjustments and other		(288,000,000)	137,000,000
Balance at the end of the period		34,956,000,000	32,293,000,000
Accumulated goodwill impairment losses
Accumulated goodwill impairment losses		$ 0	$ 0
[1] Goodwill additions related to the acquisitions of ImmunoGen and Cerevel Therapeutics (see Note 5).

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended	5 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Nov. 11, 2024
Definite-lived intangible assets
Gross carrying amount		$ 89,743	$ 89,743	$ 83,333
Accumulated amortization		(34,877)	(34,877)	(28,026)
Net carrying amount		54,866	54,866	55,307
Indefinite-lived intangible assets		5,202	5,202	303
Total intangible assets gross carrying amount		94,945	94,945	83,636
Total intangible assets, net		$ 60,068	60,068	55,610
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]	Research and development	Research and development
Indefinite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		$ 5,202	5,202	303
Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure						$ 6,900
Impairment of intangible assets			4,476	4,229	$ 770
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]	Research and development	Research and development
Emraclidine
Definite-lived intangible assets
Indefinite-lived intangible assets						2,400
Indefinite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets						$ 2,400
AGN-151607
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 630
Developed product rights
Definite-lived intangible assets
Gross carrying amount		$ 81,428	81,428	75,142
Accumulated amortization		(28,253)	(28,253)	(22,455)
Net carrying amount		53,175	53,175	52,687
License agreements
Definite-lived intangible assets
Gross carrying amount		8,315	8,315	8,191
Accumulated amortization		(6,624)	(6,624)	(5,571)
Net carrying amount		$ 1,691	$ 1,691	$ 2,620

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Definite-Lived Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended				12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Aug. 29, 2023
Definite-lived intangible assets
Amortization of intangible assets					$ 7,622	$ 7,946	$ 7,689
Finite-Lived Intangible Assets, Net		$ 55,307			54,866	55,307
Finite-Lived Intangible Assets, Fair Value Disclosure								$ 4,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]			Cost of products sold
Anticipated annual amortization expense
2025					7,300
2026					6,700
2027					6,100
2028					6,300
2029					5,700
Imbruvica
Definite-lived intangible assets
Definite-lived intangible assets impairment charges	$ 2,100
Vuity
Definite-lived intangible assets
Definite-lived intangible assets impairment charges				$ 770
Coolsculpting
Definite-lived intangible assets
Finite-Lived Intangible Assets, Fair Value Disclosure		1,300				1,300
Liletta
Definite-lived intangible assets
Finite-Lived Intangible Assets, Fair Value Disclosure		561				561
Liletta and Coolsculpting
Definite-lived intangible assets
Definite-lived intangible assets impairment charges		1,400
Developed product rights
Definite-lived intangible assets
Finite-Lived Intangible Assets, Net		52,687			53,175	52,687
Developed product rights | Imbruvica
Definite-lived intangible assets
Finite-Lived Intangible Assets, Net								$ 1,900
Developed product rights | Coolsculpting
Definite-lived intangible assets
Finite-Lived Intangible Assets, Net		290				290
Developed product rights | Liletta
Definite-lived intangible assets
Finite-Lived Intangible Assets, Net		241				241
License agreements
Definite-lived intangible assets
Finite-Lived Intangible Assets, Net		$ 2,620			$ 1,691	$ 2,620
Minimum
Definite-lived intangible assets
Amortization period					1 year
Maximum
Definite-lived intangible assets
Amortization period					16 years
Weighted Average | Developed product rights
Definite-lived intangible assets
Amortization period					12 years
Weighted Average | License agreements
Definite-lived intangible assets
Amortization period					11 years

Restructuring Plans (Details)

Restructuring Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring charges
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]		Cost of products sold, Research and development, Selling, general and administrative	Cost of products sold, Research and development, Selling, general and administrative
Allergan integration plan
Restructuring charges
Restructuring and Related Cost, Cost Incurred to Date		$ 2,500
Allergan integration plan | Employee Severance
Restructuring charges
Charges associated with integration or restructuring plans		288	$ 539
Allergan integration plan | Employee Severance | Cost of products sold
Restructuring charges
Charges associated with integration or restructuring plans		89	117
Allergan integration plan | Employee Severance | Research and development
Restructuring charges
Charges associated with integration or restructuring plans		7	23
Allergan integration plan | Employee Severance | Selling, general and administrative
Restructuring charges
Charges associated with integration or restructuring plans		192	399
Other restructuring
Restructuring reserve rollforward
Accrued balance beginning of the period	$ 196	176	33
Integration and restructuring charges	168	107	193
Payments and other adjustments	(128)	(87)	(50)
Accrued balance end of the period	236	196	176
Other restructuring | Employee Severance
Restructuring charges
Charges associated with integration or restructuring plans	$ 189	$ 132	$ 241

Leases - Balance Sheet Disclosu

Leases - Balance Sheet Disclosure (Details) - USD ($) $ in Millions	Dec. 31, 2024		Dec. 31, 2023
Assets
Operating lease assets	$ 723		$ 744
Finance lease assets	33		35
Total lease assets	$ 756		$ 779
Operating Lease assets balance sheet caption	Other assets		Other assets
Finance lease assets balance sheet caption	Property and equipment, net		Property and equipment, net
Liabilities
Current operating lease liabilities	$ 178		$ 166
Noncurrent operating lease liabilities	697		735
Current finance lease liabilities	17		15
Noncurrent finance lease liabilities	23		27
Total lease liabilities	$ 915	[1]	$ 943
Current operating lease liabilities balance sheet caption	Accounts payable and accrued liabilities		Accounts payable and accrued liabilities
Noncurrent operating lease liabilities balance sheet caption	Other long-term liabilities		Other long-term liabilities
Current finance lease liabilities balance sheet caption	Current portion of long-term debt and finance lease obligations		Current portion of long-term debt and finance lease obligations
Noncurrent finance lease liabilities balance sheet caption	Long-term debt and finance lease obligations		Long-term debt and finance lease obligations
[1] Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

Leases - Cost (Details)

Leases - Cost (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Operating lease cost		$ 196	$ 189	$ 201
Short-term lease cost		65	28	67
Variable lease cost		86	88	71
Total lease cost		$ 347	$ 305	$ 339
Operating Lease, Impairment Loss	$ 69
Property and Equipment
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]				Selling, general and administrative
Operating Lease, Impairment Loss	69
Leasehold Improvements
Property and Equipment
Impairment, Long-Lived Asset, Held-for-Use	$ 37

Leases - Weighted-Average Remai

Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Weighted-average remaining lease term for operating leases	7 years	7 years	8 years
Weighted-average remaining lease term for finance leases	5 years	3 years	2 years
Weighted-average discount rate for operating leases	3.30%	3%	2.60%
Weighted-average discount rate for finance leases	4.20%	3.60%	1.50%

Leases - Cash Flow Disclosure (

Leases - Cash Flow Disclosure (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition
Operating cash flows from operating leases	$ 204	$ 214	$ 212
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 159	$ 173	$ 235

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Millions		Dec. 31, 2024		Dec. 31, 2023
Operating leases
2025		$ 204
2026		182
2027		145
2028		118
2029		102
Thereafter		223
Total lease payments		974
Less: Interest		99
Present value of lease liabilities		875
Finance leases
2025		18
2026		15
2027		4
2028		2
2029		1
Thereafter		2
Total lease payments		42
Less: Interest		2
Present value of lease liabilities		40
Total
2025	[1]	222
2026	[1]	197
2027	[1]	149
2028	[1]	120
2029	[1]	103
Thereafter	[1]	225
Total lease payments	[1]	1,016
Less: Interest	[1]	101
Present value of lease liabilities		$ 915	[1]	$ 943
[1] Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.

Debt, Credit Facilities and C_3

Debt, Credit Facilities and Commitments and Contingencies - Summary of Long-Term Debt (Details) $ in Millions		Dec. 31, 2024 USD ($)		Dec. 31, 2024 EUR (€)		Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Long-term debt
Fair value hedges		$ 224					$ 266
Unamortized bond discounts		130					106
Unamortized deferred financing costs		(266)					(198)
Unamortized bond premiums		555					668
Noncurrent, Financing Liability		328					0
Total long-term debt and finance lease obligations		67,144					59,385
Current portion		6,804					7,191
Noncurrent portion		60,340					52,194
Other
Long-term debt
Long-term debt and lease obligations, gross		40					42
Aggregate notes due 2024
Long-term debt
Long-term debt and lease obligations, gross		$ 0					$ 7,169
Aggregate notes due 2024 | Minimum
Long-term debt
Weighted-average effective interest rate	[1]	0.65%		0.65%			0.65%
Stated interest rate (as a percent)		1.25%		1.25%
Aggregate notes due 2024 | Maximum
Long-term debt
Weighted-average effective interest rate	[1]	2.69%		2.69%			2.69%
Stated interest rate (as a percent)		3.85%		3.85%
Senior notes | 3.60% senior notes due 2025
Long-term debt
Weighted-average effective interest rate	[1]	3.66%		3.66%			3.66%
Long-term debt and lease obligations, gross		$ 3,750					$ 3,750
Stated interest rate (as a percent)		3.60%		3.60%
Senior notes | 3.80% senior notes due 2025
Long-term debt
Weighted-average effective interest rate	[1]	2.09%		2.09%			2.09%
Long-term debt and lease obligations, gross		$ 3,021					$ 3,021
Stated interest rate (as a percent)		3.80%		3.80%
Senior notes | Floating rate term loans due 2025
Long-term debt
Weighted-average effective interest rate		6.22%		6.22%
Long-term debt and lease obligations, gross		$ 0
Senior notes | 2.95% senior notes due 2026
Long-term debt
Weighted-average effective interest rate	[1]	3.02%		3.02%			3.02%
Long-term debt and lease obligations, gross		$ 4,000					$ 4,000
Stated interest rate (as a percent)		2.95%		2.95%
Senior notes | 3.20% senior notes due 2026
Long-term debt
Weighted-average effective interest rate	[1]	3.28%		3.28%			3.28%
Long-term debt and lease obligations, gross		$ 2,000					$ 2,000
Stated interest rate (as a percent)		3.20%		3.20%
Senior notes | 0.75% senior euro notes due 2027 (€750 principal)
Long-term debt
Weighted-average effective interest rate	[1]	0.86%		0.86%			0.86%
Long-term debt and lease obligations, gross		$ 778					$ 833
Stated interest rate (as a percent)		0.75%		0.75%
Aggregate principal amount of debt | €				€ 750,000,000
Senior notes | 4.25% senior notes due 2028
Long-term debt
Weighted-average effective interest rate	[1]	4.38%		4.38%			4.38%
Long-term debt and lease obligations, gross		$ 1,750					$ 1,750
Stated interest rate (as a percent)		4.25%		4.25%
Senior notes | 2.125% senior euro notes due 2028 (€750 principal)
Long-term debt
Weighted-average effective interest rate	[1]	2.18%		2.18%			2.18%
Long-term debt and lease obligations, gross		$ 778					$ 833
Stated interest rate (as a percent)		2.125%		2.125%
Aggregate principal amount of debt | €				€ 750,000,000
Senior notes | 2.625% senior euro notes due 2028 (€500 principal)
Long-term debt
Weighted-average effective interest rate	[1]	1.20%		1.20%			1.20%
Long-term debt and lease obligations, gross		$ 519					$ 555
Stated interest rate (as a percent)		2.625%		2.625%
Aggregate principal amount of debt | €				€ 500,000,000
Senior notes | 3.20% senior notes due 2029
Long-term debt
Weighted-average effective interest rate	[1]	3.25%		3.25%			3.25%
Long-term debt and lease obligations, gross		$ 5,500					$ 5,500
Stated interest rate (as a percent)		3.20%		3.20%
Senior notes | 2.125% senior euro notes due 2029 (€550 principal)
Long-term debt
Weighted-average effective interest rate	[1]	1.19%		1.19%			1.19%
Long-term debt and lease obligations, gross		$ 570					$ 611
Stated interest rate (as a percent)		2.125%		2.125%
Aggregate principal amount of debt | €				€ 550,000,000
Senior notes | 1.25% senior euro notes due 2031 (€650 principal)
Long-term debt
Weighted-average effective interest rate	[1]	1.30%		1.30%			1.30%
Long-term debt and lease obligations, gross		$ 674					$ 722
Stated interest rate (as a percent)		1.25%		1.25%
Aggregate principal amount of debt | €				€ 650,000,000
Senior notes | 4.55% senior notes due 2035
Long-term debt
Weighted-average effective interest rate	[1]	3.52%		3.52%			3.52%
Long-term debt and lease obligations, gross		$ 1,789					$ 1,789
Stated interest rate (as a percent)		4.55%		4.55%
Senior notes | 4.50% senior notes due 2035
Long-term debt
Weighted-average effective interest rate	[1]	4.58%		4.58%			4.58%
Long-term debt and lease obligations, gross		$ 2,500					$ 2,500
Stated interest rate (as a percent)		4.50%		4.50%
Senior notes | 4.30% senior notes due 2036
Long-term debt
Weighted-average effective interest rate	[1]	4.37%		4.37%			4.37%
Long-term debt and lease obligations, gross		$ 1,000					$ 1,000
Stated interest rate (as a percent)		4.30%		4.30%
Senior notes | 4.05% senior notes due 2039
Long-term debt
Weighted-average effective interest rate	[1]	4.11%		4.11%			4.11%
Long-term debt and lease obligations, gross		$ 4,000					$ 4,000
Stated interest rate (as a percent)		4.05%		4.05%
Senior notes | 4.40% senior notes due 2042
Long-term debt
Weighted-average effective interest rate	[1]	4.46%		4.46%			4.46%
Long-term debt and lease obligations, gross		$ 2,600					$ 2,600
Stated interest rate (as a percent)		4.40%		4.40%
Senior notes | 4.625% senior notes due 2042
Long-term debt
Weighted-average effective interest rate	[1]	4%		4%			4%
Long-term debt and lease obligations, gross		$ 457					$ 457
Stated interest rate (as a percent)		4.625%		4.625%
Senior notes | 4.85% senior notes due 2044
Long-term debt
Weighted-average effective interest rate	[1]	4.11%		4.11%			4.11%
Long-term debt and lease obligations, gross		$ 1,074					$ 1,074
Stated interest rate (as a percent)		4.85%		4.85%
Senior notes | 4.70% senior notes due 2045
Long-term debt
Weighted-average effective interest rate	[1]	4.73%		4.73%			4.73%
Long-term debt and lease obligations, gross		$ 2,700					$ 2,700
Stated interest rate (as a percent)		4.70%		4.70%
Senior notes | 4.75% senior notes due 2045
Long-term debt
Weighted-average effective interest rate	[1]	4.20%		4.20%			4.20%
Long-term debt and lease obligations, gross		$ 881					$ 881
Stated interest rate (as a percent)		4.75%		4.75%
Senior notes | 4.45% senior notes due 2046
Long-term debt
Weighted-average effective interest rate	[1]	4.50%		4.50%			4.50%
Long-term debt and lease obligations, gross		$ 2,000					$ 2,000
Stated interest rate (as a percent)		4.45%		4.45%
Senior notes | 4.875% senior notes due 2048
Long-term debt
Weighted-average effective interest rate	[1]	4.94%		4.94%			4.94%
Long-term debt and lease obligations, gross		$ 1,750					$ 1,750
Stated interest rate (as a percent)		4.875%		4.875%
Senior notes | 4.25% senior notes due 2049
Long-term debt
Weighted-average effective interest rate		4.29%		4.29%			4.29%	[1]
Long-term debt and lease obligations, gross		$ 5,750					$ 5,750
Stated interest rate (as a percent)		4.25%		4.25%
Senior notes | 4.549% term loan due 2027
Long-term debt
Long-term debt and lease obligations, gross		$ 2,000					$ 0
Stated interest rate (as a percent)		4.549%		4.549%
Senior notes | 4.80% senior notes due 2027
Long-term debt
Weighted-average effective interest rate							0%
Long-term debt and lease obligations, gross		$ 2,250					$ 0
Stated interest rate (as a percent)		4.80%		4.80%
Senior notes | 4.80% senior notes due 2029
Long-term debt
Weighted-average effective interest rate		4.91%		4.91%			0%
Long-term debt and lease obligations, gross		$ 2,500					$ 0
Stated interest rate (as a percent)		4.80%		4.80%
Senior notes | 4.95% senior notes due 2031
Long-term debt
Weighted-average effective interest rate		5.02%		5.02%			0%
Long-term debt and lease obligations, gross		$ 2,000					$ 0
Stated interest rate (as a percent)		4.95%		4.95%
Senior notes | 5.05% senior notes due 2034
Long-term debt
Weighted-average effective interest rate		5.13%		5.13%			0%
Long-term debt and lease obligations, gross		$ 3,000					$ 0
Stated interest rate (as a percent)		5.05%		5.05%
Senior notes | 5.35% senior notes due 2044
Long-term debt
Weighted-average effective interest rate		5.39%		5.39%			0%
Long-term debt and lease obligations, gross		$ 750					$ 0
Stated interest rate (as a percent)		5.35%		5.35%
Senior notes | 5.40% senior notes due 2054
Long-term debt
Weighted-average effective interest rate		5.44%		5.44%			0%
Long-term debt and lease obligations, gross		$ 3,000					$ 0
Stated interest rate (as a percent)		5.40%		5.40%
Senior notes | 5.50% senior notes due 2064
Long-term debt
Weighted-average effective interest rate		5.53%		5.53%			0%
Long-term debt and lease obligations, gross		$ 1,500					$ 0
Stated interest rate (as a percent)		5.50%		5.50%
Term loan facilities
Long-term debt
Total long-term debt and finance lease obligations						$ 2,000
Term loan facilities | Floating rate term loans due 2025
Long-term debt
Weighted-average effective interest rate	[1]						5.95%
Long-term debt and lease obligations, gross							$ 2,000
Term loan facilities | 4.549% term loan due 2027
Long-term debt
Weighted-average effective interest rate		4.61%	[1]	4.61%	[1]		0%
Term loan facilities | 4.80% senior notes due 2027
Long-term debt
Weighted-average effective interest rate		4.93%		4.93%
[1] Excludes the effect of any related interest rate swaps.

Debt, Credit Facilities and C_4

Debt, Credit Facilities and Commitments and Contingencies - Summary of Maturities of Long-Term Debt (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Long-term Debt, Fiscal Year Maturity [Abstract]
2025	$ 6,771
2026	6,000
2027	5,028
2028	3,047
2029	8,570
Thereafter	37,425
Long-term debt obligations, gross	66,841
Fair value hedges, unamortized bond premiums/discounts, deferred financing costs, finance lease obligations and financing liability	303
Aggregate principal amount outstanding	$ 67,144	$ 59,385

Debt, Credit Facilities and C_5

Debt, Credit Facilities and Commitments and Contingencies - Long-Term Debt - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended		2 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Jan. 31, 2023	Feb. 17, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Sep. 30, 2024	Aug. 01, 2024	Jun. 30, 2024	May 31, 2024
Long-term debt
Aggregate principal amount outstanding				$ 67,144	$ 59,385	$ 67,144
Long-term debt obligations, gross				66,841		66,841
FDA Approval
Long-term debt
Payable on Funding Agreement				531		531
Senior Notes Issued in 2024
Long-term debt
Debt Issuance Costs, Gross				99		99
Debt Instrument, Unamortized Discount				37		37
Senior notes | Senior Notes Issued in 2024
Long-term debt
Aggregate principal amount of debt				$ 15,000		$ 15,000
Senior notes | 2.5% Convertible Senior Note
Long-term debt
Stated interest rate (as a percent)								2.50%
Senior notes | Senior Euro Notes Due 2024 At 1.250 Percent [Member]
Long-term debt
Stated interest rate (as a percent)									1.25%
Senior notes | Senior Notes Due 2024 at 3.850 Percent [Member]
Long-term debt
Stated interest rate (as a percent)									3.85%
Senior notes | Senior Notes Due in 2024 At 2.60 Percent [Member]
Long-term debt
Stated interest rate (as a percent)				2.60%		2.60%
Senior notes | Senior Euro Notes 1.375 Percent Due 2024 [Member]
Long-term debt
Stated interest rate (as a percent)										1.38%
Senior notes | Senior Notes Due 2023 At 2.800 Percent [Member]
Long-term debt
Borrowings (repayments) of long-term debt	$ 350
Stated interest rate (as a percent)	2.80%
Senior notes | Senior Notes 2.85 Percent Due 2023 [Member]
Long-term debt
Stated interest rate (as a percent)		2.85%
Senior notes | Senior Euro Notes Due 2023 At 1.500 Percent [Member]
Long-term debt
Borrowings (repayments) of long-term debt					$ 500
Stated interest rate (as a percent)					1.50%
Senior notes | Senior Notes Due in 2023 At 3.75 Percent [Member]
Long-term debt
Borrowings (repayments) of long-term debt					$ 1,300
Stated interest rate (as a percent)					3.75%
Senior notes | Term Loan due April 2027
Long-term debt
Stated interest rate (as a percent)				4.549%		4.549%
Term loan facilities
Long-term debt
Aggregate principal amount outstanding							$ 2,000
Term loan facilities | Senior Euro Notes Due 2024 At 1.250 Percent [Member]
Long-term debt
Borrowings (repayments) of long-term debt						$ 700
Term loan facilities | Senior Notes Due 2024 at 3.850 Percent [Member]
Long-term debt
Borrowings (repayments) of long-term debt						1,000
Term loan facilities | Senior Notes Due in 2024 At 2.60 Percent [Member]
Long-term debt
Borrowings (repayments) of long-term debt				$ 3,800
Term loan facilities | Senior Euro Notes 1.375 Percent Due 2024 [Member]
Long-term debt
Borrowings (repayments) of long-term debt						$ 1,500
Term loan facilities | Floating Rate Term Loan Tranche Due May 2023 Refinanced [Member]
Long-term debt
Borrowings (repayments) of long-term debt			$ 1,000
Term loan facilities | Senior Notes 2.85 Percent Due 2023 [Member]
Long-term debt
Borrowings (repayments) of long-term debt		$ 1,000
Term loan facilities | Term Loan Due May 2025
Long-term debt
Borrowings (repayments) of long-term debt				2,000
Term loan facilities | Term Loan due April 2027
Long-term debt
Borrowings (repayments) of long-term debt				$ 2,000

Debt, Credit Facilities and C_6

Debt, Credit Facilities and Commitments and Contingencies - Short-Term Borrowings (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Feb. 13, 2025	Dec. 21, 2023	Dec. 06, 2023
Short-term borrowings
Repayments of Other Short-Term Debt			$ 5,008	$ 0	$ 0
Proceeds from Short-Term Debt			5,008	0	$ 0
Term loan facilities
Short-term borrowings
Long-Term Debt, Weighted Average Interest Rate, over Time		6.29%
December 2023 Term Loan Credit Agreement
Short-term borrowings
Debt Instrument, Basis Spread on Variable Rate		0.975%
Repayments of Short-Term Debt		$ 5,000
Proceeds from Short-Term Debt		$ 5,000
Revolving credit facility
Short-term borrowings
Revolving credit facility, maximum borrowing capacity			$ 5,000
Revolving credit facility term			5 years
Revolving credit facility outstanding			$ 0	0
Revolving credit facility | Subsequent event
Short-term borrowings
Revolving credit facility, maximum borrowing capacity						$ 3,000
Commercial Paper
Short-term borrowings
Proceeds from Other Short-Term Debt			7,700
Repayments of Other Short-Term Debt			$ 7,700
Short-Term Debt, Weighted Average Interest Rate, over Time			4.91%
Short-term borrowings			$ 0	$ 0
Commercial Paper | Subsequent event
Short-term borrowings
Proceeds from Short-Term Debt	$ 3,300
December 2023 Bridge Credit Facility
Short-term borrowings
Revolving credit facility, maximum borrowing capacity								$ 9,000
364 day Term Loan Credit Agreement
Short-term borrowings
Revolving credit facility, maximum borrowing capacity							$ 5,000

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measures - Financial Instruments (Details) € in Millions, SFr in Millions, $ in Millions, kr in Billions

12 Months Ended

Dec. 31, 2024 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2024 EUR (€) derivative

Dec. 31, 2024 USD ($) derivative

Dec. 31, 2024 SEK (kr) derivative

Dec. 31, 2024 CAD ($) derivative

Dec. 31, 2024 CHF (SFr) derivative

Dec. 31, 2023 EUR (€)

Dec. 31, 2023 USD ($)

Dec. 31, 2023 SEK (kr)

Dec. 31, 2023 CAD ($)

Dec. 31, 2023 CHF (SFr)

Dec. 31, 2019 USD ($)

Derivative instruments, notional amount and fair value

Number of outstanding derivative instruments containing credit risk contingent features | derivative

0

0

0

0

0

Amount excluded from the assessment of effectiveness for cash flow hedges

$ 0

$ 0

Amount excluded from the assessment of effectiveness for fair value hedges

$ 0

$ 0

Fair value - Derivatives in asset position

$ 313,000,000

$ 66,000,000

Fair value - Derivatives in liability position

266,000,000

496,000,000

Designated as hedging instrument | Net investment hedges | Senior notes

Derivative instruments, notional amount and fair value

Aggregate principal amount of senior Euro notes | €

€ 3,100

€ 5,400

Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

1,900,000,000

1,800,000,000

Duration of forward exchange contracts

18 months

Approximate length of time over which accumulated gains and losses will be recognized in cost of products sold

6 months

Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Prepaid expenses and other

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

119,000,000

12,000,000

Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Accounts payable and accrued liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

5,000,000

32,000,000

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

€ 6,200

kr 1.4

$ 500

SFr 50

4,900

kr 1.4

$ 750

SFr 50

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Prepaid expenses and other

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

4,000,000

13,000,000

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Accounts payable and accrued liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

0

66,000,000

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other assets

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

148,000,000

0

Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Other long-term liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

0

69,000,000

Designated as hedging instrument | Treasury rate lock agreements | Cash flow hedges

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

$ 10,000,000,000

Designated as hedging instrument | Interest rate swap contracts | Fair value hedges

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

3,500,000,000

5,000,000,000

Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other assets

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

0

0

Designated as hedging instrument | Interest rate swap contracts | Fair value hedges | Other long-term liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

231,000,000

293,000,000

Designated as hedging instrument | Cross-Currency Swap Contracts | Cash flow hedges

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments | €

€ 433

Not designated as hedging instrument | Foreign currency forward exchange contracts

Derivative instruments, notional amount and fair value

Notional amount of derivative instruments

5,900,000,000

7,900,000,000

Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses and other

Derivative instruments, notional amount and fair value

Fair value - Derivatives in asset position

42,000,000

41,000,000

Not designated as hedging instrument | Foreign currency forward exchange contracts | Accounts payable and accrued liabilities

Derivative instruments, notional amount and fair value

Fair value - Derivatives in liability position

$ 30,000,000

$ 36,000,000

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measures - Amount of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cost of products sold
Gain (loss) on derivatives
Pre-tax losses to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months	$ 126
Interest expense, net
Gain (loss) on derivatives
Pre-tax gains to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months	21
Designated as hedging instrument | Senior notes
Gain (loss) on derivatives
Pre-tax gains (losses) from net investment hedges recognized in other comprehensive income	305	$ (252)	$ 406
Designated as hedging instrument | Interest expense, net | Senior notes | Fair value hedges
Gain (loss) on derivatives
Debt designated as hedged item in fair value hedges gains (losses) recognized in the consolidated statements of earnings	(62)	(98)	402
Foreign currency forward exchange contracts | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	192	(2)	103
Pre-tax gains (losses) from net investment hedges recognized in other comprehensive income	435	(144)	395
Foreign currency forward exchange contracts | Designated as hedging instrument | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 73	$ 77	$ 82
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of products sold	Cost of products sold	Cost of products sold
Foreign currency forward exchange contracts | Designated as hedging instrument | Net investment hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 123	$ 112	$ 94
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing
Foreign currency forward exchange contracts | Not designated as hedging instrument
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 6	$ 33	$ (156)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain (Loss), Foreign Currency Transaction, before Tax	Gain (Loss), Foreign Currency Transaction, before Tax	Gain (Loss), Foreign Currency Transaction, before Tax
Interest rate swap contracts | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	$ 0	$ 0	$ 6
Interest rate swap contracts | Designated as hedging instrument | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 0	$ 0	$ (1)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing
Interest rate swap contracts | Designated as hedging instrument | Fair value hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 62	$ 98	$ (402)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing
Treasury rate lock agreements | Designated as hedging instrument | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 23	$ 24	$ 23
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing	Gain on derivative amount excluded from effectiveness testing
Cross-Currency Swap Contracts | Designated as hedging instrument
Gain (loss) on derivatives
Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income	$ 0	$ (6)	$ 0
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain (Loss), Foreign Currency Transaction, before Tax	Gain (Loss), Foreign Currency Transaction, before Tax	Gain (Loss), Foreign Currency Transaction, before Tax
Cross-Currency Swap Contracts | Designated as hedging instrument | Cash flow hedges
Gain (loss) on derivatives
Derivative instrument net gains (losses) recognized in the consolidated statements of earnings	$ 0	$ (6)	$ 0

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Assets
Investment, Type [Extensible Enumeration]	Money Market Funds [Member]	Money Market Funds [Member]
Foreign currency contracts	$ 313	$ 66
Liabilities
Foreign currency contracts	266	496
Noncurrent, Financing Liability	328	0
Change in fair value recognized in net earnings	(3,771)	(5,128)	$ (2,761)
Recurring
Assets
Cash and equivalents	5,524	12,814
Money market funds and time deposits	10	10
Debt securities	33	26
Equity securities	98	111
Total assets	5,978	13,027
Liabilities
Interest rate swap contracts	231	293
Noncurrent, Financing Liability	328
Contingent consideration	21,666	19,890
Total liabilities	22,260	20,386
Recurring | Foreign currency contracts
Assets
Foreign currency contracts	313	66
Liabilities
Foreign currency contracts	35	203
Recurring | Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	5,179	6,223
Money market funds and time deposits	0	0
Debt securities	0	0
Equity securities	70	86
Total assets	5,249	6,309
Liabilities
Interest rate swap contracts	0	0
Noncurrent, Financing Liability	0
Contingent consideration	0	0
Total liabilities	0	0
Recurring | Quoted prices in active markets for identical assets (Level 1) | Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Recurring | Significant other observable inputs (Level 2)
Assets
Cash and equivalents	345	6,591
Money market funds and time deposits	10	10
Debt securities	33	26
Equity securities	28	25
Total assets	729	6,718
Liabilities
Interest rate swap contracts	231	293
Noncurrent, Financing Liability	0
Contingent consideration	0	0
Total liabilities	266	496
Recurring | Significant other observable inputs (Level 2) | Foreign currency contracts
Assets
Foreign currency contracts	313	66
Liabilities
Foreign currency contracts	35	203
Recurring | Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	0	0
Money market funds and time deposits	0	0
Debt securities	0	0
Equity securities	0	0
Total assets	0	0
Liabilities
Interest rate swap contracts	0	0
Noncurrent, Financing Liability	328
Contingent consideration	21,666	19,890
Total liabilities	21,994	19,890
Recurring | Significant unobservable inputs (Level 3) | Foreign currency contracts
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	$ 0	$ 0

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details) $ in Millions		12 Months Ended
		Dec. 31, 2024 USD ($)	Dec. 31, 2023
Recurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Non-current Financing Liability, Change in Fair Value		$ 82
Minimum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		0.046	0.043
Minimum | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[1]		0.89
Minimum | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		2,025	2,024
Minimum | Probability of payment for royalties excluding approved indications
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration			0.89
Maximum | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		0.052	0.059
Maximum | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[1]	1	1
Maximum | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration		2,034	2,034
Weighted Average | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[2]	0.048	0.045
Weighted Average | Probability of payment for royalties by indication
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[1],[2]	1	0.99
Weighted Average | Projected year of payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Significant unobservable input for contingent consideration	[2]	2,029	2,027
[1] Excluding approved indications, the estimated probability of payment was 89% at December 31, 2023. Unobservable inputs were weighted by the relative fair value of the contingent consideration liabilities.

Financial Instruments and Fai_7

Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024		Dec. 31, 2023	Dec. 31, 2022
Transfers of assets between the fair value measurement levels
Transfers of assets into Level 3 of the fair value hierarchy	$ 0
Transfers of assets out of Level 3 of the fair value hierarchy	0
Transfers of liabilities between the fair value measurement levels
Transfers of liabilities into Level 3 of the fair value hierarchy	0
Transfers of liabilities out of Level 3 of the fair value hierarchy	0
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Beginning balance	19,890,000,000		$ 16,384,000,000	$ 14,887,000,000
Additions	$ 0	[1]	$ 0	$ 32,000,000	[1]
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)		Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)
Change in fair value recognized in net earnings	$ (3,771,000,000)		$ (5,128,000,000)	$ (2,761,000,000)
Payments	(1,995,000,000)		(1,622,000,000)	(1,296,000,000)
Ending balance	$ 21,666,000,000		$ 19,890,000,000	$ 16,384,000,000
[1] Additions during the year ended December 31, 2022, represent contingent consideration liabilities assumed in the DJS acquisition.

Financial Instruments and Fai_8

Financial Instruments and Fair Value Measures - Bases Used to Measure The Approximate Fair Value of Financial Instruments (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Liabilities
Carrying amount of investments in equity securities that do not have readily determinable fair values	$ 169	$ 159
Book value
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	6,797	7,191
Long-term debt and finance lease obligations, excluding fair value hedges	60,243	52,460
Total liabilities	67,040	59,651
Estimate of Fair Value Measurement
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	6,767	7,069
Long-term debt and finance lease obligations, excluding fair value hedges	55,836	49,541
Total liabilities	62,603	56,610
Estimate of Fair Value Measurement | Quoted prices in active markets for identical assets (Level 1)
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	6,620	6,862
Long-term debt and finance lease obligations, excluding fair value hedges	53,441	48,983
Total liabilities	60,061	55,845
Estimate of Fair Value Measurement | Significant other observable inputs (Level 2)
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	147	207
Long-term debt and finance lease obligations, excluding fair value hedges	2,395	558
Total liabilities	2,542	765
Estimate of Fair Value Measurement | Significant unobservable inputs (Level 3)
Liabilities
Current portion of long-term debt and finance lease obligations, excluding fair value hedges	0	0
Long-term debt and finance lease obligations, excluding fair value hedges	0	0
Total liabilities	$ 0	$ 0

Financial Instruments and Fai_9

Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Net revenues
Concentration of Risk
Number of principal customers	3	3
Accounts receivable, net | Geographic Risk | Principal U.S. Customers
Concentration of Risk
Concentrations risk (as a percent)	81%	81%

Post-Employment Benefits - Addi

Post-Employment Benefits - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated benefit obligation	$ 8,100	$ 8,600
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	8,964	9,544	$ 8,588
Actuarial (gain) loss	$ (855)	491
Defined benefit plans | Equity securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target investment allocations for Pension Plan (as a percent)	62.50%
Defined benefit plans | Debt securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target investment allocations for Pension Plan (as a percent)	22.50%
Defined benefit plans | Asset allocation strategies and other holdings
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target investment allocations for Pension Plan (as a percent)	15%
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	$ 786	796	667
Actuarial (gain) loss	$ (62)	89
Pre Sixty Five Years of Age
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Annual rate of increase in the per capita cost of covered health care obligation benefits assumed in the current year (as a percent)	6.60%
Ultimate per capita trend rate for health care costs from 2030 and thereafter (as a percent)	4.50%
Annual rate of increase in the per capita cost of covered health care cost benefits assumed in the current year (as a percent)	7.40%
Ultimate per capita trend rate for health care costs from 2029 and thereafter (as a percent)	4.50%
Post Sixty Five Years of Age
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Annual rate of increase in the per capita cost of covered health care obligation benefits assumed in the current year (as a percent)	2%
Ultimate per capita trend rate for health care costs from 2030 and thereafter (as a percent)	1.80%
Annual rate of increase in the per capita cost of covered health care cost benefits assumed in the current year (as a percent)	2.10%
Ultimate per capita trend rate for health care costs from 2029 and thereafter (as a percent)	1.80%
AbbVie Savings Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan expenses recorded	$ 425	398	$ 474
Foreign Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	$ 2,200	$ 2,400

Post-Employment Benefits - Bene

Post-Employment Benefits - Benefit Plan Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Amounts recognized on the consolidated balance sheets
Other long-term liabilities	$ (1,234)	$ (1,538)
Defined benefit plans
Projected benefit obligations
Beginning of period	9,544	8,588
Service cost	286	270	$ 454
Interest cost	451	432	297
Actuarial (gain) loss	(855)	491
Benefits paid	(347)	(316)
Other, primarily foreign currency translation adjustments	(115)	79
End of period	8,964	9,544	8,588
Fair value of plan assets
Beginning of period	9,839	8,472
Actual return on plan assets	865	1,230
Company contributions	326	366
Benefits paid	(347)	(316)
Other, primarily foreign currency translation adjustments	(132)	87
End of period	10,551	9,839	8,472
Funded status, end of period	1,587	295
Amounts recognized on the consolidated balance sheets
Other assets	2,097	1,086
Accounts payable and accrued liabilities	(20)	(17)
Other long-term liabilities	(490)	(774)
Net asset (obligation)	1,587	295
Actuarial loss, net	(1,303)	(2,290)
Prior service cost (credit)	1	1
Accumulated other comprehensive loss (income)	1,304	2,291
Other post-employment plans
Projected benefit obligations
Beginning of period	796	667
Service cost	43	37	51
Interest cost	41	37	23
Actuarial (gain) loss	(62)	89
Benefits paid	(31)	(35)
Other, primarily foreign currency translation adjustments	(1)	1
End of period	786	796	$ 667
Fair value of plan assets
Company contributions	31	35
Benefits paid	(31)	(35)
Funded status, end of period	(786)	(796)
Amounts recognized on the consolidated balance sheets
Accounts payable and accrued liabilities	(42)	(32)
Other long-term liabilities	(744)	(764)
Net asset (obligation)	(786)	(796)
Actuarial loss, net	(203)	(282)
Prior service cost (credit)	(261)	(297)
Accumulated other comprehensive loss (income)	$ (58)	$ (15)

Post-Employment Benefits - Info

Post-Employment Benefits - Information For Pension Plans With A Projected Benefit Obligation And An Accumulated Benefit Obligation In Excess Of Plan Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Postemployment Benefits [Abstract]
Accumulated benefit obligation	$ 527	$ 1,410
Fair value of plan assets	94	890
Projected benefit obligation	775	6,343
Fair value of plan assets	$ 265	$ 5,552

Post-Employment Benefits - Pret

Post-Employment Benefits - Pretax Gains and Losses Included in Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Actuarial loss (gain)	$ (935)	$ (16)	$ (925)
Amortization of prior service credit (cost)	0	(1)	(2)
Amortization of actuarial loss	(52)	(16)	(231)
Foreign exchange loss (gain) and other	0	(44)	17
Total loss (gain)	(987)	(77)	(1,141)
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Actuarial loss (gain)	(62)	89	(229)
Amortization of prior service credit (cost)	36	36	38
Amortization of actuarial loss	(17)	(12)	(26)
Prior service credit	0	0	(2)
Total loss (gain)	$ (43)	$ 113	$ (219)

Post-Employment Benefits - Net

Post-Employment Benefits - Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	$ 286	$ 270	$ 454
Interest cost	451	432	297
Expected return on plan assets	(785)	(723)	(712)
Amortization of prior service cost	0	1	2
Amortization of actuarial loss	(52)	(16)	(231)
Net periodic benefit cost (credit)	4	(4)	272
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	43	37	51
Interest cost	41	37	23
Amortization of prior service cost	(36)	(36)	(38)
Amortization of actuarial loss	(17)	(12)	(26)
Net periodic benefit cost (credit)	$ 65	$ 50	$ 62

Post-Employment Benefits - Weig

Post-Employment Benefits - Weighted-Average Assumptions Used in Determining Benefit Obligation at Measurement Date (Details)	Dec. 31, 2024	Dec. 31, 2023
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.40%	4.80%
Rate of compensation increases	4.40%	4.80%
Cash balance interest crediting rate	4%	4.40%
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.70%	5.10%

Post-Employment Benefits - We_2

Post-Employment Benefits - Weighted-Average Assumptions Used in Determining Net Periodic Benefit Cost (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate for determining service cost	4.80%	5%	3%
Discount rate for determining interest cost	4.80%	4.90%	2.60%
Expected long-term rate of return on plan assets	7.50%	7.30%	7.10%
Expected rate of change in compensation	4.40%	4.80%	5.20%
Cash balance interest crediting rate	4.40%	2.70%	2.70%
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate for determining service cost	5.20%	5.30%	3.30%
Discount rate for determining interest cost	4.90%	5.10%	2.70%

Post-Employment Benefits - Defi

Post-Employment Benefits - Defined Benefit Pension Plan Assets (Details) - Defined benefit plans - USD ($) $ in Millions		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		$ 10,551	$ 9,839	$ 8,472
Fair value measured at Levels 1, 2 and 3
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		3,631	3,795
Fair value measured at Levels 1, 2 and 3 | U.S. large cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[1]	1,131	1,018
Fair value measured at Levels 1, 2 and 3 | U.S. mid cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[2]	176	173
Fair value measured at Levels 1, 2 and 3 | International
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[3]	408	488
Fair value measured at Levels 1, 2 and 3 | U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	414	246
Fair value measured at Levels 1, 2 and 3 | Corporate debt instruments
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	609	714
Fair value measured at Levels 1, 2 and 3 | Non-U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	346	461
Fair value measured at Levels 1, 2 and 3 | Other fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	20	126
Fair value measured at Levels 1, 2 and 3 | Absolute return funds
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[5]	176	155
Fair value measured at Levels 1, 2 and 3 | Other plan assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[6]	351	414
Quoted prices in active markets for identical assets (Level 1)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		2,392	2,800
Quoted prices in active markets for identical assets (Level 1) | U.S. large cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[1]	1,131	1,018
Quoted prices in active markets for identical assets (Level 1) | U.S. mid cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[2]	176	173
Quoted prices in active markets for identical assets (Level 1) | International
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[3]	408	488
Quoted prices in active markets for identical assets (Level 1) | U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	18	62
Quoted prices in active markets for identical assets (Level 1) | Corporate debt instruments
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	29	155
Quoted prices in active markets for identical assets (Level 1) | Non-U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	183	301
Quoted prices in active markets for identical assets (Level 1) | Other fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	15	124
Quoted prices in active markets for identical assets (Level 1) | Absolute return funds
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[5]	82	66
Quoted prices in active markets for identical assets (Level 1) | Other plan assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[6]	350	413
Significant other observable inputs (Level 2)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		1,239	995
Significant other observable inputs (Level 2) | U.S. large cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[1]	0	0
Significant other observable inputs (Level 2) | U.S. mid cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[2]	0	0
Significant other observable inputs (Level 2) | International
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[3]	0	0
Significant other observable inputs (Level 2) | U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	396	184
Significant other observable inputs (Level 2) | Corporate debt instruments
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	580	559
Significant other observable inputs (Level 2) | Non-U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	163	160
Significant other observable inputs (Level 2) | Other fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	5	2
Significant other observable inputs (Level 2) | Absolute return funds
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[5]	94	89
Significant other observable inputs (Level 2) | Other plan assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[6]	1	1
Significant unobservable inputs (Level 3)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		0	0
Significant unobservable inputs (Level 3) | U.S. large cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[1]	0	0
Significant unobservable inputs (Level 3) | U.S. mid cap
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[2]	0	0
Significant unobservable inputs (Level 3) | International
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[3]	0	0
Significant unobservable inputs (Level 3) | U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	0	0
Significant unobservable inputs (Level 3) | Corporate debt instruments
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	0	0
Significant unobservable inputs (Level 3) | Non-U.S. government securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	0	0
Significant unobservable inputs (Level 3) | Other fixed income securities
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[4]	0	0
Significant unobservable inputs (Level 3) | Absolute return funds
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[5]	0	0
Significant unobservable inputs (Level 3) | Other plan assets
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	[6]	0	0
Total assets measured at NAV
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets		$ 6,920	$ 6,044
[1] A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices. A mix of index funds and actively managed equity accounts that are benchmarked to various mid cap indices. A mix of index funds and actively managed equity accounts that are benchmarked to various non-U.S. equity indices in both developed and emerging markets. Securities held by actively managed accounts, index funds and mutual funds. Primarily funds having global mandates with the flexibility to allocate capital broadly across a wide range of asset classes and strategies, including but not limited to equities, fixed income, commodities, financial futures, currencies and other securities, with objectives to outperform agreed upon benchmarks of specific return and volatility targets. Investments in cash and cash equivalents.

Post-Employment Benefits - Expe

Post-Employment Benefits - Expected Defined Benefit and Other Post-Employment Plan Payments (Details) $ in Millions	Dec. 31, 2024 USD ($)
Defined benefit plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2025	$ 363
2026	383
2027	410
2028	435
2029	464
2030 to 2034	3,007
Other post-employment plans
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2025	42
2026	46
2027	49
2028	53
2029	57
2030 to 2034	$ 330

Equity - Stock-Based Compensati

Equity - Stock-Based Compensation (Details) - USD ($) shares in Millions, $ in Millions	11 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance (in shares)	144	144
Retirement-eligible employees' age		55 years
Minimum number of years of services		10 years
Pre-tax compensation expense		$ 911	$ 747	$ 671
Tax benefit		159	136	122
After-tax compensation expense		752	611	549
Excess tax benefits realized from stock-based compensation		84	90	116
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized	$ 510
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-tax compensation expense		55	46	38
Employee Benefits and Share-Based Compensation	36
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-tax compensation expense		341	278	232
Employee Benefits and Share-Based Compensation	184
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Pre-tax compensation expense		$ 515	$ 423	$ 401
Employee Benefits and Share-Based Compensation	$ 290

Equity - Stock Options (Details

Equity - Stock Options (Details) - Stock Options - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term	10 years
Vesting period	3 years
Exercise price for awards granted as percentage of market value on the date of grant	100%
Weighted-average grant-date fair value of the stock options granted (in dollars per share)	$ 31.53	$ 29.89	$ 22.83
Options
Outstanding at the beginning of the period (in shares)	7,481
Granted (in shares)	648
Exercised (in shares)	(2,420)
Lapsed and forfeited (in shares)	(96)
Outstanding at the end of the period (in shares)	5,613	7,481
Exercisable at the end of the period (in shares)	4,295
Weighted- average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 102.80
Granted (in dollars per share)	175.26
Exercised (in dollars per share)	89.01
Lapsed and forfeited (in dollars per share)	81.16
Outstanding at the end of the period (in dollars per share)	117.48	$ 102.80
Exercisable at the end of the period (in dollars per share)	$ 104.07
Weighted-average remaining life (in years)
Outstanding	5 years 7 months 6 days	5 years
Exercisable	4 years 8 months 12 days
Aggregate intrinsic value
Outstanding	$ 338	$ 390
Exercisable	316
Aggregate intrinsic value of options exercised	202	$ 189	$ 295
Total fair value of options vested	18
Unrecognized compensation cost	$ 6
Period for recognition of unrecognized compensation cost	2 years

Equity - RSUs and Performance S

Equity - RSUs and Performance Shares (Details) $ / shares in Units, $ in Millions	5 Months Ended	11 Months Ended	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)
RSUs
Share units
Granted (in shares)	300,000	300,000	600,000
RSUs | Minimum vesting period
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Performance-vested RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period			3 years
Common stock received for each vested award (in shares)			1
Weighted-average grant date fair value
Incremental vesting			0.33
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period			3 years
Weighted-average grant date fair value
Incremental vesting			0.33
RSUs and performance shares
Share units
Shares units outstanding at the beginning of the period (in shares)			10,739,000
Granted (in shares)			5,558,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Due To Acquisition			605,000
Vested (in shares)			(6,052,000)
Forfeited (in shares)			(463,000)
Shares units outstanding at the end of the period (in shares)	10,387,000	10,387,000	10,387,000	10,739,000
Weighted-average grant date fair value
Weighted average fair value outstanding at the beginning of the period (in dollars per share) | $ / shares			$ 136.42
Granted (in dollars per share) | $ / shares			168.62
Granted in acquisitions | $ / shares			168.24
Vested (in dollars per share) | $ / shares			128.28
Forfeited (in dollars per share) | $ / shares			152.79
Weighted average fair value outstanding at the end of the period (in dollars per share) | $ / shares	$ 159.52	$ 159.52	$ 159.52	$ 136.42
Fair market value of awards vested | $			$ 1,100	$ 1,000	$ 1,000
Unrecognized compensation cost | $	$ 655	$ 655	$ 655
Period for recognition of unrecognized compensation cost			2 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Weighted-average grant date fair value
Period for recognition of unrecognized compensation cost			2 years
Incremental vesting			0.33

Equity - Cash Dividends (Detail

Equity - Cash Dividends (Details) - $ / shares	3 Months Ended												12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Equity [Abstract]
Cash dividends declared per common share (in dollars per share)	$ 1.64	$ 1.55	$ 1.55	$ 1.55	$ 1.55	$ 1.48	$ 1.48	$ 1.48	$ 1.48	$ 1.41	$ 1.41	$ 1.41	$ 6.29	$ 5.99	$ 5.71

Equity - Share Repurchase Progr

Equity - Share Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Feb. 16, 2023
Equity, Class of Treasury Stock [Line Items]
Payment for shares repurchased	$ 1,703	$ 1,978	$ 1,487
December 2018 Stock Repurchase Authorization
Equity, Class of Treasury Stock [Line Items]
Shares repurchased (in shares)	7	10	8
Payment for shares repurchased	$ 1,300	$ 1,600	$ 1,100
Remaining share repurchase authorization amount	$ 3,500
Stock Repurchase Program, Increase in Authorized Amount				$ 5,000

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
AOCI Attributable to Parent, Net of Tax
Beginning balance	$ 10,397	$ 17,287	$ 15,436
Other comprehensive income (loss)	380	(106)	700
Ending balance	3,364	10,397	17,287
AOCI Attributable to Parent
AOCI Attributable to Parent, Net of Tax
Beginning balance	(2,305)	(2,199)	(2,899)
Other comprehensive income (loss)	380	(106)	700
Ending balance	(1,925)	(2,305)	(2,199)
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax
Beginning balance	(1,106)	(1,513)	(570)
Other comprehensive income (loss) before reclassifications	(1,008)	407	(943)
Net losses (gains) reclassified from accumulated other comprehensive loss	0	0	0
Other comprehensive income (loss)	(1,008)	407	(943)
Ending balance	(2,114)	(1,106)	(1,513)
Net investment hedging activities
AOCI Attributable to Parent, Net of Tax
Beginning balance	65	464	(91)
Other comprehensive income (loss) before reclassifications	580	(311)	629
Net losses (gains) reclassified from accumulated other comprehensive loss	(96)	(88)	(74)
Other comprehensive income (loss)	484	(399)	555
Ending balance	549	65	464
Pension and post-employment benefits
AOCI Attributable to Parent, Net of Tax
Beginning balance	(1,488)	(1,458)	(2,546)
Other comprehensive income (loss) before reclassifications	799	(23)	915
Net losses (gains) reclassified from accumulated other comprehensive loss	25	(7)	173
Other comprehensive income (loss)	824	(30)	1,088
Ending balance	(664)	(1,488)	(1,458)
Cash flow hedging activities
AOCI Attributable to Parent, Net of Tax
Beginning balance	224	308	308
Other comprehensive income (loss) before reclassifications	155	(10)	91
Net losses (gains) reclassified from accumulated other comprehensive loss	(75)	(74)	(91)
Other comprehensive income (loss)	80	(84)	0
Ending balance	304	224	308
Accumulated other comprehensive income (loss)
AOCI Attributable to Parent, Net of Tax
Beginning balance	(2,305)	(2,199)	(2,899)
Other comprehensive income (loss) before reclassifications	526	63	692
Net losses (gains) reclassified from accumulated other comprehensive loss	(146)	(169)	8
Other comprehensive income (loss)	380	(106)	700
Ending balance	$ (1,925)	$ (2,305)	$ (2,199)

Equity - Amounts Reclassified O

Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
		Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Significant amounts reclassified out of each component of AOCI
Gain on derivative amount excluded from effectiveness testing			$ (2,160)	$ (1,684)	$ (2,044)
Tax expense (benefit)			(570)	1,377	1,632
Total reclassifications, net of tax		$ 22	(4,278)	(4,863)	(11,836)
Losses (gains) on foreign currency exchange contracts			16,904	20,415	17,414
Other comprehensive income, net of tax			380	(106)	700
Gain (Loss), Foreign Currency Transaction, before Tax			21	146	148
Pension and post-employment benefits
Significant amounts reclassified out of each component of AOCI
Amortization of actuarial losses and other	[1]		33	(7)	221
Tax benefit			(8)	0	(48)
Total reclassifications, net of tax			25	(7)	173
Other comprehensive income, net of tax			824	(30)	1,088
Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Total reclassifications, net of tax			(75)	(74)	(91)
Other comprehensive income, net of tax			80	(84)	0
Foreign currency translation adjustments
Significant amounts reclassified out of each component of AOCI
Total reclassifications, net of tax			0	0	0
Other comprehensive income, net of tax			(1,008)	407	(943)
Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Tax expense (benefit)			21	21	13
Total reclassifications, net of tax			(75)	(74)	(91)
Reclassification out of accumulated other comprehensive loss | Net investment hedges | Net investment hedging activities
Significant amounts reclassified out of each component of AOCI
Gain on derivative amount excluded from effectiveness testing	[2]		123	112	94
Tax expense (benefit)			27	24	20
Total reclassifications, net of tax			(96)	(88)	(74)
Foreign currency forward exchange contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Losses (gains) on foreign currency exchange contracts	[3]		(73)	(77)	(82)
Treasury rate lock agreements | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gain on derivative amount excluded from effectiveness testing	[2]		(23)	(24)	(23)
Interest rate swap contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gain on derivative amount excluded from effectiveness testing	[2]		0	0	1
Cross-Currency Swap Contracts | Reclassification out of accumulated other comprehensive loss | Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Gain (Loss), Foreign Currency Transaction, before Tax			$ 0	$ 6	$ 0
[1] Amounts are included in the computation of net periodic benefit cost (see Note 12). Amounts are included in interest expense, net (see Note 11). Amounts are included in cost of products sold (see Note 11). (d) Amounts are included in net foreign exchange loss (see Note 11).

Equity - Other (Details)

Equity - Other (Details)	Dec. 31, 2024 $ / shares shares
Equity [Abstract]
Preferred stock authorized (in shares)	200,000,000
Preferred stock par value (in dollars per share) | $ / shares	$ 0.01
Preferred stock issued (in shares)	0

Income Taxes - Earnings Before

Income Taxes - Earnings Before Income Tax Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Domestic	$ (7,743)	$ (3,475)	$ (4,608)
Foreign	11,459	9,725	18,085
Earnings before income tax expense	$ 3,716	$ 6,250	$ 13,477

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current
Domestic	$ (331)	$ 3,272	$ 2,647
Foreign	1,210	994	916
Total current taxes	879	4,266	3,563
Deferred
Domestic	(1,303)	(2,324)	(1,512)
Foreign	(146)	(565)	(419)
Total deferred taxes	(1,449)	(2,889)	(1,931)
Total income tax expense (benefit)	$ (570)	$ 1,377	$ 1,632

Income Taxes - Effective Tax Ra

Income Taxes - Effective Tax Rate Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory tax rate	21%	21%	21%
Effect of foreign operations	7.60%	8%	(4.40%)
U.S. tax credits	(5.40%)	(3.10%)	(2.80%)
Stock-based compensation	(1.20%)	(1.00%)	(0.60%)
Non-deductible expenses	1.10%	0.70%	0.40%
Tax law changes and related structuring	(0.30%)	(3.80%)	(2.40%)
Tax audits, settlements and reserves	(51.40%)	(1.10%)	0.90%
Acquisition costs	13.40%	0.20%	0%
All other, net	(0.10%)	1.10%	0%
Effective tax rate	(15.30%)	22%	12.10%
Effective income Tax Rate Reconciliation Puerto Rico Act			$ 323

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets
Compensation and employee benefits	$ 215	$ 519
Accruals and reserves	1,253	1,113
Chargebacks and rebates	1,354	1,431
Advance payments	66	298
Net operating losses and other carryforwards	15,815	14,316
Other	2,156	2,259
Total deferred tax assets	20,859	19,936
Valuation allowances	(14,823)	(13,478)
Total net deferred tax assets	6,036	6,458
Deferred tax liabilities
Excess of book basis over tax basis of intangible assets	(1,969)	(1,535)
Excess of book basis over tax basis in investments	(302)	(374)
Other	(718)	(746)
Total deferred tax liabilities	(2,989)	(2,655)
Net deferred tax assets (liabilities)	3,047	3,803
Tax Credit Carryforward
Valuation allowances	(14,823)	$ (13,478)
U.S. Federal, State and Non-U.S.
Tax Credit Carryforward
Operating loss carryforwards with expiration through 2041	38,900
U.S. Federal and Non-U.S.
Tax Credit Carryforward
Operating loss carryforwards	33,300
U.S. Federal and State
Tax Credit Carryforward
Tax credit carryforwards	$ 669

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unrecognized Tax Benefits
Beginning balance	$ 5,762	$ 5,670	$ 5,489
Increase due to current year tax positions	173	129	88
Increase due to prior year tax positions	454	109	243
Decrease due to prior year tax positions	(1,741)	(21)	(33)
Settlements	(284)	(86)	(7)
Increase due to acquisitions	82	0	0
Lapse of statutes of limitations	(45)	(39)	(110)
Ending balance	4,401	5,762	5,670
Net amount of potential tax benefits that would impact the entity's effective tax rate	4,300	5,600
Interest and penalties		(430)	(339)
Accrued interest and penalties	1,400	$ 1,600	$ 1,100
Reasonably possible amount that gross unrecognized tax benefits may change within the next twelve months, high end of range	40
Unrecognized Tax Benefit, Benefit	$ 179

Legal Proceedings and Conting_2

Legal Proceedings and Contingencies (Details) $ in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2023 USD ($)	Dec. 31, 2024 USD ($) lawsuit	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2024 claim	Dec. 31, 2024 company	Dec. 31, 2024 claims
Legal Proceedings and Contingencies
Income tax expense (benefit) | $		$ (570)	$ 1,377	$ 1,632
Estimated Litigation Liability | $		$ 2,500	$ 2,000
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits | lawsuit		6
Prescription drug abuse litigation
Legal Proceedings and Contingencies
Number of claims pending					435		435
Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Number of claims pending | company						35
Tax court petition
Legal Proceedings and Contingencies
Income tax expense (benefit) | $	$ 572
Prescription Drug Abuse Litigation In State Courts In process of Being Dismissed
Legal Proceedings and Contingencies
Number of claims pending							5
Prescription Drug Abuse Litigation Covered by a Proposed Class Settlement
Legal Proceedings and Contingencies
Number of claims pending							45
Product Liability ALCL Litigation
Legal Proceedings and Contingencies
Number of claims pending							135
Product Liability Other Litigation
Legal Proceedings and Contingencies
Number of claims pending							1,100
Product Liability ALCL Litigation in State Court
Legal Proceedings and Contingencies
Number of claims pending							75
Product Liability ALCL Litigation in Other Countries
Legal Proceedings and Contingencies
Number of claims pending							60
Prescription Drug Abuse Litigation brought by States, Counties, Cities and other Municipal Entities
Legal Proceedings and Contingencies
Number of claims pending							25
Product Liability Other Litigation in State Court
Legal Proceedings and Contingencies
Number of claims pending							460
Product Liability Other Litigation in Other Countries
Legal Proceedings and Contingencies
Number of claims pending							1,000

Segment and Geographic Area I_3

Segment and Geographic Area Information - Additional Information (Details)	12 Months Ended
	Dec. 31, 2024 segment
Segment Reporting [Abstract]
Number of Operating Segments	1

Segment and Geographic Area I_4

Segment and Geographic Area Information - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue
Net revenues		$ 56,334	$ 54,318	$ 58,054
Total net revenues	$ 15,102	$ 56,334	$ 54,318	$ 58,054
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]		Total net revenues	Total net revenues	Total net revenues
United States
Disaggregation of Revenue
Net revenues		$ 43,029	$ 41,883	$ 45,713
All other
Disaggregation of Revenue
Net revenues		3,032	3,035	4,137
Immunology | Humira
Disaggregation of Revenue
Net revenues		8,993	14,404	21,237
Immunology | Humira | United States
Disaggregation of Revenue
Net revenues		7,142	12,160	18,619
Immunology | Humira | International
Disaggregation of Revenue
Net revenues		1,851	2,244	2,618
Immunology | Skyrizi
Disaggregation of Revenue
Net revenues		11,718	7,763	5,165
Immunology | Skyrizi | United States
Disaggregation of Revenue
Net revenues		10,086	6,753	4,484
Immunology | Skyrizi | International
Disaggregation of Revenue
Net revenues		1,632	1,010	681
Immunology | Rinvoq
Disaggregation of Revenue
Net revenues		5,971	3,969	2,522
Immunology | Rinvoq | United States
Disaggregation of Revenue
Net revenues		4,259	2,824	1,794
Immunology | Rinvoq | International
Disaggregation of Revenue
Net revenues		1,712	1,145	728
Oncology | Imbruvica
Disaggregation of Revenue
Net revenues		3,347	3,596	4,568
Oncology | Imbruvica | United States
Disaggregation of Revenue
Net revenues		2,448	2,665	3,426
Oncology | Imbruvica | International
Disaggregation of Revenue
Collaboration revenues		899	931	1,142
Oncology | Venclexta
Disaggregation of Revenue
Net revenues		2,583	2,288	2,009
Oncology | Venclexta | United States
Disaggregation of Revenue
Net revenues		1,234	1,087	1,009
Oncology | Venclexta | International
Disaggregation of Revenue
Net revenues		1,349	1,201	1,000
Oncology | Epkinly
Disaggregation of Revenue
Net revenues		146	31
Collaboration revenues		118	28	0
Oncology | Epkinly | International
Disaggregation of Revenue
Net revenues		28	3	0
Oncology | Elahere
Disaggregation of Revenue
Net revenues		479	0	0
Oncology | Elahere | United States
Disaggregation of Revenue
Net revenues		477	0	0
Oncology | Elahere | International
Disaggregation of Revenue
Net revenues		2	0	0
Aesthetics | Botox Cosmetic
Disaggregation of Revenue
Net revenues		2,720	2,682	2,615
Aesthetics | Botox Cosmetic | United States
Disaggregation of Revenue
Net revenues		1,682	1,670	1,654
Aesthetics | Botox Cosmetic | International
Disaggregation of Revenue
Net revenues		1,038	1,012	961
Aesthetics | Juvederm Collection
Disaggregation of Revenue
Net revenues		1,177	1,378	1,428
Aesthetics | Juvederm Collection | United States
Disaggregation of Revenue
Net revenues		469	519	548
Aesthetics | Juvederm Collection | International
Disaggregation of Revenue
Net revenues		708	859	880
Aesthetics | Other Aesthetics
Disaggregation of Revenue
Net revenues		1,279	1,234	1,290
Aesthetics | Other Aesthetics | United States
Disaggregation of Revenue
Net revenues		1,118	1,060	1,122
Aesthetics | Other Aesthetics | International
Disaggregation of Revenue
Net revenues		161	174	168
Neuroscience | Botox Therapeutic
Disaggregation of Revenue
Net revenues		3,283	2,991	2,719
Neuroscience | Botox Therapeutic | United States
Disaggregation of Revenue
Net revenues		2,718	2,476	2,255
Neuroscience | Botox Therapeutic | International
Disaggregation of Revenue
Net revenues		565	515	464
Neuroscience | Vraylar
Disaggregation of Revenue
Net revenues		3,267	2,759	2,038
Neuroscience | Vraylar | United States
Disaggregation of Revenue
Net revenues		3,260	2,755	2,037
Neuroscience | Vraylar | International
Disaggregation of Revenue
Net revenues		7	4	1
Neuroscience | Duodopa
Disaggregation of Revenue
Net revenues		447	468	458
Neuroscience | Duodopa | United States
Disaggregation of Revenue
Net revenues		96	97	95
Neuroscience | Duodopa | International
Disaggregation of Revenue
Net revenues		351	371	363
Neuroscience | Ubrelvy
Disaggregation of Revenue
Net revenues		1,006	815	680
Neuroscience | Ubrelvy | United States
Disaggregation of Revenue
Net revenues		981	803	680
Neuroscience | Ubrelvy | International
Disaggregation of Revenue
Net revenues		25	12	0
Neuroscience | Qulipta
Disaggregation of Revenue
Net revenues		658	408	158
Neuroscience | Qulipta | United States
Disaggregation of Revenue
Net revenues		628	405	158
Neuroscience | Qulipta | International
Disaggregation of Revenue
Net revenues		30	3	0
Neuroscience | Other Neuroscience
Disaggregation of Revenue
Net revenues		338	276	475
Neuroscience | Other Neuroscience | United States
Disaggregation of Revenue
Net revenues		224	254	456
Neuroscience | Other Neuroscience | International
Disaggregation of Revenue
Net revenues		114	22	19
Eye Care | Lumigan/Ganfort
Disaggregation of Revenue
Net revenues		429	432	514
Eye Care | Lumigan/Ganfort | United States
Disaggregation of Revenue
Net revenues		187	173	242
Eye Care | Lumigan/Ganfort | International
Disaggregation of Revenue
Net revenues		242	259	272
Eye Care | Alphagan/Combigan
Disaggregation of Revenue
Net revenues		248	272	346
Eye Care | Alphagan/Combigan | United States
Disaggregation of Revenue
Net revenues		95	121	202
Eye Care | Alphagan/Combigan | International
Disaggregation of Revenue
Net revenues		153	151	144
Eye Care | Restasis
Disaggregation of Revenue
Net revenues		224	436	666
Eye Care | Restasis | United States
Disaggregation of Revenue
Net revenues		172	382	621
Eye Care | Restasis | International
Disaggregation of Revenue
Net revenues		52	54	45
Eye Care | Other Eye Care
Disaggregation of Revenue
Net revenues		847	803	747
Eye Care | Other Eye Care | United States
Disaggregation of Revenue
Net revenues		472	433	399
Eye Care | Other Eye Care | International
Disaggregation of Revenue
Net revenues		375	370	348
Eye Care | Ozurdex
Disaggregation of Revenue
Net revenues		494	472	428
Eye Care | Ozurdex | United States
Disaggregation of Revenue
Net revenues		138	143	139
Eye Care | Ozurdex | International
Disaggregation of Revenue
Net revenues		356	329	289
Other Key Products | Mavyret
Disaggregation of Revenue
Net revenues		1,311	1,430	1,541
Other Key Products | Mavyret | United States
Disaggregation of Revenue
Net revenues		595	659	755
Other Key Products | Mavyret | International
Disaggregation of Revenue
Net revenues		716	771	786
Other Key Products | Creon | United States
Disaggregation of Revenue
Net revenues		1,383	1,268	1,278
Other Key Products | Linzess/Constella
Disaggregation of Revenue
Net revenues		954	1,108	1,035
Other Key Products | Linzess/Constella | United States
Disaggregation of Revenue
Net revenues		916	1,073	1,003
Other Key Products | Linzess/Constella | International
Disaggregation of Revenue
Net revenues		$ 38	$ 35	$ 32

Segment and Geographic Area I_5

Segment and Geographic Area Information - Net Revenues to External Customers by Geographic Area (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets
Net revenues	$ 56,334	$ 54,318	$ 58,054
United States
Revenues from External Customers and Long-Lived Assets
Net revenues	43,029	41,883	45,713
Germany
Revenues from External Customers and Long-Lived Assets
Net revenues	1,465	1,266	1,340
Canada
Revenues from External Customers and Long-Lived Assets
Net revenues	1,088	1,076	1,159
Japan
Revenues from External Customers and Long-Lived Assets
Net revenues	1,122	1,008	956
China
Revenues from External Customers and Long-Lived Assets
Net revenues	917	950	912
France
Revenues from External Customers and Long-Lived Assets
Net revenues	776	780	787
Australia
Revenues from External Customers and Long-Lived Assets
Net revenues	463	472	508
Spain
Revenues from External Customers and Long-Lived Assets
Net revenues	528	501	506
United Kingdom
Revenues from External Customers and Long-Lived Assets
Net revenues	522	417	462
Italy
Revenues from External Customers and Long-Lived Assets
Net revenues	511	484	444
Brazil
Revenues from External Customers and Long-Lived Assets
Net revenues	464	439	430
All other countries
Revenues from External Customers and Long-Lived Assets
Net revenues	$ 5,449	$ 5,042	$ 4,837

Segment and Geographic Area I_6

Segment and Geographic Area Information - Long-lived Assets by Geographic Region (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets
Total long-lived assets	$ 5,134	$ 4,989
United States
Revenues from External Customers and Long-Lived Assets
Total long-lived assets	3,331	3,139
Europe
Revenues from External Customers and Long-Lived Assets
Total long-lived assets	1,485	1,433
All other
Revenues from External Customers and Long-Lived Assets
Total long-lived assets	$ 318	$ 417

Fourth Quarter Financial Resu_3

Fourth Quarter Financial Results (unaudited) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended												12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 15,102												$ 56,334	$ 54,318	$ 58,054
Gross margin	10,706
Net earnings attributable to AbbVie Inc.	$ (22)												$ 4,278	$ 4,863	$ 11,836
Basic earnings per share (in dollars per share)	$ (0.02)												$ 2.40	$ 2.73	$ 6.65
Diluted earnings per share (in dollars per share)	(0.02)												2.39	2.72	6.63
Cash dividends declared per common share (in dollars per share)	$ 1.64	$ 1.55	$ 1.55	$ 1.55	$ 1.55	$ 1.48	$ 1.48	$ 1.48	$ 1.48	$ 1.41	$ 1.41	$ 1.41	$ 6.29	$ 5.99	$ 5.71